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III. Abstract 
 
The receptor for advanced glycation end-products (RAGE) was identified as cell membrane-
bound pattern recognition receptor sensing endogenous alarming signals. Previous work 
revealed the existence of a plethora of RAGE isoforms and of a complex regulatory 
machinery enabling their controlled expression. While mainly expressed at low levels in 
healthy tissues, pathological disorders are often connected with increased RAGE expression. 
Indeed, besides providing evidence for an upregulation of RAGE in melanoma, we 
demonstrated recently that diminished sRAGE and esRAGE levels serve as prognostic 
markers, suggesting a differential expression of distinct RAGE variants in malignant 
melanoma. To date, the functional role of RAGE in melanoma has not been systematically 
investigated so far. 
This study demonstrated an upregulation of AGER transcripts in benign melanocytic nevi in 
line with a sufficiency of RAGE overexpression in establishing melanoma hallmarks in a 
melanocytic cell line. In addition, combining gain- and loss-of-function studies with gene 
expression analysis led to the identification of RAGE as negative regulator of in trans 
molecules, such as DNA repair proteins, and consequently of genomic integrity in human 
and mouse. These findings illustrate that the early occurrence of melanoma-associated 
mutations found in benign melanocytic nevi and the high genomic instability of melanoma 
cells might be a consequence of dysregulated RAGE expression. Furthermore, the study 
provided evidence that the observed benefits of a high RAGE expression on melanoma cells, 
including sustained proliferation, deregulation of cellular energetics, and prolonged survival, 
also come along with negative effects such as higher vulnerability to exogenous genotoxic 
insults. Such negative consequences, which might be another issue of the impact of RAGE 
on genomic integrity, implicate the existence of strategies regulating RAGE functionality in 
melanoma. As demonstrated in this study, these might not only comprise the control of gene 
expression but also alternative splicing and subcellular translocation. Indeed, this work 
showed for the first time that RAGE protein in melanocytes can also be translocated to the 
nucleus via active cargo transport, and indicated a loss of nuclear RAGE as characteristic of 
human malignant melanoma. The study further indicated a pathological upregulation of 
nuclear export proteins as well as a differential expression of RAGE splicing factors as 
potential mechanisms behind the aberrant compartmentalization of RAGE upon malignant 
transformation.  
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IV. Zusammenfassung 
 
Der Mustererkennungsrezeptor RAGE (engl. 'receptor for advanced glycation end-products’) 
wurde als Zellmembran-ständiges Molekül beschrieben, dessen Rezeptorbindungsprofil 
Moleküle der sogenannten DAMP (engl. ‘damage-associated molecular pattern‘) - Familie 
umfasst. Frühere Studien konnten neben der Existenz einer Vielzahl von RAGE-
Proteinvarianten, komplexe Regulationsmaschinerien nachweisen, die eine gezielte 
Steuerung deren Expression ermöglichen. Dies deutet daraufhin, dass die Funktionen von 
RAGE durch eine größere Komplexität gekennzeichnet sind als ursprünglich angenommen. 
Während in gesundem Gewebe eine meist geringe RAGE-Expression zu finden ist, sind 
pathologische Zustände häufig mit einer erhöhten RAGE-Proteinexpression verbunden. In 
einer bereits eingereichten Studie konnten wir in Patienten mit malignem Melanom neben 
einem erhöhtem RAGE Gesamtprotein eine verminderte Menge zweier sezernierter RAGE-
Varianten nachweisen und damit die differenzielle Expression verschiedener RAGE-
Proteinvarianten auch im Melanom bestätigen. Ungeachtet des großen Interesses, ist die 
funktionelle Rolle von RAGE im malignen Melanom bisher weitgehend unbekannt. 
In der vorliegenden Arbeit konnte die Induktion der AGER-spezifischen Expression im 
benignen, melanozytären Naevus demonstriert, wie auch der Nachweis tumorspezifischer 
Merkmale in einer melanozytären Zelllinie durch die Überexpression von RAGE erbracht 
werden. Dies weist auf eine mögliche Rolle von RAGE in der frühen Melanomentstehung hin. 
Überexpressions- und Knockdown-Studien zusammen mit Genexpressionsanalysen 
ermöglichten zudem die Charakterisierung von RAGE als negativem Regulator sogenannter 
in trans Moleküle, zu denen unter anderem DNA Reparaturproteine gezählt werden, mit 
Auswirkungen auf die Genomintegrität im humanen System als auch in der Maus. 
Darausfolgernd, könnte eine gesteigerte genomische Instabilität aufgrund erhöhter RAGE-
Expression einer der Faktoren sein, die die bereits in melanozytären Naevi auftauchenden 
Melanom-spezifischen Mutationen und die hohe Mutationsrate im Melanom selbst bedingen. 
Ferner konnte gezeigt werden, dass eine erhöhte Expression von RAGE neben primär 
tumor-promovierenden Auswirkungen, die eine kontinuierliche Proliferation, als auch die 
Aneignung eines tumorspezifischen Stoffwechsels und eines gesteigerten Zellüberlebens 
umfassen, auch anti-tumorigene Effekte zur Folge hat. Zu letzteren zählt die gesteigerte 
Sensibilität von RAGE-überexprimierenden Melanomzellen gegenüber exogen-induzierten 
DNA Schäden. Basierend auf der hohen Adaptionsmöglichkeit von Melanomzellen wurden 
Regulationsmechanismen vermutet, die eine Umgehung solcher Effekte ermöglichen. Diese 
Arbeit zeigt, dass diese nicht nur eine Genexpressionskontrolle, sondern auch alternatives 
Spleißen und subzelluläre Kompartimentierung zu umfassen scheinen. Zudem demonstriert 
 VIII 
diese Arbeit erstmalig, dass in Melanozyten RAGE über einen aktiven Cargotransport in den 
Nukleus transloziert werden kann und diese Eigenschaft bei der malignen Transformation in 
Melanomzellen verloren geht. Die Ergebnisse weisen darauf hin, dass dieser Effekt zum 
einen auf der Melanom-spezifischen Hochregulation nukleärer Exportproteine wie auch auf 
der differenziellen Expression von RAGE Spleißfaktoren und RAGE Spleißvarianten beruhen 
könnte. 
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V. Introduction 
 
Despite recent advances in managing malignant melanoma, the progress in developing 
therapeutic approaches is limited due to remaining questions regarding melanoma growth 
and progression. Among others the role of pattern recognition receptors, such as the 
receptor for advanced glycation end-products (RAGE), is unresolved in melanoma biology. In 
this chapter information on malignant melanoma development, characteristics of the disease, 
and treatment options will be provided. Furthermore, the receptor RAGE, and its function in 
physiological and pathophysiological processes, including cancer will be introduced.  
V.1. Melanoma 
In the next few pages, the development of malignant melanoma, and common characteristics 
of melanoma cells will be described. In addition, information on diagnosis, treatment options 
and therapy-associated complications will be provided. 
 The pathogenesis of melanoma: A general overview 
Malignant melanoma can arise in any anatomic region occupied by pigment-producing 
melanocytes, including the skin, the choroidal layer of the eye, meninges, and mucosal 
tissues [1]. Accounting for about 75 % of all skin cancer-related deaths, cutaneous 
melanoma represents the most aggressive and fatal form of skin cancer with persistent 
increase in incidence and mortality [2]. In 20 to 50 % of all cases, melanomas can be traced 
back to pre-existing nevi formed by proliferating melanocytes within the basal cell layer of the 
epidermis [3, 4]. This shows that an aberrant proliferation of melanocytes is not necessarily 
linked with the development and growth of malignant melanoma. Melanocytic proliferation 
only occurs in a horizontal pattern, whereas melanoma growth is characterized by a so called 
vertical growth phase (VGP), either with or without a preceding radial growth phase (RGP). 
During the vertical growth the tumor adapts, e.g. by deregulation of the expression of distinct 
adhesion molecules, thereby allowing the formation of metastases [5, 6]. This high plasticity 
of melanoma cells leads to a significant change regarding the clinical outcome. For localized 
melanoma, i.e. primary tumor with 1 mm vertical diameter, the five-year survival rate is over 
90 %, whereas the progression to a distant metastatic disease is accompanied by drop to 
16 % [2]. 
In order to identify the molecular events propagating malignant transformation of normal 
human melanocytes, factors associated with melanoma development must be investigated. 
Besides a familiar predisposition, epidemiologic studies have implicated three closely 
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associated factors, namely intense intermittent UV light exposure, severe sunburns during 
childhood, and a “red hair phenotype” (red/blonde hair, blue eyes, fair skin and high 
sensitivity to UV light), in conferring the highest risk [7-9]. These risk factors, as well as the 
fact that the signature spectrum of UV mutagenesis accounts for approximately 50 % of 
driver mutations found in melanoma [10], directly link UV radiation, which negatively 
influences genomic integrity by introducing DNA damage, and melanocytic transformation. 
Melanocytes possess features like the production of the photoprotective pigment eumelanin 
in order to e.g. shield their genomes from UV-induced DNA damage. The Caucasian 
population, having only impaired attenuation of UV radiation due to low levels of eumelanin, 
is associated with a ten - fold greater risk to develop melanoma compared to ethnic groups 
with deeply pigmented skin [11]. The red hair phenotype is characterized by a high ratio of 
red pheomelanin to black eumelanin and connects UV-dependent and UV-independent risk 
factors for melanoma development. Pheomelanin does not have the same photoprotective 
characteristics as eumelanin; instead, it is involved in the generation of reactive oxygen 
species (ROS), thereby representing an UV-independent mechanism to melanomagenesis 
[12-15]. Evidence for other UV-independent mechanisms is given by the fact, that sunscreen 
has shown significant [16] but, nevertheless, incomplete [17] protection against melanoma.  
Furthermore, an increased number of nevi (> 50) and familiar predisposition are also ranked 
among risk factors for melanoma [7, 18, 19]. More precisely, a family history of melanoma is 
found in approximately 10 % of melanoma patients conferring a two - fold increase in 
melanoma risk. Hereditary melanoma is often associated with multiple family members 
affected with melanoma, multiple primary melanomas per individual, and an early onset of 
the malignancy [19]. Among the genetic loci and variants conferring a high susceptibility to 
melanoma is the retinoblastoma protein 1 gene (RB1) [20-23], CDK4 [24-26], and the 
CKDN2A locus [27], encoding for the two distinct protein p16INK4a and p14ARF through 
alternative splicing. Alterations in RB1, p16INK4a, and CDK4 expression mainly result in cell 
cycle progression, thereby facilitating tumor onset [28-31]. Instead, the net effect of p14ARF 
loss is the destabilization of the tumor suppressor P53 [32, 33].  
In comparison to the rare hereditary genetic alterations, melanoma cells often acquired 
mutations that are responsible for the malignant transformation and distinct to additional 
acquired passenger mutations, forming a so-called landscape of driver mutations [10]. In 
fact, the observed mutation frequency is even higher compared to most other solid tumors 
[34]. The genes mainly affected by somatic mutations in melanoma, namely BRAF (B-rapidly 
accelerating fibrosarcoma) and NRAS (N-rat sarcoma), are belonging to the mitogen-
activated protein kinase (MAPK) pathway, thereby leading to its dysregulation [35]. This 
pathway transduces signals from the extracellular milieu into the cell, and also into the 
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nucleus, where specific genes are activated in order to induce cell growth, division and 
differentiation. Accordingly, dysregulation of this pathway is a common event in cancer. 
BRAF mutations, which result mostly in a valine-to-glutamic acid substitution at codon 600 
(V600E), have been found in about 60 % of melanomas [10]. It is noteworthy, that many of 
the melanoma-associated mutations are commonly found in benign nevi, in terms of BRAF 
mutations in 80 %, proving their insufficient capacity to transform melanocytes without 
cooperating mutations [36-40]. In fact, it is believed that BRAF V600E induces checkpoint 
mechanisms forcing melanocytes lacking additional driver mutations into a senescence-like 
state [41]. Interestingly, in cutaneous melanoma BRAF and NRAS mutations, with the latter 
being associated with approximately 30 % of melanomas, are in general mutually exclusive 
[10]. Most NRAS mutations in melanoma lead to mutant proteins with glutamine substitutions 
at codon 61, namely Q61R and Q61K [42]. In melanoma, BRAF as well as NRAS mutations 
lead to a continuous downstream signaling of the MAPK pathway with consequent activation 
of extracellular-signal-regulated kinases (ERK) [35]. 
Another important pathway, which is aberrantly activated in melanoma, is the 
phosphatidylinositol– 4,5–bisphosphate 3-kinase (PI3K) pathway. Active PI3K is able to 
phosphorylate the 3′-OH group on phosphatidylinositols in the plasma membrane, thereby 
leading to the recruitment and activation of the protein kinase B (PKB), also known as AKT, 
and to the consequent induction of the transcription factor NF-κB (nuclear factor 'kappa-light-
chain-enhancer' of activated B-cell) [43, 44]. 20 to 30% of melanoma cells display a loss of 
the phosphatase PTEN (phosphatase and tensin homolog) [10], a potent inhibitor of the PI3K 
pathway, resulting in the hyperactivation of the pathway [45].  
The MAPK pathway as well as the PI3K pathway are involved in many molecular networks, 
including cell-intrinsic networks sensing metabolic stress and DNA damage, as well as cell-
extrinsic signaling mediated by cell-cell or cell-matrix interactions [46, 47]. With 17 % P53 is 
frequently mutated in melanoma, resulting in aberrant proteins with increased half-life and 
dominant negative and/or gain of function phenotypes mediating resistance towards 
apoptosis [10, 48]. Nevertheless, the majority of cancers display even higher frequencies of 
P53 mutations, raising the question whether melanoma cells display a distinct mechanism of 
avoiding apoptosis and other regulatory checkpoints. 
The recent progress in the genome-wide mutation analysis unraveled key mutations involved 
in melanomagenesis leading to the development of novel therapeutics. Nevertheless, the 
genetic and epigenetic instability giving rise to a remarkable diversity of melanoma cells 
holds responsible for the complexity of the disease and the high percentage of acquired 
therapy resistance. Therefore, the investigation of characteristics and functional behaviors of 
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melanoma cells and their cell states is required. The current level of knowledge regarding 
this topic will be outlined in the next section. 
 Hallmarks of melanoma cells 
In 2000, Hanahan and Weinberg postulated several hallmarks of cancer cells acquired 
during transformation, thereby providing an organizing principle for rationalizing the nexus of 
malignancies [49]. The list of hallmarks was updated in 2011, and comprises genomic 
instability and mutation, resistance to cell death, deregulation of cellular energetics, 
sustained proliferative signaling, replicative immortality, growth suppressor evasion, invasion 
and metastasis formation, prevention of immune destruction, the establishment of a tumor-
promoting inflammation, as well as the induction of angiogenesis [50]. These general 
characteristics of cancer cells can be achieved in a number of different ways; here, methods 
used by melanoma cells will be described and illustrated (see Figure 1, Hallmarks of 
melanoma, page 10). 
Genomic instability is on the one hand clearly a hallmark of cancer cells, on the other hand 
it is not well understood by now. Bastian and colleagues demonstrated in 2000, that 
cutaneous melanomas have specific genomic instability patterns [51] not knowing if these 
are causative for or effects of the malignant transformation [52]. As already mentioned in the 
last section, genomic aberrations have also been found in benign nevi suggesting an early 
role in melanomagenesis [53]. 95 % of melanomas exhibit chromosomal aberrations [54] with 
non-metastatic tumors being genomically more stable than metastatic ones, indicating 
genomic instability as an ongoing process with importance not only for development but also 
for the progression of the disease [52, 53, 55, 56]. Causes for the lack of genomic integrity 
might be excessive oxidative stress, or failure of cellular functions ensuring the accuracy of 
DNA transactions like defective DNA repair, and telomere dysfunction [52]. It has been 
shown that different kinds of cancer, including melanoma, exhibit high levels of ROS [57, 58], 
thereby being prone for oxidative DNA damage.  
In addition, alterations in DNA damage repair and signaling have been linked to melanoma. 
For instance, patients with xeroderma pigmentosum (XP), a rare disease caused by 
mutations in DNA repair genes, show a 1000 - fold higher frequency as well as early onset of 
malignant melanoma [59]. Many of the genes affected by mutations leading to XP are part of 
the nucleotide excision repair (NER) [60]. Besides NER, also the characterized deregulation 
of molecules involved in double-strand break (DSB) repair mechanisms like the non-POU 
domain containing octamer-binding (NONO) protein, significantly influence melanoma cell 
behavior and progression [61, 62]. Furthermore, Zhang and colleagues demonstrated that 
SNPs within two DNA damage repair genes, namely ATR and PARP1, significantly 
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correlated with an increased susceptibility to melanoma [63]. Although one of the common 
ways of cancer cells circumventing DNA damage signaling, which is the direct P53 
mutagenesis, is less frequent in melanoma, its inactivation mediated by the loss of p14ARF 
[32, 33] or amplification of HDM2 [64] leads to comparable effects. The net effect of all these 
alterations is an increased tolerance towards DNA damage and enhanced resistance to cell 
death. One indication for a prolonged survival of melanoma cells is the fact, that they often 
harbor long telomeres [65]. Usually, during the lifespan of a normal somatic cell, mitosis will 
result in gradual shortening of telomeres. As response to short telomeres, cells undergo 
destabilization, followed by loss of chromosomes, and induction of senescence and cell 
death. Therefore, untransformed cells display a kind of ‘mitotic clock’ restricting their lifespan 
[66]. Since non-melanoma skin cancers are associated with short telomeres [66], thereby 
presenting an inverse correlation to melanoma, the latter seem to have different strategies 
ensuring replicative immortality. 
Indeed, melanoma cells found several ways to adjust this ‘clock’. One strategy of melanoma 
is to benefit from intrinsic mechanisms of their cells of origin, namely melanocytes. 
Melanocytes are characterized by many different intrinsic pro-survival mechanisms 
counteracting environmental stress, including UV radiation and toxic intermediates of 
melanogenesis [67, 68]. For instance, the microphthalmia-associated transcription factor 
(MITF), a master regulator of melanocyte differentiation, is known to be involved in the 
regulation of pigment synthesis, an important tool of melanocytes to shield their genomes 
from DNA damage [69, 70]. Besides melanin synthesis, MITF has been demonstrated to 
have additional pro-survival functions in melanomas. Among MITF targets various anti-
apoptotic genes, such as BCL2 (B-cell leukemia 2) or BCL2A1 (BCL2 related protein A1), 
can be found. Whereas BCL2 shows a relatively low expression in melanoma, BCL2A1 seem 
to have tremendous importance, not only because of its high expression levels in melanoma 
but since it is also associated with an increased therapy resistance [71-73]. Furthermore, 
there is evidence for MITF inducing BIRC7, a gene encoding for the so-called melanoma 
inhibitor of apoptosis (ML-IAP). BIRC7 harbors two predictive MITF binding sites, and the 
respective transcript levels, which are not detectable in melanocytes, positively correlate with 
MITF in melanoma [74, 75]. Via direct interaction with caspases ML-IAP inhibits intrinsic and 
extrinsic apoptosis pathways in melanoma; a function which results in diminished patient 
survival [76, 77]. Although these are only a few examples for the pro-survival effects of MITF, 
also other features of melanoma cells like the reduction of the apoptotic-protease-activating 
factor 1 (APAF1) [78], or the aberrant activation states of MAPK and PI3K pathways 
significantly enhance the viability of melanoma cells. Evidence for the latter has been 
provided by the study of Koo et al. [79], showing that the inhibition of the MAPK pathway 
induces apoptosis in melanoma cells but not in normal melanocytes. Further studies 
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revealed that the phosphorylation of pro-apoptotic proteins like BAD and BIM by MAP 
kinases results in their inactivation, representing one of the MAPK-dependent mechanisms 
for propagation of survival [80-82]. Since Stambolic and colleagues demonstrated in 1998 
that murine embryonic fibroblasts (MEFs) displayed reduced apoptosis upon PTEN knockout 
[83], the finding that loss of PTEN is a frequent event in melanoma has soon been connected 
to the improved survival of melanoma cells. Indeed, ectopic expression of PTEN in 
melanoma cells lacking the functional protein, led to an impaired activation of AKT3 and 
downstream mediators, thereby resulting in decreased cell survival [84-86].  
The activation state of AKT proteins does not only affect the survival of melanoma cells; it 
also impacts cell energetics and metabolism. More specifically, changes in AKT activation 
have been linked to an impaired mitochondrial-dependent glucose oxidation. For energetic 
compensation melanoma cells induce glycolysis, which results in an immense uptake of 
glucose and in the generation of high lactate levels [87, 88]. Several studies linked increased 
lactate dehydrogenase (LDH) levels to metastatic spread of melanoma cells. The 
establishment of a selective environment might be an intelligent strategy of cancer cells, 
which seem to easily adapt to acidic conditions in comparison to surrounding cells [89-91]. 
Melanoma cells seem to have the possibility to pursue different strategies; indeed, they are 
also capable of switching strategies. Two different states of melanoma cells have been 
reported: Melanoma cells in the ‘proliferative’ state undergo excessive cell divisions, while 
enhanced motility and migration are defined as characteristics of ‘invasive’ melanoma cells. 
The high proliferation capacity of melanoma cells can be easily demonstrated by 
comparing doubling times of melanoma cell lines (A375, MeWo, RPMI7951), which lay in 
between 21 to 36 hours [92], to the doubling time of isolated normal human melanocytes, 
which has been determined as four to ten days [93]. This is based on hyperactivation of 
MAPK and PI3K pathways and subsequent activation of transcription factors like NF-κB and 
ERK [94-96]. Primary melanoma cells as well as melanoma cell lines with a ‘proliferative’ 
signature are characterized by melanocyte differentiation antigens, including MITF and 
several of its targets, while cells of the ‘invasive’ state are defined by the expression of 
negative regulators of the Wnt signaling pathway, like WNT5A (wingless-type MMTV 
integration site family member 5A), DKK1 (Dickkopf-related protein 1), and CTGF 
(connective tissue growth factor) [97, 98]. These and additional features discriminating the 
two phenotypes are well-established characteristics of the ‘epithelial-to-mesenchymal 
transition’ (EMT) [99, 100], a process involved in invasion and metastatic dissemination of 
many epithelial cancers [101]. To acquire the capacity to invade, melanoma cells need to 
lose cell-cell-contact with keratinocytes. Several groups were able to show that switching 
between E-cadherin and N-cadherin enables melanoma cells to rather interact with stromal 
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fibroblasts and endothelial cells. The cadherin switch, a main hallmark of the EMT, is induced 
by epithelial-mesenchymal transition regulators (EMTRs), such as Snail and Twist [102-104]. 
Furthermore, melanoma cells need to adhere to extracellular matrices (ECM) and 
proteolytically degrade ECM proteins. Indeed, invasion and metastasis formation have been 
linked to the deregulation of different proteolytic enzyme systems, including the family of 
matrix metalloproteinases (MMP) [105-108]. After migration through the basement 
membrane into veins and lymphatic vessels potential metastatic cells are then selected for 
resistance to apoptosis, immunological evasion, adhesion, and migration to a new metastatic 
site [109]. 
Melanomas spread in three different ways: locally within the dermis; via the lymphatic 
system, and via the bloodstream. Since melanoma tumors acquire rich vascular networks 
[110] a connection between angiogenesis and metastasis formation has been long 
hypothesized. Schietroma and colleagues could demonstrate in 2003 that an increased 
vascular endothelial growth factor C (VEGF-C) expression significantly correlates with higher 
frequency of metastasis in sentinel lymph nodes [111].  
Beside cell-intrinsic factors affecting the reversible phenotype switch, also 
microenvironmental components such as nutrients, oxygen, cytokines, and growth factors 
play an important role. Widmer and colleagues suggested hypoxia as one of the 
environmental factors influencing the phenotype switch of melanoma cells. They found that 
tumor regions displaying an ‘invasive’ signature with decreased expression of melanocytic 
differentiation markers, correlate with hypoxic regions defined by the expression of the 
glucose transporter 1 (GLUT1) and the hypoxia-inducible factor 1 alpha (HIF1α) [112]. 
Another environmental influence regulating the two states is the transforming growth factor β 
(TGF-β). Upon in vitro stimulation with TGF-β, cells of the ‘proliferative’ subgroup were 
inhibited and started to downregulate MITF expression, whereas cells with the ‘invasive’ 
phenotype responded with increased invasiveness [113, 114]. In order to switch between 
these two states, melanoma cells need to induce dramatic changes. Therefore, the 
phenotype switch requires complex molecular regulation and restructuration, illustrating the 
enormous plasticity of melanoma cells.  
The plasticity of melanoma cells is not only useful in the adaption to environmental stress, 
but also in the evasion of growth suppression and immune destruction. As mentioned 
earlier, melanoma cells can drive cell cycle progression through mutations or aberrant 
expression of molecules involved in cell cycle checkpoints like RB1, p16INK4a, or CDK4 [28-
31]. It has been shown that MITF, which is upregulated upon switching into the ‘proliferative’ 
state, induces the cyclin-dependent kinase inhibitor gene CDKN1A, thereby regulating the 
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phosphorylation status of RB1, leading to its activation and consequently to cell cycle 
progression [28]. 
Although melanoma cells harbor many genetic as well as epigenetic changes associated 
with the aberrant expression of multiple molecules, their capacity to up- and downregulate 
these potential tumor antigens, represents one of the characteristics of melanoma cells 
making them less vulnerable to host immune responses. In human melanoma various 
classes of tumor antigens have been identified, including autologous tumor-specific, tissue-
specific, and common cancer-specific antigens [115]. Despite the selection of non-
immunogenic melanoma cell variants, which belongs to the phenomenon called 
‘immunoediting’, melanoma cells can also conduct ‘immunosubversion’ by suppressing anti-
tumor immune response actively [116]. 
In 1969, Clark and colleagues first described the lymphocytic infiltration of primary 
melanomas [117]. The immune system plays an important role in melanomagenesis which 
has later been proven by the fact that the presence of tumor-infiltrating T lymphocytes (TILs) 
represents a useful prognostic marker for melanoma [118, 119]. A higher percentage of TILs 
within primary melanomas has been demonstrated to significantly correlate with lower 
numbers of lymph node metastases [120], a better prognosis and a higher survival rate [118]. 
It is noteworthy that these findings are still under discussion since other studies failed to 
verify the positive correlation of marked TIL infiltrations and improved survival [121-123]. This 
discrepancy may be partly explained by differences in patient populations, e.g. in terms of 
clinical stages [124]. Another reason might be the great variance of the tumor 
microenvironment regarding the immune cell composition between individual patients. For 
instance, the pattern of infiltrating T cell subsets can range from predominant CD4+ T cell 
infiltrations to infiltrates with almost 90 % CD8+ T cells [125-127]. In addition, the function of 
TILs is often impaired by the accumulation of immunosuppressive cells. Accumulations of 
CD4+CD25+Foxp3+ regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), 
tumor-associated macrophages (TAMs), as well as other immunosuppressive cells are 
detected in the tumor microenvironment of melanomas [128-134]. Accordingly, the presence 
of Tregs predicts reduced patient survival [135], as confirmed by the in vitro depletion of 
Tregs from melanoma TIL populations leading to increased tumor cell lysis mediated by NK 
cells [136]. 
Beside indirect effects on the tumor stroma, melanoma cells can also directly contribute to 
immunosuppression. In addition to the already described phenomenon of immunoselection, 
melanoma cells are able to decrease the expression of co-stimulatory molecules [128], major 
histocompatibility complex (MHC) class I molecules [137], ligands for natural killer cell 
receptors [138], and to induce the production and secretion of immunosuppressive factors 
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such as VEGF, TGF-β, nitric oxide (NO), prostaglandins, or interleukins (IL) [128, 139]. Just 
recently, Dong and colleagues were able to link loss of PTEN with the induction of 
immunosuppressive cytokines. In fact, ectopic PTEN expression in a PTEN-defective human 
melanoma cell line restored the transcriptional repression of IL-10, IL-6 and VEGF in a dose-
dependent and STAT-3 (signal transducer and activator of transcription)-driven manner. 
Furthermore, they were able to demonstrate an inverse correlation of PTEN and 
programmed death-ligand 1 (PD-L1) expression [140]. Binding of PD-L1 to its receptors, PD-
1 (programmed cell death protein 1) and CD80, on T lymphocytes results in the inhibition of 
proliferation and cytokine production of activated T cells [141]. In fact, T cells found within the 
melanoma microenvironment are in a so-called state of ‘exhaustion’, as characterized by 
functional deficiency, impaired cytokine production, and upregulation of inhibitory receptors 
like PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and T cell immunoglobulin 
mucin domain containing molecule-3 (TIM-3) [142-145]. 
The suppressive environment of cutaneous melanoma is governed by chronic 
inflammatory conditions mediated by the activation of several inflammatory signaling 
pathways resulting in the activation of NF-κB and STAT3 [146-150]. Beside the accumulation 
of immune suppressor cells, chronic inflammatory processes also involve the production and 
secretion of pro-inflammatory cytokines, chemokines, growth factors and angiogenesis-
inducing molecules. These factors help the tumor to enable the described hallmarks thereby 
directly linking chronic inflammation with tumor development and progression [151-155]. 
Chronic inflammation in the melanoma microenvironment can be induced by infection-
associated inflammatory responses. Nevertheless, most likely immune activation occurs after 
traumatic injury and in non-pathogen-associated disease processes. This points towards an 
existence of other inflammatory signals able to induce inflammations in the absence of 
infections, i.e. under sterile conditions [156].  
In fact, it has been shown that viral infections play a role in the onset and progression of 
some cancers, including non-melanoma skin cancers [157, 158], whereas data on 
correlations between the presence of viruses and melanoma progression are rare [159]. 
Instead, members of the so-called damage-associated molecular pattern (DAMP) family like 
S100 proteins, known to induce ‘sterile inflammations’, are not only upregulated in melanoma 
but at least one S100 family member, S100B, also serves as diagnostic and prognostic 
marker [160, 161]. Further diagnostic but also therapeutic approaches in melanoma will be 
described in the next section. 
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 Melanoma in the clinic: diagnosis, management, and 
complications 
After introducing the high plasticity of melanoma cells, not only regarding phenotype but also 
function, it is not surprising that histological diagnosis as well as therapeutic approaches may 
prove difficult. In this section, the current state of diagnosis, management, and complications 
of malignant melanoma is described. 
V.1.3.1. Diagnostic and prognostic aides for melanoma 
As mentioned above, there are difficulties regarding the histological diagnosis of melanoma 
since it can occur in many different cytomorphological variants. Furthermore, melanomas can 
also resemble different tumors, such as carcinomas, sarcomas or germ cell tumors [162]. 
Therefore, immunohistochemical stainings for melanocytic differentiation markers are often 
applied in the diagnosis of melanoma [163]. The most frequently used marker in clinical 
Figure 1 Hallmarks of melanoma cells (adapted from Hanahan and Weinberg [50] with permission 
from Elsevier). Illustrated are examples of strategies and features displayed by melanoma cells, 
enabling them to circumvent barriers and regulatory mechanisms of normal, untransformed somatic 
cells. 
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practice is S100B, a member of the DAMP family, and a well-known ligand of the receptor for 
advanced glycation end-products (RAGE). Since reacting with about 90 % of melanomas, 
S100B represents a quite sensitive marker. Nevertheless, S100B is also expressed by 
adipocytes, chondrocytes, Schwann cells, and myoepithelial cells, as well as by some other 
benign and malignant neoplasms. Therefore, its value as melanocytic marker is limited [164, 
165]. In contrast, the melanosome-specific glycoprotein 100 (GP100) shows a higher 
specificity for melanocytic neoplasms, but a lower sensitivity compared to S100B [13-15]. 
Furthermore, also markers like MITF, TYR (tyrosinase), and MART-1 (melanoma antigen 
recognized by T cells 1) are used in routine diagnostic [166-168]. 
Besides immunohistochemical analyses, biopsy specimens are also used for determining the 
maximal diameters of lesion penetration, known as Breslow depth [169], as well as the level 
of invaded tissue layers, referred to as Clark level [117]. Although sharing similarities 
Breslow depth and Clark level measure two different things: tumor volume and metastatic 
potential [170]. The system most often used for staging melanoma is the American Joint 
Commission on Cancer (AJCC) TNM system, which is based on a combination of histologic 
and clinical characteristics. Histologic features comprise Breslow depth, mitotic rate, defined 
as number of mitoses per square millimeter, and ulceration. Among clinical features the 
absence or presence of lymph node metastases, or metastases to distant organs, as well as 
LDH levels are numbered. The analyzed criteria are then combined and assigned to four 
main stages (I to IV) that can also be subgrouped. In general, patients with lower stage 
melanomas have a better outlook regarding cure or long-term survival [171]. Accurate 
staging does not only provide important prognostic information but also steers the choice of 
further therapy. 
V.1.3.2. Melanoma management 
Early diagnosis combined with appropriate surgical removal is currently the best treatment 
option for melanoma [172, 173]. Whereas the prognosis for patients with small primary 
melanomas (AJCC stage IA), which have been successfully resected, is similar to healthy 
individuals, the median overall survival for patients with AJCC stage IV melanoma drops to 
7.5 months [174]. As soon as melanomas have spread and formed distant metastases, they 
become non-removable and difficult to treat. Over a long period, dacarbazine, an alkylating 
agent interfering with the growth of cancer cells, was the only worldwide-approved drug for 
stage IV melanoma patients without improving patient overall survival [175]. Although clinical 
trials using diverse combinations of chemotherapy and immunotherapy managed to increase 
response rates and alleviate toxic effects, they failed to provide evidence for prolonging 
survival of these stage IV patients [176, 177]. Important molecular characteristics, such as 
the role BRAF and NRAS mutations [35, 42], as well as the role of the immunosuppressive 
Introduction 
12 
tumor microenvironment [144, 178] resulted in a better understanding of melanoma 
pathogenesis. These advances in melanoma research where then rapidly translated into 
therapeutic approaches like immunomodulation and mutation-targeted therapy providing 
survival benefits for patients with metastatic melanoma [179, 180]. 
Between 2011 and 2014 the U.S. Food and Drug Administration (FDA) approved three 
targeted agents for the treatment of patients with advanced melanoma and mutations in 
BRAF: the two BRAF inhibitors vemurafenib and dabrafenib, as well as the ‘downstream’-
acting MEK inhibitor trametinib [176]. In Germany, only BRAF inhibitors vemurafenib and 
dabrafenib are approved whereas the MEK inhibitors trametinib and cobimetinib are planned 
for approval by the end of 2015. Since clinical trials comparing vemurafenib with dacarbazine 
were able to demonstrate significant benefits in median progression-free and overall survival, 
vemurafenib has been set as first-line treatment of advanced V600E BRAF-mutated 
melanoma [180]. Comparable results have been recorded in clinical trials with dabrafenib 
[181]. Also studies using the MEK inhibitors trametinib or cobimetinib were able to register 
survival benefits, endorsing a dual pathway inhibition strategy [182, 183].  
As described before, another member of the MAPK pathway, namely NRAS, is also often 
affected in melanoma. Until now, there are no targeted therapies against NRAS; however, as 
studies revealed enhanced MAPK signaling and aberrant cell cycle checkpoints in NRAS-
mutated melanomas, patients have been treated with MEK and CDK4/6 inhibitors in the hope 
to receive off-target effects. Indeed, clinical trials using MEK inhibitors [184], as well as 
combinations of MEK and CDK4/6 inhibitors resulted in partial responses of patients with 
NRAS-mutated tumors [185].  
For targeting advanced melanoma in a mutation-independent manner, targeted agents 
interfering with the control of immune checkpoints have been developed. For instance, 
effects of agonistic antibodies blocking CTLA-4, PD-1, or PD-L1, molecules involved in 
immunosuppressive signaling, have been investigated. The monoclonal anti-CTLA-4 
antibody ipilimumab is able to mediate inhibition of immune tolerance and induction of tumor 
regression in clinical trials, thereby resulting in a prolonged median overall survival of 
patients with stage IV melanoma [179, 186]. Ipilimumab was then approved for advanced 
melanoma in the U.S. and in Europe. Furthermore, antibodies targeting PD-1 and PD-L1 
interaction revealed significantly enhanced pro-survival effects and high response rates 
compared to ipilimumab when tested in clinical trials [187]. Two monoclonal anti-PD-1 
antibodies, pembrolizumab and nivolumab, were approved for advanced melanoma in the 
U.S. in 2014 and will get approval in Europe by mid-2015 [188, 189]. 
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Two cytokine-based immunotherapies have been approved, so far. For instance, interferon 
alpha-2b (IFNα-2b) is used as adjuvant for therapies aiming to overcome tumor-induced 
immune suppression. It functions by promoting anti-tumor immune responses via recruiting 
lymphocytes, activating dendritic cells (DC), and switching Th2-biased to Th1-mediated T cell 
responses resulting in enhanced cytotoxicity [190-195]. Another possibility is the treatment 
with high doses of IL-2. Although responses are only induced in about 17 % of the patients, 
the finding that approximately 5 % achieve durable complete responses led to its approval by 
the FDA [196-198]. 
Since 2010, the treatment of patients with stage IV melanoma has been continuously shifted 
from chemotherapy towards targeted immunotherapy. The high adaptation capacity of 
melanoma cells leading to the development of various resistance mechanisms, as well as 
drastic side effects limit recent advances of novel therapeutic approaches. An overview on 
described side effects and resistance mechanisms in melanoma will be provided in the next 
section. 
V.1.3.3. Complications in melanoma management 
Although the advances in immunotherapy bring new hope into the melanoma field, the recent 
therapeutic options still resemble a double-edged sword. In general, patients with advanced 
melanoma show an initial response to treatment resulting in prolonged overall and 
progression-free survival; however, the clinical benefits only last for a short period of time, 
and are often severely limited because of therapy-associated adverse effects.  
For instance, high-grade toxicities of BRAF inhibitors have been frequently recorded, here in 
over 15 % of the treated patients [199], and include dermatologic complications, such as 
rash, photosensitivity reactions, and hyperkeratosis, as well as arthralgia, fatigue, alopecia, 
nausea, and diarrhea. Furthermore, up to 26 % of patients treated with either vemurafenib or 
dabrafenib develop clinically significant cutaneous side effects, such as squamous cell 
carcinomas [200-202]. A phase III trial with 423 patients randomly assigned to treatment with 
either combined BRAF and MEK or single BRAF inhibition suggested that the observed skin 
toxicity is due to the development of a paradoxical MAPK pathway activation despite BRAF 
inhibition. The combination with MEK inhibitors significantly reduced the incidence of 
squamous cell carcinomas in this trial [203]. However, clinical trials also showed that MEK 
inhibitors themselves induce adverse effects at high frequencies, such as cutaneous toxicity, 
diarrhea and edema [182].  
As described above, findings of clinical trials testing combinations of BRAF and MEK 
inhibitors suggested that some of the adverse effects are mediated by a reactivation of the 
MAPK pathway. For verification and in order to investigate if such reactivation may be also a 
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reason for observed relapses, a large phase II clinical trial set up Sanger DNA sequencing 
and histological examinations of relapse tumor specimens. The analyses demonstrated that 
nearly all tumors display reactivations of the MAPK pathway with consequent elevation of 
phosphorylated ERK at time of resistance. A prominent mechanism is the upregulation of 
redundant paralogs of BRAF, namely CRAF or ARAF [204, 205]. Furthermore, progression 
of some patients was accompanied with the acquirement of new mutations of molecules 
within the MAPK pathway, including mutations in NRAS and MEK [206, 207]. Besides MAPK 
pathway reactivation, alterations in ERK1/2-regulated cell cycle events, activation of 
alternative signaling pathways, as well as chromatin-regulating events have been suggested 
as additional mechanisms of melanoma cell resistance against BRAF-targeted therapy [205, 
208-210]. For instance, Villanueva and colleagues identified several receptor tyrosine 
kinases (RTKs) to be differentially phosphorylated between pre-treatment and post-relapse 
samples. Indeed, pharmacological inhibition of the insulin-like growth factor 1 receptor (IGF-
1R) led to decreased viability of melanomas resistant to BRAF inhibitors [205]. Furthermore, 
enhanced expression of JARID1A, a histone demethylase, has been shown to induce 
chromatin remodeling, thereby transferring melanoma cells into a drug-tolerant state [211]. 
Unfortunately, also immunomodulatory therapeutic approaches are associated with high-
grade adverse side effects. For instance, the desired function of the anti-CTLA-4 or anti-PD-1 
antibodies, which is the activation of T cell-mediated anti-tumor responses, can also 
negatively affect the melanoma therapy due to adverse side effects. Among the most 
common clinical manifestations autoimmune disorders leading to entercolitis, hepatitis, 
dermatitis, neuropathy, and endocrinopathy, are listed. The ipilimumab-induced enterocolitis, 
which is present in 10 to 20 % of the treated patients, presents a potentially life-threatening 
disorder due to bowel perforation [212].  
Also cytokine-based adjuvant therapies have been demonstrated to result in adverse side 
effects in most of the patients. A clinical trial with 294 patients with malignant melanoma on 
high-dose IFNα-2B treatment demonstrated a high frequency of concomitant phenomena, 
such as influenza-like illness, fatigue, nausea, diarrhea, and neutropenia [213]. Furthermore, 
although showing low response rates in melanoma patients, treatment with high-dose IL-2 
can also be one of the most effective treatments since it can induce complete remissions in 
some of the patients. Nevertheless, it also belongs to one of the most toxic therapies. For 
instance, due to the massive inflammation caused by IL-2 patients can develop a capillary 
leak syndrome, which resembles the clinical picture of a septic shock. Additional adverse 
effects, such as pulmonary edema, hypotension, cardiac insufficiency, cerebral edema, and 
renal failure have been described [214, 215]. 
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By targeting tumor-intrinsic aberrations, and immunosuppressive features of melanoma cells 
great progress has been made in melanoma therapy. Besides improving the clinical benefits 
of these therapies, a major goal for future melanoma management will be an extended 
understanding of melanoma pathogenesis, immunosurveillance, and mechanisms leading to 
therapy resistance. For instance, only little is known about the pathways involved in the 
induction of a sterile inflammation, which is directly linked to the establishment of an 
immunosuppressive melanoma microenvironment. One of these pathways with a potential 
role in melanomagenesis might be regulated by the receptor for advanced glycation end-
products (RAGE). In the next main section, some information about characteristics of RAGE, 
its ligands, and its functions in health and disease is provided. 
V.2. The receptor for advanced glycation end-products (RAGE) 
The receptor for advanced glycation end-products (RAGE) is a pattern recognition receptor 
belonging to the immunoglobulin superfamily. Since its discovery in 1992 as a 
transmembrane receptor for advanced glycation end-products (AGEs), which are generated 
via non-enzymatic crosslinking of carbohydrates to proteins and other biological molecules, 
RAGE has not only been identified to bind several other ligands but also to have important 
functions in physiological processes, and more important as pathogenic factor of several 
diseases [216-222]. 
 Structure and polymorphism of RAGE 
The gene encoding for human RAGE, namely AGER, is located on the chromosome six 
within the major histocompatibility complex (MHC) III locus and contains eleven exons and 
ten introns. The leader sequence upstream of the coding region of AGER contains many 
functional elements, such as binding sites for transcription factors like NF-κB, specificity 
protein 1 (SP1), activator protein 1 and 2 (AP1/2), E-twenty-six 1 (ETS1), HIF-1, early growth 
response gene 1 (EGR-1), and for thyroid transcription factor 1 (TTF-1) [223-226]. 
Furthermore, several single nucleotide polymorphisms (SNPs) located within the promoter 
region of AGER have been reported. Among those the threonine to alanine substitution at 
position -374 (-374T/A), threonine to cysteine at -429 (-429T/C), and glycine to serine at +82 
(82G/S) have been listed. Additionally a 63 base pair deletion polymorphism has been 
described for the region encompassing -374. These promoter polymorphisms correlated in 
most studies with enhanced expression of the AGER gene [227-232]. In addition, also the 
presence of alternative promoters has been demonstrated [233].  
In 1999, Malherbe and colleagues successfully identified a secreted splice variant of RAGE, 
followed by several others [234]. Almost ten years later, in 2008, Hudson et al. published a 
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detailed study on RAGE isoforms showing that AGER transcripts are indeed, extensively 
modulated by alternative splicing. In total, 19 different splicing variants of RAGE have been 
described and labeled according the HUGO terminology: RAGE_v1 to RAGE_v19 [233].  
The most abundant protein form, hereinafter referred to as full-length RAGE (fl-RAGE), 
consists of 404 amino acids (aa) resulting in a molecular mass of 55 kDa. It contains a N-
terminal portion, comprising a signal sequence for secretion (1-22aa), three immunoglobulin 
domains (Ig domains, 23-317aa), as well as a transmembrane helix (343-363aa), and a short 
cytoplasmic tail at the C-terminus (364-404aa) [216, 218, 233]. According to the definition of 
Williams and Barclay from 1988, the Ig-like regions of RAGE are either of a so-called 
‘variable’ (V) type, or of a more ‘constant’ (C) character. The classification refers to the length 
of the amino acid sequence between conserved disulfide bonds [216, 235]. Nevertheless, it 
has been suggested that the V domain (23-116aa) of RAGE forms a structural unit with the 
connected C1 domain (124-221aa); a formation (VC1) resulting in a large cationic surface 
area, which is required for at least some of the ligand binding properties. In contrast, it has 
been reported that the C2 domain (277-317aa) attached to the VC1 unit via a flexible linker, 
is able to function in a fully independent manner [236-238]. Interestingly, the cytoplasmic tail 
does neither have enzymatic activity nor homology to any known signaling domains, thereby 
complicating the search for cytosolic interaction partners [216]. The cytoplasmic part of 
RAGE can be subdivided in three parts: The part laying proximal to the cell membrane is 
characterized by a high proportion of basic amino acids, the central region by acidic amino 
acids, whereas the C-terminal part is less conserved [239].  
Alternative splicing of the AGER transcripts can result in proteins that differ tremendously 
from fl-RAGE, not only regarding their structure but also their function. Beside soluble 
variants of RAGE lacking both, transmembrane region and cytoplasmic tail, other variants 
show extensive changes within the extracellular domain. These include changes within the V 
domain (RAGE_v4, v5) or widespread deletions of the extracellular domain (RAGE_v2 and 
v13), thereby potentially enhancing the ligand spectrum of the receptor [233]. Recent studies 
provided evidence of the existence of a complex regulation machinery enabling the selection 
of alternative AGER exons depending on the intracellular concentration or activity of nuclear 
RNA binding proteins, such as the heterogeneous nuclear ribonucleoprotein H (HNRNP H) 
and A1 (HNRNP A1), and the transformer2-β1 (TRA2-β1) protein [240, 241]. Indeed, studies 
were able to demonstrate differentially expressed RAGE splicing forms in Alzheimer’s 
disease and their association with neurodegeneration [241, 242]. This indicates that the 
regulation of RAGE splicing or of the splicing frequency may affect the functional outcome of 
total RAGE.  
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Another way to regulate the function of a protein is posttranslational modification. Fl-RAGE 
as well as its isoforms can be posttranslationally modified by disulfide bond formation, 
phosphorylation, proteolysis, and glycosylation. Disulfide bond formation can occur 
intermolecular between conserved cysteines (C259, C301) of the C2 domain [243], or of the 
V1 domain [238]. Indeed, fluorescence resonance energy transfer (FRET) could show that 
RAGE molecules can form homodimers, as well as homooligomers and heterodimers with 
heparin sulfate proteoglycans (HSPGs) and Toll-like receptors (TLRs) [244]. Proximity 
ligation assays demonstrated preformed complexes of RAGE and HSPG, which increased in 
number after stimulation with high-mobility group box 1 protein (HMGB1), possibly as a result 
of receptor complex stabilization upon ligand binding [245, 246]. Similar results were also 
found for RAGE and TLR-2 upon stimulation with S100B [247]. Wei and colleagues were 
able to demonstrate that this multimerization is not only eligible but rather represents a 
quality control mechanism. Converting the two cysteines to serines significantly reduced 
RAGE expression on the cell surface in their experiments [243]. If different splicing variants 
of RAGE can assemble to form multimers remains to be investigated.  
Furthermore, RAGE can be posttranslationally modified by phosphorylation as well as by 
glycosylation within the V domain. For instance, RAGE is phosphorylated by MAP kinases 
such as ERK1/2 upon HMGB1 binding [248, 249]. Kang and colleagues showed that a 
phosphorylation at serine 377 enabled the RAGE protein to translocate into the mitochondria, 
where it influences the bioenergetics of the cell [249].  
Proteolysis of membrane-bound RAGE by enzymes like matrix metalloproteinases and γ-
secretase can produce soluble ectodomain fragments, fragments containing the 
transmembrane domain, as well as soluble forms of the cytoplasmic domain. Matrix 
metalloproteinases, which are known to exert such function are MMP9 and ADAM10 (a 
disintegrin and metalloproteinase 10). The ectodomain can be either secreted into the 
extracellular space or localized into intracellular vesicles [250-252] whereas the C-terminal 
fragment is found in the cytoplasm but has also been demonstrated to be transported into the 
nucleus [250]. 
The structure of a protein is closely related to its function. In terms of RAGE, the complexity 
is extended due to the variety of isoforms and formation of tissue-specific heterocomplexes 
on the cell surface. In addition, a tissue-specific expression of ligands and modulators allows 
an individually regulation of RAGE proteins, leading to inconsistent findings regarding its 
functional role.  
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 RAGE ligands 
As mentioned before, RAGE is listed among the pattern recognition receptors. However, 
RAGE does not recognize a common molecular pattern; instead, it binds to a broad spectrum 
of mostly negatively charged ligands.  
V.2.2.1. Advanced glycation end-products (AGEs) 
Advanced glycation end-products (AGEs) are generated by a frequent nonenzymatic 
glycation and oxidation of proteins and lipids [253]. Increased levels of protein glycosylation 
have been found to be associated with ageing, diabetes mellitus (DM), active inflammation, 
as well as malignancies, such as melanoma [254-256]. The generation of AGEs results in the 
increase of the overall negative surface charge of the substrate, thereby enabling binding to 
RAGE.  
V.2.2.2. Damage-associated molecular pattern molecules (DAMPs) 
Damage-associated molecular pattern molecules, from here on referred to as DAMPs, are 
either actively or passively released cellular molecules, many of them proteins, which induce 
responses following stress situations like nutrient deprivation, hypoxia, trauma, and 
chemotherapy treatment. As the endogenous homolog to pathogen-associated molecular 
patterns (PAMPs), DAMPs can activate the innate immunity, thereby providing a way to 
induce systemic inflammatory responses in the absence of an infection. DAMPs comprise 
various molecules such as the HMGB1 protein, S100 family members, heat shock proteins 
(HSP), uric acid, heparan sulfate (HS), adenosine triphosphate (ATP), and DNA [156, 257]. 
Since HMGB1 and members of the S100 family are well-described ligands for RAGE, and 
also known to be involved in melanomagenesis [258-262], they will be used as examples for 
describing main characteristics of DAMPs, also in regard to their role in malignant melanoma. 
 S100 protein family 
The S100 protein family contains 21 small EF-hand calcium binding proteins, which have 
been named according to their solubility in 100 % saturated ammonium sulfate [263-265]. 
The majority of the S100 proteins all cluster to one region of the chromosome 1 (1q21), 
which is highly susceptible to deletion and rearrangements, linking S100 proteins and 
carcinogenesis [266]. 
Although S100 family members share high similarities in their amino-acid sequence and tri-
dimensional structure they are not always functionally redundant [267, 268]. For instance, 
structural similarities enable S100B and S100A2 to interact with the tumor suppressor P53; 
however, the interaction with S100B leads to its inhibition, while S100A2 is able to activate 
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P53 [269, 270]. The sequence and structural homology of S100 family members allows them 
to form homo- and heterodimers, as well as oligomers [271, 272].  
The cytosolic function of S100 proteins, including their role as calcium sensors, is enlarged 
by the secretion of distinct S100 family members. Individual S100 proteins display cytokine-
like functions, involved in a wide range of biological processes such as proliferation, 
migration, invasion, inflammation and differentiation [273-275]. Since these proteins lack a 
conventional secretion signal, it is still unclear whether the extracellular S100 dimers or 
oligomers are actively secreted by living cells or passively released upon cellular 
disintegration e.g. during necrosis [273, 275]. Recent studies suggested that RAGE might 
participate in the translocation of S100 proteins, such as S100B [276, 277]. 
As mentioned earlier, S100B is an established immunohistological as well as serum 
biomarker for melanoma although its role in melanomagenesis remains unknown [164]. 
Certainly, extracellular S100B as well as other S100 proteins are able to interact with a 
variety of cell-surface receptors, including RAGE. Besides S100B, also other S100 family 
members are suggested to play a role in melanoma. For instance, S100A2, which is believed 
to function as a tumor suppressor, is downregulated in melanoma, thereby showing a 
negative correlation to S100B expression [278-280]. Other members, such as S100A4, 
S100A6, S100A8 and S100A9, are linked to progression and metastasis formation in 
melanoma, although studies revealed partly conflicting results [279, 281-283]. Despite recent 
advances in S100 protein biology, there is still a need to understand how each family 
member contributes to the pathogenesis of malignant melanoma. 
 High-mobility group box 1 (HMGB1) protein 
The HMGB1 protein has an ambivalent character: On the one hand it has been described as 
a non-histone DNA-binding nuclear protein [284, 285], on the other hand several cytosolic as 
well as extracellular functions have been reported for HMGB1 [286-288]. Within the nucleus 
HMGB1 binds DNA in conformation-dependent, but sequence-independent manner and 
functions as DNA chaperone, participates in DNA replication and repair, and acts as 
transcriptional regulator [284, 289]. Active secretion of HMGB1 requires the inhibition of its 
nuclear import, mediated via posttranslational modifications, such as phosphorylation, 
methylation, and acetylation [290-292]. Similar to the S100 family members HMGB1 lacks 
conventional secretion signals, thereby depending on non-classical pathways [293]. 
HMGB1 has not only been demonstrated to be upregulated in several solid tumors, including 
melanoma, but to be directly associated with increased invasion and metastasis [262]. 
Secreted HMGB1 is thought to directly promote metastasis formation through its ability to 
induce cell migration, to modulate the adhesion potential of cells, and to modify extracellular 
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matrix composition [289, 294]. In addition, Bald and colleagues were able to demonstrate 
that the UV radiation-induced progression of primary tumors in the genetically engineered 
melanoma mouse model Hgf-Cdk4R24C could be abolished by pharmacologic inhibition of 
extracellular HMGB1 [295]. In its function as a transcriptional regulator, and by enhancing the 
activity of NF-κB it can induce the melanoma inhibitory activity (MIA) protein in an indirect 
manner. MIA is a secreted protein, which is low expressed in benign nevi but highly in 
metastatic melanoma, and which has been shown to enhance the migrative and invasive 
capacity of tumor cells by binding to fibronectin and to integrins [262, 296].  
In general, engagement of RAGE by a ligand triggers the activation of key cell signaling 
pathways. The current knowledge on involved molecules and activated or repressed 
transcription factors will be outlined in the next section. 
 RAGE signaling 
Engagement of RAGE by its ligands elicits the immediate activation of multiple signaling 
pathways, dependent on the specific ligand, environmental conditions, and on the cell type. 
As mentioned before, RAGE is able to form homo- or heteromultimers within the plasma 
membrane. It is believed that RAGE pre-assembles already in the absence of a ligand, and 
that receptor engagement by multimeric ligands stabilizes these constitutive complexes, 
thereby shifting the equilibrium from monomers to higher order oligomerizations [297]. This 
explains why diverse ligands might have a different outcome regarding pathway activation 
and subsequent transcription factor induction. If the observed complexes consist only of full-
length RAGE molecules, or if different RAGE isoforms contribute has not been described, 
yet. Also differences in receptor-ligand affinities leading to different dissociation rates might 
influence receptor activation and consequently signal transduction. RAGE has been shown 
to bind glycosylated HMGB1 with a higher affinity than the unmodified counterpart [248], 
thereby probably inducing a prolonged and enhanced receptor activation [298]. 
As mentioned above, the investigation of mechanisms behind downstream events induced 
by ligand engagement of RAGE has been impeded by the unique nature of the cytosolic tail 
of the receptor. Recent studies applying yeast two-hybrid systems as well as 
immunoprecipitation assays suggested the protein diaphaneous 1 (DIA-1) and the MAP 
kinases ERK1 and 2 to be direct interactors [239, 299]. Furthermore, it has been shown that 
the cytosolic tail of RAGE gets phosphorylated at S391 by protein kinase C type ζ (PKCζ) 
upon ligand binding, then serving as a docking station for TIRAP (toll-interleukin 1 receptor 
(TIR) domain containing adaptor protein) and MyD88 (myeloid differentiation primary 
response gene 88) [300]. TIRAP and MyD88 are well-known adaptor proteins for TLR2 and 
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TLR4, suggesting that the described receptor complexes of RAGE and TLRs at the cell 
surface represent not the only connection of these pathways.  
Molecules interacting with the cytosolic portion of RAGE are able to specifically activate the 
MAPK cascade, and family members of the RHO (RAS homolog) small G-proteins, such as 
RAC-1 (Ras-related C3 botulinum toxin substrate 1) and CDC42 (cell division control protein 
42), leading to the induction of several transcription factors [301, 302]. The RAGE-dependent 
activation of the MAPK pathway activates ERK1/2 and leads to an enhanced phosphorylation 
of the P38 MAP kinase and the stress-activated protein kinase/c-Jun-NH2-terminal kinase 
(SAPK/JNK) [222]. In neutrophils, RAGE signaling was abolished by application of PI3K 
inhibitors but not affected by inhibition of ERK or P38 [303], indicating the presence of tissue-
specific modulators interacting with RAGE. These cytoplasmic signaling cascades result in 
the induction of transcription factors like NF-κB, AP-1, SP-1, and CREB [301, 302, 304-306].  
Beside the transcription factor-based regulation of gene expression, RAGE has been also 
implicated to function within epigenetic regulation mechanisms. For instance, RAGE has 
been shown to induce the thioredoxin interacting protein (TXNIP), which subsequently alters 
chromatin conformation by histone remodeling, resulting in a higher accessibility for distinct 
transcription factors [307]. 
Interestingly, RAGE does not only induce a diverse set of other signaling molecules, but also 
its own expression via a feed-forward loop. In fact, RAGE uses a simple strategy: By 
activating transcription factors, such as NF-κB, which are able to bind to functional elements 
within the RAGE promoter, it consequently induces its own expression [308, 309]. This 
strategy enables the cell to generate fast responses towards stress conditions, but when 
deregulated, it can also lead to the hyperactivation of important signaling pathways, and 
consequently to pathological features. 
 Function of RAGE in health and disease 
In normal healthy tissues RAGE is expressed at low to undetectable levels. The only 
exception is the lung, which demonstrates a high basal expression of RAGE [310, 311]. 
Pathological disorders are often connected with an upregulation of the RAGE protein, as well 
as of its ligands. In this section, physiological characteristics, as well as features of 
pathological RAGE signaling are described that are found in the human system or by 
applying mouse models (the murine homolog of RAGE will be referred to as Rage). 
V.2.4.1. Physiological function of RAGE signaling 
Since RAGE is expressed in only minor amounts under physiological conditions, its 
relevance during pathological processes has been in focus of research. Even in the lung, the 
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role of RAGE remains unclear although data indicate that it supports the organ’s well-
functioning [312, 313]. 
Genetically engineered Rage knockout (Rage-/-) mice were viable, displayed normal 
reproductive fitness, and did not develop spontaneous diseases up to the age of 6 months 
[314].  
A closer examination of Rage-/- mice uncovered a potential role in neuronal signaling, 
indicated by behavioral abnormalities, such as higher activity in darkness, higher sensitivity 
to auditory signals, and minimal effects on the animals' spatial learning ability [315]. Other 
studies observed an osteosclerotic-like phenotype in Rage-/- mice. Analyzing in vitro 
differentiated Rage-/- osteoclasts, Zhou and colleagues were able to demonstrate defects in 
their cytoskeletal reorganization, adhesion, and function [316]. Furthermore, Rage has been 
reported to be required for neurite outgrowth in regeneration after nerve injury as 
pharmacological blockade showed antagonistic effects [317, 318]. 
Most studies investigating the physiological function of Rage have not considered potential 
compensatory mechanisms like the upregulation of Toll-like receptors. Small molecule 
inhibitors targeting RAGE and their application in clinical trials, as for Alzheimer’s disease 
[319], will probably unveil undiscovered tasks of RAGE signaling.  
V.2.4.2. Function of RAGE in inflammatory responses 
Due to its genetic location within the MHC class III region, a role for RAGE in inflammatory 
responses has been assumed early. Neighboring genes comprise TNF-α as well as several 
complement components [228, 320]. Further notion came from the analysis of signaling 
pathways downstream of RAGE that are similarly activated in inflammatory conditions. 
Evidence has been provided by comparing Rage-/- and wildtype (wt) mice under different 
inflammatory settings. Models predominantly inducing adaptive immune responses, such as 
the induction of enterocolitis or of a delayed type hypersensitivity (DTH), revealed no 
differences between the two mouse strains. However, settings largely dependent on the 
innate immunity like the cecal ligation and puncture (CLP) -mediated sepsis showed different 
patterns. In contrast to wt mice, mice lacking the Rage protein were protected and survived 
the induced septic challenge [314]. 
In humans, an increased expression of RAGE has been reported for a diverse set of acute 
and chronic inflammatory diseases and diseases accompanied with inflammatory conditions, 
such as psoriasis [321, 322], rheumatoid arthritis [323], atherosclerosis [324], diabetes 
mellitus [325], Alzheimer’s disease (AD) [24], and multiple sclerosis [326]. In general, RAGE 
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functions via inflammation-associated cell recruitment [219], production and secretion of pro-
inflammatory cytokines [218, 327], and ROS [328]. 
The main cause of mortality in late diabetes is its association with sclerotic cardiovascular 
diseases, leading to heart attacks and strokes [329]. Interestingly, vasculature retrieved from 
individuals suffering from diabetes showed an enhanced RAGE expression [325]. Indeed, 
sustained RAGE signaling has been connected with endothelial dysfunction defined by 
deregulated cytokine secretion and altered membrane composition [330, 331]. In addition, 
Muhammad and colleagues were able to show that Rage contributes to inflammation and 
ischemic brain damage as chimeric mice, generated by transplanting Rage-/- bone marrow to 
wt mice, displayed significantly reduced infarct sizes [332].  
Since the major histopathological hallmark of the Alzheimer’s disease is the amyloid plaque, 
consisting of RAGE ligand amyloid-β (Aβ) peptide, a connection between AD pathogenesis 
and RAGE signaling has been hypothesized [333, 334]. As mentioned above (V.2.1), two 
independent studies were able to demonstrate a differential expression of RAGE splicing 
forms in AD. More specifically, higher expression of membrane-bound RAGE and lower 
levels of soluble forms, which usually impair RAGE signaling due to their function as decoy 
receptors, were directly associated with neurodegeneration [240, 241]. In fact, sustained 
RAGE signaling has been demonstrated to mediate blood–brain barrier interruption and 
neuronal dysfunction by inflammation-associated processes [335, 336]. 
An elevated AGE and RAGE expression was also found in the hippocampi of multiple 
sclerosis patients, similar to AD patients [326, 334]. Most interestingly, a recent study was 
able to demonstrate decreased levels of soluble RAGE in the cerebrospinal fluid of MS 
patients at clinical onset [337], indicating that alternative splicing is a common mechanism 
behind the deregulation of RAGE signaling leading to chronic inflammatory processes. 
Epidemiologic findings as well as studies on different mouse models have highlighted a 
strong contribution of chronic inflammation and accompanied tissue remodeling and 
maladaptation to tumor development [153, 338]. It is now believed that most solid tumors, 
including melanoma, are surrounded by an inflammatory microenvironment [154]. The role of 
RAGE in this context as well as other tumor-intrinsic features of RAGE will be described in 
the next section. 
V.2.4.3. Role of RAGE in tumor development, growth, and progression 
As described in the last sections, various RAGE isoforms, diverse signaling pathways, as 
well as differential expression of RAGE modifiers can lead to different cell- and tissue-
specific net effects of RAGE signaling. Therefore, findings for one cell type cannot be easily 
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transferred to another. However, this holds also true for the role of RAGE in tumorigenesis. 
There are some common patterns, but also cancer-specific differences. In the first part of this 
section, a general overview will be presented about the role of RAGE in the onset and 
progression of tumorigenesis, guided by selected examples. In the second part, the impact of 
RAGE signaling on melanomagenesis will be outlined. 
 RAGE: Connecting inflammation and tumorigenesis 
The importance of RAGE signaling in tumor development has been recently illustrated by a 
meta-analysis comprising data of 27 studies. The study by Xia and colleagues revealed that 
some promoter polymorphisms of RAGE were connected with an either increased or 
decreased risk of lung cancer. More specifically, the 82G/S polymorphism was associated 
with significantly increased tumor risk, while the -374T/A polymorphism was linked to 
reduced lung cancer susceptibility [339]. Another study, investigating oral squamous cell 
carcinoma (OSCC), correlated the -429T/C polymorphism with increased susceptibility, 
elevated risk of late-stage and large-size oral tumors [340]. 
RAGE expression has been detected in a variety of human tumors, such as breast [341], 
colon [341, 342], gastric [343], lung [344], prostate [345], liver tumors [341], OSCC [346], as 
well as melanoma [280, 347]. The role of RAGE depends on the different types of tumors 
and coherent signaling networks. For instance, in some tumors, such as OSCC, RAGE 
promotes primary tumor growth, but not metastasis formation [346]. In contrast, gastric and 
prostate cancers upregulate RAGE in terms of invasion to new metastatic sites [343, 345]. In 
the case of gastric cancer, RAGE expression represents an independent prognostic marker, 
correlating to histological grade, nodal status, metastasis status, and AJCC stage [348] 
Already in the year 2000, Taguchi and colleagues suggested a tumor-promoting role for 
RAGE. They were able to connect Rage expression with the growth capacity of gliomas and 
lung carcinomas in xenograft mouse models, as well as in phorbol 12-myristate 13- acetate-
inducible papillomas in mice overexpressing v-Ha-ras transgene [222]. 
In 2008, Gebhardt and colleagues provided additional evidence for a role of RAGE in skin 
carcinogenesis. They were able to demonstrate a higher resistance of Rage-/- mice to 
chemically-induced skin carcinogenesis compared to wt mice. Besides a lower tumor 
incidence and lower tumor multiplicities, 12-O-tetradecanoylphorbol-13-acetate/7,12-
dimethylbenz-[a]-anthracene (TPA/DMBA) treatment revealed hampered inflammatory 
responses in Rage-/- mice accompanied with decreased levels of pro-inflammatory mediators 
and epidermal hyperplasia [349], thereby providing evidence for a Rage-driven positive 
signaling feed-forward loop that creates a tumor-promoting chronic inflammation. In line with 
the findings for pancreatic cancer [249], and colitis-associated carcinogenesis [342], the 
Introduction 
25 
study by Gebhardt et al. provided evidence of an impaired infiltration of myeloid precursor 
cells, implying that Rage signaling also contributes to the recruitment of innate immune cells. 
Generated bone-marrow chimera proved that Rage expression on immune cells, and not on 
keratinocytes or endothelial cells, mediated cell recruitment, inflammation, and consequently 
epidermal hyperplasia [349]. 
Kang and colleagues investigated the role of RAGE in the pathogenesis of pancreatic tumors 
and found, that Rage-/- mice were resistant to mutant Kras-induced pancreatic tumorigenesis 
[350]. Investigating the mechanism behind the RAGE-dependency, they demonstrated that 
cytosolic RAGE directly induces tumor growth survival by altering bioenergetics of tumor 
cells. Indeed, HMGB1-induced phosphorylation of RAGE leads to its mitochondrial 
translocation, where it stimulates ATP production [249]. Furthermore, they observed that 
RAGE can protect pancreatic tumor cells from ROS-induced cell damage [351], as well as 
cell damage by chemotherapy-induced genotoxic stress in an autophagy-dependent manner. 
shRNA-mediated interference was able to abolish the ATP production as well as its pro-
survival effects on murine pancreatic tumor cells in vivo as demonstrated by the analysis of 
apoptosis marker. Autophagy-mediated pro-survival effects have not only been 
demonstrated for pancreatic but also for gastric cancer [352]. Beside these tumor cell-
intrinsic effects, a decreased infiltration of CD11b-positive inflammatory cells was observed in 
the microenvironment of tumors with impaired Hmgb1/Rage axis. Comparing normal tumor 
growth between wt and Rage-/- mice further demonstrated that also Rage on stroma cells has 
a tumor-promoting function, as Rage-/- mice displayed significantly decreased tumor growth 
and ATP production [249]. In line with this finding, Turovskaya and colleagues demonstrated 
a resistance of Rage-/- mice to colitis-associated carcinogenesis (CAC) partly caused by the 
inability of Rage-/- mice to sustain a tumor-promoting chronic inflammation. Indeed, they 
found a decreased number of infiltrating myeloid precursor cells [342].  
Most data suggest that RAGE is commonly overexpressed in most types of solid tumors. 
This is in sharp contrast to the situation found in the lung, where RAGE is highly expressed 
in healthy tissue but downregulated in non-small cell lung carcinomas (NSCLCs), squamous 
cell lung carcinomas, adenocarcinomas, as well as in benign lung hamartomas [312, 313]. 
This opposite direction highly suggests an involvement of RAGE in the well-functioning of 
lung cells. Comparable results have been reported for rhabdomyosarcoma, which is a highly 
malignant tumor of skeletal muscle origin, where RAGE expression also resulted in a more 
benign phenotype with reduced proliferation, migration, and invasiveness [353]. 
As explained in section V.2.3 there are various possibilities explaining these tissue-specific 
differences in RAGE signaling. In terms of tumor development, the study by Jules and 
colleagues highlighted an important explanation. They were able to show that distinct RAGE 
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isoforms differentially affect tumor cell properties, such as migration, invasion, adhesion and 
viability in C6 glioma cells [354]. This illustrates the importance of investigating the role of 
RAGE and its isoforms specifically in the growth and progression of malignant melanoma. 
Therefore, the next section addresses effects of RAGE on melanomagenesis. 
 RAGE signaling and it impacts onto the pathogenesis of malignant 
melanoma 
Already in 1999, Masaki and colleagues suggested that oxidative stress-induced formation of 
advanced glycation end products (AGE) might be involved in melanomagenesis [355]. 
Indeed, the administration of AGEs has been shown to successfully induce melanoma 
growth, migration and invasion in vitro [356]. Furthermore, in vivo evidence for a role of 
AGEs has been provided by the fact that administration of a DNA aptamer directed against 
AGEs (AGE-aptamer) significantly decreased melanoma growth in a xenograft mouse model 
[357]. As mentioned before (V.2.2), melanoma cells have also been shown to express other 
RAGE ligands, such as members of the S100 family [164] and HMGB1 [262]. Most 
importantly, expression of these ligands have been often directly connected to melanoma 
onset and progression [262, 279]. 
Not only ligands for RAGE but also the receptor itself might play a role in the pathogenesis of 
melanoma as indicated by the detection of RAGE in melanoma tissue [347]. In fact, the 
application of an anti-RAGE blocking antibody has been shown to abolish the tumor-
promoting effects of AGE stimulation. Applying xenograft transplantation models, similar 
effects of anti-RAGE antibodies on melanoma growth have been demonstrated in vivo. More 
specifically, they showed that upon subcutaneous injection of melanoma cells athymic mice 
showed a two - fold reduction in tumor size by intraperitoneally-administered anti-RAGE 
antibodies compared to IgG-treatment. Histological analysis of harvested tumor tissues did 
not reveal any differences in vascularization [356]. In contrast, the impaired tumor growth 
induced by application of an AGE-aptamer was associated with a significantly reduced 
angiogenesis [357]. However, if the observed in vivo effects have been mediated by tumor 
cells or by surrounding stroma cells could not be addressed in these settings.  
Recent studies tried to get deeper insights into the tumor-cell intrinsic role of RAGE in 
melanoma. For instance, Meghnani and colleagues overexpressed one human melanoma 
cell line with RAGE and studied accompanied effects. They found characteristics of an EMT-
like process, such as mesenchymal-like morphologies, higher migration abilities and reduced 
proliferation properties. The morphological and functional alterations have been 
accompanied with a further upregulation of the RAGE ligand S100B and downregulation of 
P53, ERK1/2, cyclin E and NF-κB [358]. The fact that melanoma cells usually depend on a 
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sustained MAPK and NF-κB activation, as well as the experimental set up in this analysis, 
focusing on a single melanoma cell line, requires additional experiments in order to clarify if 
these findings are cell-type or melanoma-specific. When implanting the RAGE 
overexpressing melanoma cells into mice, they reported an increased tumor growth 
compared to control cells, which could be partly reversed when mice were additionally 
treated with anti-RAGE antibodies [359]. Another study tried to get more insights into tumor-
cell intrinsic functions of RAGE by RNAi-mediated RAGE silencing. Using two different 
human melanoma cell lines they found conflicting results regarding the influence of RAGE 
onto cell migration. Since differences regarding the oligomerization state of RAGE on the cell 
surface between the two cell lines were noted, differential RAGE isoform expression and 
subcellular localization were claimed to be important determinants for the regulation of its 
function in tumor progression [360]. Indeed, Leclerc and colleagues could demonstrate a 
differential expression of fl-RAGE and sRAGE in melanoma. They found fl-RAGE to be 
upregulated between stage III and stage IV tumors, whereas sRAGE showed an inverse 
correlation [280]. Recently, our group was able to demonstrate that diminished sRAGE and 
esRAGE levels are indeed prognostic marker for malignant melanoma [361]. 
Beside the findings of the few functional studies, the tumor-cell-intrinsic role of RAGE in 
melanoma and its impact on the ‘melanoma hallmarks’ remains unclear. In this study, 
different experimental approaches were used, such as RAGE overexpression, RNAi-
mediated interference of RAGE in murine and human melanoma cell lines, and induction of 
genotoxic stress, to clarify unsolved questions. These approaches as well as chosen read-
out systems are described in the next section. 
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VI. Material and Methods 
VI.1. Materials 
Reagents and kits Company Catalog # 
20 % sodium dodecyl sulfate (SDS) G-Biosciences 786016 
2- [4 - (2 – hydroxyethyl) piperazin-1- yl ] 
ethanesulfonic acid (HEPES) 
Carl Roth HN78.1 
2-(4-aminophenyl)-1H-indole-6-carboxamidine 
(DAPI) 
Roche Diagnostics 10236276001 
5-(6)-carboxyfluorescein diacetate succinimidyl 
ester (CSFE) 
affymetrix 650850 
7-aminoactinomycin (7-AAD) viability staining 
solution 
affymetrix 699350 
AlamarBlue® Invitrogen DAL1100 
Albumin fraction V Carl Roth 8076 
Amersham ECL prime western blotting 
detection reagent 
GE Healthcare RPN2232 
Ammonium persulfate solution (APS) Carl Roth 9592 
Calcium chloride (CaCl2) Carl Roth CN93.1 
Complete mini protease inhibitor cocktail Roche Diagnostics 04693159001 
Cultrex® BME cell invasion assay TREVIGEN 3455096K 
Dako antibody diluent Dako S0809 
Dako fluorescent mounting medium Dako S302380-2 
Dako peroxidase block solution Dako S2023 
DCFDA - cellular reactive oxygen species 
detection assay kit 
abcam ab113851 
Endofree plasmid maxi kit QIAGEN 12362 
Ethylene diamine tetraacetic acid (EDTA) Gerbu 1034 
Glycerine Carl Roth 3783.1 
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HIER citrate buffer ZYTOMED SYSTEMS ZUC028 
Hoechst 33342 Thermo Scientific 62249 
Immobilion PVDF membrane pore size 0.45 µm Merck Millipore IPVH00010 
Methanol Sigma-Aldrich 32213 
Phosphate buffered saline (PBS) Biochrom L182-50 
Pierce BCA protein assay kit Thermo Scientific 23225 
Potassium chloride (KCl) Carl Roth 6781.3 
RevertAid first strand cDNA synthesis kit Thermo Scientific K1622 
RNase-free DNase set QIAGEN 79254 
RNeasy mini kit QIAGEN 74106 
Rotiphorese® gel 30 Carl Roth 3029 
Skim milk powder Sigma-Aldrich 70166 
Sodium chloride (NaCl) Sigma-Aldrich 31434 
SYBR Green PCR master mix Applied Biosystems 4309155 
Tetramethylethylenediamine (TEMED) Carl Roth 2367 
Triton® X 100 Carl Roth 3051 
Tween® 20 Applichem A1389 
Vybrant Violet DyeCycle Invitrogen V35003 
Table 1 Reagents and kits          
 
Cell culture reagents Company Catalog # 
2-Mercaptoethanol Gibco®  
Life Technologies 
31350-010 
Corning™ cell scraper Sigma-Aldrich CLS3010 
Dimethylsulfoxide (DMSO) Carl Roth A994 
DMEM AQmediaTM Sigma-Aldrich D0819 
Dulbecco’s phosphate buffered saline Sigma-Aldrich D8537 
Fetal calf serum (FCS) Biochrom S0415 
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Human melanocyte growth supplement (HMGS) 
100x 
Gibco®  
Life Technologies 
S0025 
Lipofectamine® LTX reagent Life Technologies 15338100 
Lipofectamine® RNAiMAX transfection reagent Life Technologies 13778075 
Medium 254 Gibco®  
Life Technologies 
M254500 
Mission® lentiviral transduction particles Sigma-Aldrich SHCLNV 
Non-essential amino acids (NEAA) Sigma-Aldrich M7145 
Opti-MEM® I reduced serum medium Gibco®  
Life Technologies 
31985062 
Penicillin-Streptomycin Sigma-Aldrich P4333 
Stealth RNAi™ siRNA negative control, med 
GC 
Life Technologies 12935300 
Stealth RNAi™ siRNA targeting ager mRNA Life Technologies 1299001 
Trypsin-EDTA solution Sigma-Aldrich T3924 
Table 2 Cell culture reagents 
 
Inhibitors Company Catalog # 
Doxorubicin Sigma-Aldrich D1515 
Leptomycin B (LMB) Cayman  10004976 
Mitomycin C Carl Roth 4150 
Z VAD FMK Invivogen tlrl-vad 
Table 3 Inhibitors 
 
Antibodies Company Catalog # 
Primary Antibodies 
Alexa Fluor 488 Annexin V Life Technologies A13201 
Isotype rabbit IgG Dianova DLN13124 
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Mouse-anti-RAGE abcam ab54641 
Rabbit-anti-Histone 3 New England Biolabs 5192 
Rabbit-anti-RAGE abcam ab37647 
Rabbit-anti-RAGE SantaCruz sc5563 
Rabbit-anti-βACTIN/βActin Cell Signaling 
Technology 
mAb5125 
Rabbit-anti-βCATENIN  Cell Signaling 
Technology 
mAb9582 
Secondary Antibodies 
Goat-anti-rabbit Cy3 Dianova 111165045 
Goat-anti-rabbit HRP New England Biolabs 7074 
Anti-mouse EnVisionTM HRP AEC+ Dako K400511-2 
Anti-rabbit EnVisionTM HRP AEC+ Dako K400911-2 
Table 4 Antibodies 
 
Analysis software Source 
7500 Software v2.0.5 Applied Bioscience 
BD FACSDivaTM Biolegend 
CELLO http://cello.life.nctu.edu.tw/; [362] 
cNLS Mapper http://nls-mapper.iab.keio.ac.jp/cgi-
bin/NLS_Mapper_form.cgi; [363] 
FlowJo 7.2.2. FlowJo 
GraphPad Prism 5 GraphPad Prism 
iControl 1.10©2012 TECAN 
ImageJ National Institute of Health (NIH) 
NDP.view2 Hamamatsu Photonics K.K. 
NetNES http://www.cbs.dtu.dk/services/NetNES/; [364] 
NetNGlyc 1.0 http://www.cbs.dtu.dk/services/NetNGlyc/; [365] 
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NetOGlyc 3.1 http://www.cbs.dtu.dk/services/NetOGlyc/; [366] 
NetPhos 2.0 http://www.cbs.dtu.dk/services/NetPhos/; [367] 
NetPhosK 1.0 http://www.cbs.dtu.dk/services/NetPhosK/; [368] 
NIS-Elements Viewer Nikon 
NLStradamus  http://www.mosesweb.csb.utoronto.ca/NLStradamus/; 
[369] 
NucPred http://www.sbc.su.se/~maccallr/nucpred/cgi-bin/single.cgi; 
[370] 
SignalP 3.0 http://www.cbs.dtu.dk/services/SignalP-3.0/; [371] 
Table 5 Analysis software 
 
Table 6 Devices 
 
Buffer solutions  
Tris buffered saline (TBS) pH 7.6 
137 mM NaCl 
20 mM Tris  
Running buffer pH 8.3 
25 mM Tris 
190 mM glycine 
0.1 % SDS 
 
Devices Company 
AB 7500 Real Time PCR machine Applied Biosciences 
ImageQuant LAS biomolecular imager GE Healthcare 
NanoDrop ND-1000 Spectrophotometer Peqlab Biotechnologie GmbH 
Nikon Eclipse Ti Fluorescence microscope Nikon 
TECAN infinite F200 pro microplate reader TECAN 
Stratagene Stratalinker UV Crosslinker 
2400 
Stratagene 
FACS CantoTM II BD Bioscience 
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Transfer buffer pH 8.3 
25 mM Tris 
190 mM glycine 
20 % methanol 
Washing buffer (WB) pH 7.6 
TBS 
0.02 % Tween® 20 
Laemmli 4x buffer pH 6.8 
2 % SDS 
10 % glycerol 
1 % 2-mercaptoethanol 
0.02 % bromophenol blue 
12.5 mM EDTA 
0.05 M Tris HCl 
Cell lysis buffer for protein isolation 
1x cOmplete mini protease inhibitor cocktail 
1 % Triton® X 100 
in TBS 
Washing buffer (IF) pH 7.6 
TBS 
0.05 % Tween® 20 
Annexin binding buffer pH 7.4 
10 mM HEPES 
140 mM NaCl 
2.5 mM CaCl2 
Table 7 Buffer solutions 
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VI.2. Methods 
 Tissue microarray 
All analyses involving primary human material were performed in accordance with the Ethics 
Committee II of the University of Heidelberg. The tissue microarray (TMA) used in this study 
contained 13, 27 primary melanomas and 37 melanoma metastases samples, and was 
generated at the Tissue Bank of the National Center for Tumor Diseases (NCT), Department 
of Pathology, University Hospital Heidelberg. Characteristics and clinical parameters of 
patients whose samples were enclosed in the TMA analysis are illustrated in Table 8. 
    TMA 1   TMA 2 
TMA characteristics n   n 
       
TMA Spots No. of spots 52  90 
      
Patients No. of patients 19  20 
       
Clinicopathological 
characteristics 
n %   n % 
       
Age Mean  
[years (range)] 
62.5 (43-81)  62.1 (50-84) 
       
Sex Male 12 63.2     
 Female 7 36.8    
       
Histology 
 
Melanoma 16 100.0   11 100.0 
 SSM 7 43.8  0 0 
 NMM 5 31.2  4 36.4 
 LMM 0 0  1 9.1 
 ALM 1 6.2  1 9.1 
 not classifiable 3 18.8  5 45.4 
       
Ulceration No 11 68.8  8 72.7 
 Yes 5 31.2  3 27.3 
       
Histology 
 
Nevi 13 100.0   0 0 
 compound 9 69.2    
 junctional 1 7.7    
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 lentiginous 0 0    
 Dermal 3 23.1    
 Nevus bleu 0 0    
 not classifiable 0 0    
       
Histology Metastases 0 0   37 100.0 
 Loco-regional    37 100 
      sub-   
     /cutaneous 
   20 54 
       lymph-node    17 46 
 
Abbreviations: SSM, superficial spreading melanoma; NMM, nodular melanoma; LMM, 
lentigo maligna melanoma; ALM, acro-lentiginous melanoma. 
 
*Tumor classification was performed according to the 2009 AJCC melanoma staging 
system of the American Joint Committee on Cancer. 
Table 8 Characteristics and clinical parameters of melanoma patients enclosed in this study 
 
The TMA slides contain each tissue sample in duplicates and were stained with specific anti-
RAGE antibody (ab37647, abcam) overnight at 4 °C according to the immunohistochemistry 
protocol. The samples were stabilized with mounting medium (Dako), and scanned with the 
help of the Tissue Bank of the National Center for Tumor Diseases (NCT). Applying the 
NanoZoomer software NDP.view2 (Hamamatsu Photonics K.K.) two blinded individuals 
visually scored TMAs according to a quantity/intensity-based IHC scoring system. 
Intensity was scored as 0 = negative, 1 = weak, 2 = moderate, and 3 = high; percentage was 
scored as 0 = 0 %, 1 = 1 – 25 %, 2 = 26 – 50 %, 3 = 51 – 75 %, 4 = 76 – 100 %).  
In addition, the intracellular distribution of RAGE protein (nuclear or cytosolic only, as well as 
predominant nuclear or cytosolic) was analyzed on a percentage basis. 
 Cell culture 
All cells used in this study were cultivated at 37 °C in a humidified chamber with an 
atmosphere of 5 % CO2 and have been routinely tested for mycoplasma. Cells were 
subcultured before reaching 90 % confluence using a 0.025 % to 0.5 % trypsin solution. Cells 
and cell lines used in this study are listed in section VI.2.2.1, while their individual culture 
conditions can be found in the paragraphs VI.2.2.2 and VI.2.2.3. 
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VI.2.2.1. Cell lines 
Cell line Mutational status Reference  
Human melanoma 
cell lines 
BRAF status NRAS status  
Skmel 23 wt wt [372] 
Skmel 173 wt Q61K [373] 
C32 V600E wt [372] 
WM2664 wt wt [372] 
A375 V600E wt [372] 
HT144 V600E wt [372] 
MeWo wt wt [374] 
Skmel 147 wt Q61R [372] 
    
Human melanocytic 
cell line 
Mutational status   
MelSTV hTERT introduction, disruption of P53 & RB activity 
by introducing SV40 early region 
[375] 
 
   
Murine melanoma 
cell line 
Background Notes  
B16F10 C57BL/6 Derived from 
spontaneous melanoma 
from DMBA treated 
backskin of C57BL/6 mice 
[376] 
Table 9 Cell lines 
 
VI.2.2.2. Cell culture of immortalized melanocytes and tumor cells 
Human and murine tumor cell lines as well as the immortalized melanocyte cell line MelSTV 
were cultivated in Dulbecco’s Modified Eagle Medium (DMEM) containing 4,500 mg/l glucose 
and 4 mM L-alanyl-L-glutamine supplemented with 10 % heat-inactivated fetal bovine serum 
(FCS), 1 % 100X non-essential amino acids (NEAA), 100 units/ml penicillin, 100 µg/ml 
streptomycin and 0.1 mM 2-mercaptoethanol, from here on referred as MEF medium.  
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VI.2.2.3. Cell culture of primary melanocytes 
Primary normal human melanocytes (NHM) obtained from foreskins were kindly provided by 
Dr. Uysal, Mannheim. NHM were cultured in Medium 254 (Gibco® Life Technologies) 
supplemented with 1 % 100x human melanocyte growth supplement (HMGS) resulting in a 
final concentration of 0.2 % bovine pituitary extract, 0.5 % fetal bovine serum, 1 µg/ml 
recombinant human insulin-like growth factor-I, 5 µg/ml bovine transferrin, 3 ng/ml basic 
fibroblast growth factor (bFGF), 0.18 µg/ml hydrocortisone, 3 µg/ml heparin and 10 ng/ml 
phorbol 12-myristate 13-acetate.  
VI.2.2.4. UV irradiation 
UV irradiation of cells was performed applying the Stratagene’s Stratalinker UV-Crosslinker. 
Cell culture plates without lids were irradiated with either 10 or 50 J/m2. 
VI.2.2.5. Inhibitors 
Inhibitor Target Mechanism of Action Resolvent 
Doxorubicin DNA 
topoisomerase 
type II 
Two different mechanisms: (1) Blocking 
DNA synthesis and transcription by DNA 
intercalation; (2) Inhibition of topoisomerase 
type II leading to breaks in the genomic 
DNA. 
DMSO 
Leptomycin 
B (LMB) 
CRM-1/XPO Covalent modification of Cys528 in the 
central conserved region of CRM-1 
preventing the binding to the cargo protein 
NES 
Ethanol 
Mitomycin C 
(MTC) 
5′-CpG-3′  Alkylating agent forming crosslinks between 
complementary strands of DNA leading to 
the inhibition of DNA replication 
H2O 
Z VAD FMK Caspases Irreversibly binds to the catalytic site of 
caspase proteases 
DMSO 
Table 10 Characteristics of applied inhibitors 
 
Aliquots of the inhibitor (Table 10) solutions were stored at -20 °C and applied in MEF media 
at the indicated concentrations: Leptomycin B, 4 nM; Mitomycin C, 0.25 µg/ml; Z VAD FMK, 
20 µM; Doxorubicin, 100 nM. Control cells were treated with media containing the same 
amount of resolvent but without compound. 
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 Transformation and plasmid isolation 
To introduce the plasmid of interest into competent Dh5α E.coli cells, plasmid DNA was 
mixed with chilled cells, incubated on ice for 30 min, and briefly heated to 42 °C (90 s). After 
a resting phase on ice for 2 minutes 500 µl LB media were added and bacteria were shaked 
for 60 minutes at 37 °C. Transformed bacteria were plated on pre-warmed LB agar plates 
with 100 µg/ml ampicillin for selection and incubated overnight at 37 °C. Single colonies were 
manually picked and transferred to sterile culture tubes containing 5 ml LB media 
supplemented with 100 µg/ml ampicillin and incubated overnight at 37 °C. Plasmid DNA was 
isolated using the QIAGEN Plasmid Purification Mini Kit according to the manufacturer’s 
protocol. The amplification of the plasmid of interest was confirmed by restriction digestion 
and sequencing. Sterile Erlenmeyer flasks containing 200 ml ampicillin-supplemented LB 
media were inoculated with bacteria containing verified plasmids and were incubated at 
37 °C overnight in an orbital shaker. Bacteria were then pelleted, lysed and the plasmid DNA 
was purified using the EndoFree® QIAGEN Plasmid Purification Maxi Kit according to the 
manufacturer’s protocol. After isopropanol/ethanol precipitation air-dried plasmid DNA was 
solved in endogen-free water and analyzed using a NanoDrop ND-1000 spectrophotometer 
for quality and quantity. 
 Transfection and transduction 
Prior to transfection and transduction cells were seeded at distinct concentrations resulting in 
a cell density of 60 – 80 % on the day of transfection/transduction. 
VI.2.4.1. RAGE overexpression in immortalized human melanocytes and 
melanoma Cells 
Gain-of-function experiments with immortalized human melanocyte and melanoma cell lines 
were performed using pcDNA3.1., containing a G418 resistance gene as an empty vector 
control, and, when additionally containing full-length RAGE (HM-310, HMGBiotech), as 
overexpression construct (RAGE OE). Prior to transfection 5 x 104 cells per 24 well were 
seeded in MEF medium and incubated overnight at 37 °C (5 % CO2). Using Lipofectamine® 
LTX cells were transfected with 0.5 µg DNA per well according to the manufacturer’s protocol 
and cultivated for 24 hours. 
Cells were then passaged at a one to ten ratio and after 48 hours of incubation with MEF 
medium at 37 °C (5 % CO2) selected with MEF medium containing defined G418 
concentrations optimized for each cell line. Optimal selection concentrations were defined as 
the minimal antibiotic concentration sufficient to kill all cells after one week (Table 11). For 
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long-term culture, the G418 concentration was reduced to 50 % of the optimized selection 
concentration. 
Human melanocytic or melanoma cell line G418 selection concentration 
MelSTV 800 µg/ml 
A375 1000 µg/ml 
MeWo 1000 µg/ml 
Table 11 G418 concentrations for selection 
 
VI.2.4.2. siRNA-mediated reversion of RAGE overexpression effects  
For transient knockdown 1 x 105 RAGE OE or control cells were seeded in 6 wells and, after 
proper attachment, transfected with Lipofectamine RNAiMAX and 25 pmol Stealth RNAi™ 
siRNA targeting RAGE or 25 pmol Stealth RNAi™ siRNA negative control with a medium GC 
content diluted in Opti-MEM® I Reduced Serum Medium according to manufacturer’s 
protocol. After another 48 hours of incubation at 37 °C (5 % CO2) cells were validated, and 
upon successful verification of the knockdown used for functional assays. Due to the 
transient character of the siRNA-mediated knockdown all functional assays were performed 
within 5 days after transfection. 
VI.2.4.3. shRNA-mediated, stable Rage knockdown in murine B16F10 
melanoma cells using lentiviral particles 
Murine B16F10 melanoma cells were seeded in MEF medium at a concentration of 1 x 104 
cells per 96 well and incubated overnight at 37 °C (5 % CO2). On the day of transduction the 
medium was exchanged with MEF medium containing hexadimethrine bromide (Polybrene) 
at a final concentration of 8 µg/ml. MISSION® Lentiviral Transduction Particles containing 
shRNA targeting the mRNA encoding for RAGE (TRCN0000071743, 1.2 x 107 Transducing 
Units (TU)/ml; TRCN0000071744, 1.1 x 107 TU/ml; TRCN0000071745, 8.4 x 106 TU/ml; 
TRCN0000071746, 1 x 107 TU/ml; TRCN0000071747, 1.8 x 107 TU/ml) as well as 
MISSION® Lentiviral Transduction Particles containing non-targeting shRNA (2.8 x 107 
TU/ml) were added to the cells at desired multiplicity of infection (MOI). The plate was gently 
shaked to ensure proper mixing and incubated for 20 hours at 37 °C (5 % CO2). The next day 
medium was exchanged with fresh MEF medium. After another 24 hours of incubation at 
37 °C (5 % CO2) cells were selected with 1 µg puromycin per ml, which was the minimal 
concentration killing all cells after one week of selection. After the identification of resistant 
colonies, clones were picked and expanded. For long-term culture, the puromycin 
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concentration was reduced to 50 % of the optimized selection concentration. Until clones 
were picked all steps were performed according to the safety class two requirements. 
 RNA isolation and reverse transcription 
RNA extraction was performed using the RNeasy Mini Kit (QIAGEN) according to 
manufacturer’s instructions. Briefly, pelleted cells were dissolved using RLT lysis buffer 
containing 1 % 2-mercaptoethanol followed by RNA extraction using a column-based 
purification. Every sample was DNase I-treated for 15 minutes at room temperature followed 
by two washing steps and the elution in RNase-free H2O.  
RNA concentration and quality was measured using a NanoDrop ND-1000 
spectrophotometer. Samples fulfilling the quality recommendations (260 nm/ 280 nm ratio: 
2.0 +/- 0.2; 260 nm/ 230nm ratio: 2.0 + 0.2) were further processed.  
500 ng RNA of each sample were then used for cDNA generation. In brief, RNA and non-
template controls were incubated with oligo (dT)18 primers in a volume of 12 µl for five 
minutes at 65 °C. Reverse transcription was performed using the RevertAid First Strand 
cDNA Synthesis Kit according to the manufacturer’s protocol. As control for successful 
removal of genomic DNA within the samples also reactions without reverse transcriptase 
were performed. Before use cDNA was diluted at a one to five ratio in nuclease-free H2O 
resulting in a concentration of 5 ng/µl. 
 Quantitative real-time polymerase chain reaction (qPCR) 
VI.2.6.1. Standard qPCR Analysis 
qPCR was performed using 2x SYBR Green PCR master mix and an Applied Biosystems 
7500 Real-Time PCR System. In each qPCR experiment 12.5 ng cDNA per sample were 
applied and amended by a non-template control as well as minus-reverse-transcriptase 
controls to monitor the quality of the assay. All primers used in this study show an efficiency 
within the range of 85 – 110 % as analyzed by cDNA dilution curves.  
After testing all samples for low variances of housekeeping gene expression (< 2 cycles) the 
results of human targets were normalized to 18S, βACTIN, or both, and for murine targets to 
Hprt, Gapdh, or both. All samples were analyzed in triplicates and gene quantification was 
calculated using the Pfaffl method calculating the delta-delta Ct (∆∆Ct) [377]. Statistical 
analysis was carried out in Excel and visualization of graphs in GraphPad Prism 5. Primers 
used in this study are listed in Table 12. 
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 Forward primer Reverse primer 
Human Primer   
Hs_Ager CCAGCCCGGGGAGGAGAT GAAGGGGCAAGGGCACACCAT 
Hs_18S GAGGATGAGGTGGAAACGTGT TCTTCAGTCGCTCCAGGTCT 
Hs_βACTIN GGATGCCACAGGATTCCATACCCA TCACCCACACTGTGCCGATCTACGA 
Hs_HMGB1 CTAAGAAGTGCTCAGAGAGGTG GGAAGAAGGCCGAAGGAG 
Murine Primer   
Mm_Ager TGGGCAGAGATGGCACAGGT AGCTGGCACTTAGATGGGAAACTT 
Mm_Hprt CAGCCATTGCAGTACATTGAG TTTTGCCTCTCGGCTTTTTA 
Mm-Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Table 12 qPCR primer 
 
VI.2.6.2. Profiling changes in ‘in trans’ molecules mediated by RAGE 
overexpression or Rage knockdown  
The applied RT² Profiler™ Human and Mouse DNA Damage Signaling Pathway PCR Array 
allows the simultaneous monitoring of 79 DNA damage signaling-related genes, five house-
keeping genes, as well as reverse transcriptase- and positive controls. 
Relevant genes out of following signaling pathways were analyzed and normalized to two 
house-keeping genes (human: βACTIN, RPLO; mouse: βActin, Hsp90ab1): ATM/ATR 
signaling, nucleotide excision repair (NER), base excision repair (BER), mismatch repair 
(MMR), double-strand break repair (DSB), other DNA repair genes, apoptosis, and cell cycle. 
Abbreviations for all genes are listed in Table 13. 
The average correlation coefficients of these arrays is higher than 0.99, ensuring reliable 
detection of differences in the expression between biological samples. cDNA from RAGE 
gain-of-function (A375 pcDNA3.1. vs A375 RAGE OE; human) and loss-of-function studies 
(B16F10 Ctrl Kd vs. B16F10 RAGE Kd; mouse) served as biological samples in these 
assays. The arrays were performed using 2x SYBR Green PCR Master Mix and an Applied 
Biosystems 7500 Real-Time PCR System according manufacturer’s protocol. 
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RT² Profiler™ DNA Damage Signaling Pathway PCR array 
Pathway Genes 
Human Profiler 
ATM / ATR ATM, ATR, ATRIP, BARD1, BRCA1, CDC25A, CHEK1, CHEK2, CSNK2A2, 
FANCD2, H2AFX, HUS1, MDC1, PARP1, RAD1, RAD17, RAD50, RAD9A, 
RBBP8, RNF168, RNF8, SMC1A, TOPBP1, TP53. 
 
NER CDK7, DDB1, DDB2, ERCC1, ERCC2, LIG1, NTHL1, OGG1, PCNA, PNKP, 
RPA1, SIRT1, TP53, XPA, XPC. 
 
BER APEX1, FEN1, LIG1, MBD4, MPG, NTHL1, OGG1, PARP1, PCNA, TP53, 
UNG, XRCC1. 
 
MMR ABL1, EXO1, MLH1, MLH3, MSH2, MSH3, PCNA, PMS1, PMS2, TP73. 
 
DSB Repair ATM, BLM, BRCA1, CHEK1, H2AFX, HUS1, LIG1, MDC1, MLH1, MRE11A, 
NBN, PRKDC, RAD50, RAD51, RPA1, TP53BP1, XRCC2, XRCC6. 
 
Other DNA 
Repair 
ATR, ATRIP, ATRX, BARD1, BRIP1, CHEK2, CIB1, CRY1, FANCA, 
FANCD2, FANCG, GADD45A, GADD45G, RAD1, RAD17, RAD18, RAD21, 
RAD51B, RAD9A, RBBP8, REV1, RNF168, RNF8, SMC1A, SUMO1, 
TOPBP1, XRCC3. 
 
Apoptosis 
 
ABL1, ATM, BARD1, BAX, BBC3, BRCA1, CDKN1A, CHEK2 (RAD53), 
CIB1, CSNK2A2, PPP1R15A, PRKDC, RAD21, RAD9A, SIRT1, TP53, 
TP73. 
 
Cell Cycle ATM, ATR, ATRIP, CDC25A, CDC25C, CDK7, CDKN1A, CHEK1, CHEK2 
(RAD53), DDIT3, MAPK12, MCPH1, MDC1, PPM1D, PPP1R15A 
(GADD34), TP53, TP73. 
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Murine Profiler 
ATM / ATR Atm, Atr, Brca1, Cdc25a, Chek1, Chek2, Fancd2, H2afx, Hus1, Mdc1, 
Parp1, Parp2, Rad1, Rad17, Rad50, Rad9a, Rnf8, Smc1a, Topbp1, Trp53. 
NER Brca2, Ddb2, Dclre1a, Ercc1, Ercc2, Fancc, Lig1, Nthl1, Ogg1, Pcna, Pole, 
Rpa1, Trp53, Xpa, Xpc. 
 
BER Apex1, Fen1, Lig1, Mbd4, Mpg, Nthl1, Ogg1, Parp1, Parp2, Pcna, Pole, 
Trp53, Ung, Xrcc1, Wrn. 
 
MMR Abl1, Exo1, Mlh1, Mlh3, Msh2, Msh3, Pcna, Pms2. 
 
DSB Repair Atm, Blm, Brca1, Brca2, Chek1, H2afx, Hus1, Lig1, Mdc1, Mlh1, Mre11a, 
Nbn, Prkdc, Rad50, Rad51, Rad52, Rpa1, Trp53bp1, Xrcc2, Xrcc6. 
 
Other DNA 
Repair  
Atr, Atrx, Brip1, Chek2, Fanca, Fancd2, Fancg, Gadd45a, Gadd45g, Mgmt, 
Polh, Poli, Pttg1, Rad1, Rad17, Rad18, Rad21, Rad51c, Rad51b, Rad9a, 
Rev1, Rnf8, Smc1a, Smc3, Sumo1, Topbp1, Xrcc3. 
 
Apoptosis 
 
Abl1, Atm, Bax, Brca1, Cdkn1a, Chek2, Ppp1r15a, Prkdc, Rad21, Rad9a, 
Terf1, Trp53. 
 
Cell Cycle 
 
Atm, Atr, Cdc25a, Cdc25c, Cdkn1a, Chek1, Chek2, Ddit3, Mcph1, Mdc1, 
Mif, Ppm1d, Ppp1r15a, Terf1, Trp53. 
Table 13 Genes encoding for in trans molecules involved in the regulation of genomic integrity, and 
analyzed by RT² Profiler™ 
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 Immunoblotting 
Cells used for protein extraction were harvested before reaching 90 % confluence using ice-
cold PBS and Corning® cell scrapers. For cell fractionation experiments cells were incubated 
with MEF medium containing Leptomycin B (4 nM), or resolvent only for 24 hours in 
humidified atmosphere at 37 °C prior to cell lysis. 
VI.2.7.1. Generation of total cell lysates 
For the extraction of proteins cells were washed twice with ice-cold PBS and lysed with TBS 
supplemented with 1 % Triton X-100 and Roche cOmplete mini protease inhibitor cocktail. All 
steps were performed at 4 °C. Protein yield was then measured using the Thermo 
Scientific™ Pierce™ BCA method.  
VI.2.7.2. Generation of cell fractions 
For the extraction of proteins from different specific cellular compartments the Thermo 
Scientific subcellular protein fractionation kit was applied according to the manufacturer’s 
protocol.  
Four different extraction buffers supplemented with Thermo Scientific Halt protease inhibitor 
cocktail enable the extraction of proteins from distinct compartments. Briefly, the first 
extraction buffer selectively permeabilizes the cell membrane, thereby releasing soluble 
cytoplasmic contents. The second extraction buffer solubilizes membranes of plasma, 
mitochondria and ER-golgi but does not affect nuclear membranes. In the next step intact 
nuclei were isolated via centrifugation and treated with the third extraction buffer leading to 
the release of soluble nuclear extract. Supplementation of the third extraction buffer with 
micrococcal nuclease in an additional extraction step isolates chromatin-bound nuclear 
proteins. The remaining insoluble pellet was then treated with the fourth extraction buffer, 
thereby isolating cytoskeletal proteins. All steps were performed at 4 °C. Protein yield was 
then measured using the Thermo Scientific™ Pierce™ BCA method. 
VI.2.7.3. Western Blot 
Under denaturating conditions 30 µg protein were separated on self-made 12 % Tris/glycine 
SDS-polyacrylamide gels according to the scheme below (Table 14). 
Proteins were transferred onto methanol-activated polyvinylidene difluoride (PVDF) 
membranes with 60 V for 2 hours at 4 °C. Unspecific binding was blocked by incubating the 
membrane with 5 % non-fat dried milk in TBST (TBS supplemented with 0.02 % Tween-20) 
for 1 hour at room temperature. Primary antibodies were diluted in TBST containing 5 % BSA 
or non-fat dried milk according to the manufacturer’s protocol: rabbit anti-RAGE (ab37647; 
Material and Methods 
45 
abcam), 1 : 1,000; rabbit anti-RAGE (H300, SantaCruz), 1 : 1,000; rabbit anti-HISTONE 3 
(sc-10809, SantaCruz), 1 : 1,000; rabbit anti-β-CATENIN (sc-7199, SantaCruz), 1 : 10,000. 
After incubation with the primary antibodies overnight at 4 °C, membranes were washed 
three times in TBST and incubated with secondary antibodies against rabbit IgG labeled with 
horseradish peroxidase diluted (1 : 10,000) in TBST containing 5 % non-fat dried milk in 
TBST at room temperature for 2 h. After washing three times with TBST, signals were 
visualized using ECL™ Western Blotting Detection Reagents (GE Healthcare) and the 
ImageQuant LAS biomolecular imager. Protein quantification was performed using ImageJ. 
Resolving gel Stacking gel 
3.3 ml  
3.0 ml  
2.5 ml  
100 µl  
100 µl  
  20 µl  
H2O 
30 % acrylamide/bisacrylamide 
1.5 M Tris pH 8.8 
10 % SDS 
10 % ammonium persulfate (APS)  
tetramethylenediamine (TEMED) 
3.40 ml 
0.83 ml 
0.63 ml 
   50 µl 
   50 µl 
     5 µl 
H2O 
30 % acrylamide/bisacrylamide 
1 M Tris pH 6.8 
10 % SDS 
10 % ammonium persulfate (APS) 
tetramethylenediamine (TEMED) 
Table 14 SDS-Gel preparation 
 
 Immunofluorescence  
Human melanocytic and melanoma cell lines were seeded into Lab-Tek® Chamber Slides™. 
After proper attachment cells were starved in FCS-free MEF medium overnight. Surface and 
nuclear staining was performed according to the protocol published in Nature Methods [378]. 
Briefly, cells for nuclear staining were fixed in 4 % paraformaldehyde (PFA) for 5 min on ice 
and 10 min on room temperature followed by a treatment with 100 % methanol for 2 min at  
- 20 °C. For surface staining the permeabilization step using methanol was excluded. 
Blocking was performed with PBS containing 1 % BSA and 0.05 % Tween-20 for 30 min at 
room temperature. Cells were then incubated overnight at 4 °C with primary antibodies 
diluted in blocking solution according to the manufacturer’s suggestions to indicated 
concentrations: rabbit anti-RAGE (ab37647, abcam), 1 : 100; rabbit IgG isotype control 
(DLN13124; Dianova), 1 : 100. After washing, samples were incubated with blocking solution 
containing DAPI (1 : 50,000) and the secondary antibody goat anti-rabbit Cy3 (1 : 500) for 
2 hours at room temperature. Afterwards cells were washed and mounted with Dako 
Fluorescent Mounting Medium (S3023, Dako). Samples were analyzed with a 
Nikon ECLIPSE Ti fluorescent microscope. Exposure time was set with isotype control 
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stained samples to achieve minimal background and further applied for the analysis of all 
stainings. 
 Immunohistochemistry of TMA 
For immunohistochemistry TMA slides containing each patient sample in duplicates were 
deparaffinized and rehydrated by three washes with xylene, 5 min each, followed by a series 
of 3min washes in 100, 90, 80 and 70 % ethanol, and rinsed distilled water (dH2O) and Tris-
buffered saline (TBS). Antigen retrieval was performed by heating the samples for 60 min at 
100 °C in Zytomed HIER Citrate Buffer (pH 6.0). After cooling and additional washing steps 
with TBS/TBST, blocking of the endogenous peroxidase activity with 0.03% hydrogen 
peroxide containing sodium azide for 10 min followed. Then, the TMA was again washed with 
dH2O, TBS and TBS containing 1 % Tween-20, and then stained with specific anti-RAGE 
antibodies (ab37647, abcam, 1:200) in Dako antibody diluent overnight at 4 °C. After three 
washes, 2 min each with PBS, the sections were incubated with Dako EnVisionTM anti-rabbit 
or anti-mouse secondary antibodies conjugated with horse-radish peroxidase (HRP) for 
60 min. After two washes with TBS/TBST for 5 min each the samples were developed with 
AEC (Dako EnVisionTM) for 15 min, followed by an additional washing step, and 
counterstaining with haemotoxylin. The samples were then stabilized with mounting medium 
(Dako) for storage and scanned with the help of the Tissue Bank of the National Center for 
Tumor Diseases (NCT), Department of Pathology, University Hospital Heidelberg. Applying 
the NDP.view2 software (Hamamutsu) two blinded individuals visually scored TMAs 
according to a quantity/intensity-based IHC scoring system. 
 Measuring cell metabolic activity as indicator of cell health and 
proliferation 
The alamarBlue® method monitors the metabolic activity of cells via measuring their capacity 
to reduce the non-toxic, cell permeable, and non-fluorescent compound resazurin to 
resorufin, which produces red fluorescence. Viable cells continuously convert resazurin to 
resorufin, thereby allowing a quantitative measurement of viability and, as the reduction of 
resazurin is cell number-dependent, proliferation. 1 x 103 human melanocytic or melanoma 
cell lines showing empty vector or RAGE OE construct expression, as well as those from the 
reversion of the overexpression experiment, were resuspended in 150 µl MEF medium 
containing either DMSO or 10 µM Doxorubicin and plated into black 96-well plates. The 
same cell number was used for non-treated or UV-radiated (10 J/m2) murine B16F10 
melanoma cells from the RAGE knockdown experiment. Proper attachment of cells was 
controlled by adding 15 µl alamarBlue on day 1 to the cells while all other plates were 
incubated for 72 hours in a humidified atmosphere at 37 °C. After administration of 
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alamarBlue® cells were allowed to reduce the reagent for two to four hours at 37 °C followed 
by fluorescence measurement using the TECAN infinite F200 pro microplate reader and the 
TECAN iControl 1.10.©2012 software with a set gain of 30 and the 535 nm (+/- 25 nm) 
excitation and 590 nm (+/- 20 nm) emission filter. For the human melanocytic and melanoma 
cells effects were calculated from the resulting change in fluorescent intensity normalized to 
untreated cells, carrying the empty vector construct. Differences between the murine B16F10 
clones were measured via normalization to the untransfected B16F10 control cells. 
 Cell cycle analysis 
Cell cycle analysis was performed using the DNA-selective, cell membrane-permeant, non-
fluorescent Vybrant® DyeCycle™ Violet stain. Briefly, cells were seeded and after proper 
attachment their cell cycle was synchronized by starving overnight in serum-free MEF 
medium. Afterwards normal MEF medium was added followed by 24 hours incubation in a 
humidified atmosphere at 37 °C cells were harvested, and resuspended in MEF medium 
resulting in a cell concentration of 1 x 106. To flow cytometry tubes containing 1 ml of cell 
suspension DAPI (1 : 50,000) and 1 μl of Vybrant® DyeCycle™ Violet stain (5 µM) were 
added. The Vybrant® DyeCycle™ Violet stain is fluorescent upon binding to double-stranded 
DNA. Samples were analyzed for differences in the percentages of cells being in different 
cell cycle stages using FACS Canto 4.0 and FACSDiva provided by the DKFZ Flow 
Cytometry Core Facility and the FlowJo Single Cell Analysis software 7.2.2. 
 Proliferation analysis using CSFE dilution assay 
To investigate differences in proliferation, cells were labeled with the fluorescent dye 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE). Based on the inheritance of the dye 
from parental to daughter cells resulting in its dilution, cells with an advantage in proliferation 
show a reduction in CFSE mean fluorescence intensity (MFI) which is measured directly by 
flow cytometry. Prior to CSFE staining, cells were starved overnight at 37 °C using serum-
free MEF medium in a humidified atmosphere to synchronize their cell cycle. After 
harvesting, cells were washed extensively with PBS to get rid of residual FCS, which would 
quench CSFE staining. Cells were then resuspended in prewarmed PBS containing 0.1 % 
BSA resulting in a final cell concentration of 1 x 106 cells/ml and then stained with 10 µM 
CSFE for 10 min at 37 °C. Staining was stopped in ice-cold MEF medium and cells were 
washed and resuspended in fresh MEF medium. Stained cells were then plated into 24 well 
plates and treated as indicated in the experiments. To control CSFE stability some cells were 
additionally treated with 0.25 µg/ml Mitomycin C. After 24 hours cells were harvested using 
PBS/EDTA and counterstained with DAPI (1 : 50,000). CSFE staining was analyzed by 
comparing the geometric mean of the fluorescence intensity (MFI) using FACS Canto 4.0 
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and FACSDiva provided by the DKFZ Flow Cytometry Core Facility and the FlowJo Single 
Cell Analysis software 7.2.2. 
 Apoptosis staining 
For Apoptosis staining 2 x 104 untreated or UV-irradiated cells were seeded into 48 well 
plates either using normal MEF medium or MEF medium containing DMSO or 10 µM 
doxorubicin as indicated in the respective experiments. The cells were incubated for 
72 hours in humidified atmosphere at 37 °C. As internal control some cells were also treated 
with the pan caspase inhibitor Z VAD FMK (20 µM). 
Supernatants containing detached, dead cells were collected in the same tubes used to 
harvest the remaining cells using PBS/EDTA. After centrifugation the cells were washed for 
two times using Annexin V binding buffer. Cells were then resuspended in 50 µl Annexin V 
binding buffer (100,000 cells/100 µl) containing 1.25 µl Alexa Fluor 488 Annexin V 488 and 
1 µl of Hoechst (0.25 µg/µl). After 10 min incubation in the dark at room temperature 1 µl of 
7AAD was added per sample and cells were incubated under the same conditions for 5 more 
minutes. Then 200 µl Annexin V binding buffer were added and cells were analyzed using 
FACS Canto 4.0 and FACSDiva provided by the DKFZ Flow Cytometry Core Facility and the 
FlowJo Single Cell Analysis software 7.2.2. 
 DCFDA – cellular reactive oxygen species detection 
Reactive oxygen species (ROS) production was determined by the oxidation reaction of the 
cell-permeant, non-fluorescent compound 2’,7’–dichlorofluorescin diacetate (DCFDA) into 2’, 
7’ –dichlorofluorescein (DCF) by ROS within cells. DCF is a highly fluorescent compound 
which can be detected by fluorescence spectroscopy. The assay was performed after 
manufacturer’s protocol. Briefly, 2.5 x 104 cells per well were seeded into a black 96 well 
plate with transparent bottom and incubated in humidified atmosphere overnight. After 
staining with 25 µM DCFDA in 1X Buffer for 45 minutes, ROS production was induced by 
treating the cells for 4 hours with MEF medium containing 50 µM TBHP as positive control, 
and medium only. The incubations were performed in humidified atmosphere at 37 °C. 
Fluorescence was measured using the TECAN infinite F200 pro microplate reader and the 
TECAN iControl 1.10.©2012 software with optimal gain and the 485 nm (+/- 20 nm) 
excitation and 535 nm (+/- 25 nm) emission filter. After background subtraction the 
differences were normalized to the untreated empty vector control (for the human 
melanocytic and melanoma cell lines) or to untransfected B16F10 cells (murine RAGE Kd). 
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 Invasion assay 
Cell invasiveness was determined by the use of the Cultrex® 96 Well BME Cell Invasion 
Assay (©2008, Trevigen Inc.) according to the manufacturer’s protocol. Briefly, transwell 
chambers were coated with 0.1X basal membrane equivalent (BME) coating solution and 
cells were starved in serum-free medium overnight. After starvation cells were seeded in 
50 µl serum-free MEF medium at a density of 50,000 cells per well into the coated transwell 
inserts. The bottom chambers were filled with 150 µl normal MEF medium containing FCS. 
Cells that migrated into the bottom chamber within a 24 h-period were lysed and stained with 
the fluorescent dye Calcein. Fluorescence was measured using the TECAN infinite F200 pro 
microplate reader and the TECAN iControl 1.10.©2012 software with optimal gain and the 
485 nm (+/- 20 nm) excitation and 535 nm (+/- 25 nm) emission filter. Relative migratory and 
invasive potential was determined by comparing RFUs. 
 In silico characterization of RAGE isoforms 
In silico analyses of described RAGE isoforms (Uniprot IDs: Q15109-1, Q15109-2, Q15109-
3, Q15109-4, Q15109-5, Q15109-6, Q15109-7, Q15109-8, Q15109-9, Q15109-10, Q101R2, 
Q15109, Q101R5, Q3L1R3, Q3L1R2, Q71BB6, E9LVY7, E9LVY6, E9LVY5) were performed 
regarding their structural capacity to translocate into the nucleus using the following 
computational online tools (Table 15): 
Prediction 
Tool 
Description Based on 
BindN predicts DNA- and RNA-binding 
sites 
applies support vector machines 
based on sequence features, including 
side chain pKa values, hydrophobicity 
index and molecular mass of amino 
acids [379] 
CELLO protein subcellular localization 
prediction 
applies support vector machines 
based on multiple n-peptide 
composition [362] 
cNLS 
Mapper 
prediction of importin-α-
dependent nuclear localization 
signals 
Bayesian network [363] 
NetNES  predicts leucine-rich nuclear 
export signals (NES) 
neural networks as well as Hidden 
Markov Models [364] 
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NetNGlyc 1.0 predicts N-Glycosylation sites neural networks [365] 
NetOGlyc 3.1 predictions of mucin type GalNAc 
O-glycosylation sites 
neural networks [366] 
NetPhos 2.0 predictions for serine, threonine 
and tyrosine phosphorylation 
sites 
neural networks [367] 
 
NetPhosK 
highest score 
predictions of kinase*- specific 
eukaryotic protein 
phosphorylation sites 
neural networks [368] 
 
NLStrada-
mus  
predicts NLSs in nuclear proteins  Hidden Markov Models [369] 
NucPred 
score 
predicts if the protein spends at 
least some time in the nucleus or 
if it spends no time in the nucleus 
ensemble of 100 sequence-based 
predictors [370] 
SignalP 3.0 predicts the presence and 
location of signal peptide 
cleavage sites 
neural networks as well as Hidden 
Markov Models [371] 
 
*PKA, PKC, PKG, CKII, CDC2, CaM-II, ATM, DNA PK, CDK5, p38 MAPK, GSK3, CKI, 
PKB, RSK, INSR, EGFR and SRC 
**centromere, chromosome, nucleolus, nuclear envelope, nuclear speckles, telomere, 
nucleoplasm, nuclear matrix, PML body, and nuclear pore complex 
Table 15 Prediction tools for in silico characterization of RAGE isoforms 
 
 Statistical analyses 
Tests for all data were performed using GraphPad Prism version 5.00 (2007) with the 
appropriate tests. Significance in two-tailed t-tests and Mann-Whitney U test for non-
gaussian distribution was assumed for p-values < 0.05 (*), < 0.01 (**) or < 0.0001 (***). 
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VII. Aims of the thesis 
 
The identification of driver mutations resulted in a better understanding of melanoma 
pathogenesis. Nevertheless, the high plasticity of melanoma cells as well as multiple 
resistance mechanisms to novel therapies demonstrate the existence of complex but flexible 
regulatory mechanisms beyond genetics. 
Recent studies indicated that the receptor for advanced glycation end-products (RAGE) 
represents a key element within a network of tumor-promoting pathways. The plethora of 
alternative splicing forms, ways of posttranslational modifications, including protein shedding, 
phosphorylation and acetylation, represent only a few characteristics of RAGE enabling a 
fast adaptive response to extrinsic and intrinsic signals. Since RAGE has been found to be 
upregulated in malignant melanoma, a tumor-promoting role has been hypothesized early. 
Although first evidence for a tumor-promoting role of RAGE expressed by stroma cells within 
the melanoma microenvironment, and partially for a melanoma-cell intrinsic function has 
been provided, mechanisms of action remain completely unknown. 
Taken together, within the present thesis the following questions will be addressed: 
a) Is there a connection between RAGE expression and melanocyte transformation as 
well as melanoma pathogenesis? If so, what are the mechanisms behind? 
 
b) Are the enhanced levels of RAGE in melanoma sufficient to explain potential effects 
on melanoma cell behavior, or are other regulatory mechanisms controlling the 
activity of the pathway involved?  
 
 
By investigating the impact of RAGE on melanocyte and melanoma cell behavior as well as 
possible regulation mechanisms behind, the study may identify new levels of control 
operating in melanoma pathogenesis and melanoma plasticity, thereby leading to a better 
understanding of this complex and fatal disease. 
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VIII. Results 
 
The aforementioned techniques were applied in order to elucidate the functional tumor cell-
intrinsic role of RAGE in melanoma. The findings are outlined in this section. 
VIII.1. RAGE is overexpressed in malignant melanoma 
First, a comparative evaluation of RAGE expression between healthy tissues and malignant 
melanoma samples was accomplished.  
 
 
Figure 2 RAGE is overexpressed in human melanoma tissue. Comparative expression analysis of 
AGER transcript levels based on data of a human genome U133A array [388] provided by the 
Oncomine database. Illustration of AGER levels in normal skin (n = 7), benign nevi (n = 18), and 
melanoma samples (n = 45) with normalized expression units compared to the reporter (A). TMAs 
containing benign nevi (n = 13, circles), primary melanoma (n = 27, squares), and metastases (n = 37, 
triangles) samples were stained with a rabbit anti-RAGE antibody and scored by two blinded 
individuals (IHC Score = intensity x percentage of RAGE+ cells; intensity was scored as 0 = negative, 
1 = weak, 2 = moderate, and 3 = high; percentage was scored as 0 = 0 %, 1 = 1 – 25 %, 2 = 26 –
 50 %, 3 = 51 – 75 %, 4 = 76 - 100 %). All samples were analyzed in duplicates; each symbol 
represents the respective mean value (B). Representative cases of immunohistochemical expression 
of RAGE for benign nevi, primary melanoma, metastases (C). (*p < 0.05, ***p < 0.0001, unpaired 
student‘s t-test)  
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Differences in AGER transcript levels between normal skin (n = 7), benign nevi (n = 18), and 
melanoma samples (n = 45) were analyzed by the Oncomine database using microarray 
data provided by Talantov and colleagues [388] (Figure 2A). Levels were found to be 
significantly increased in benign nevi (*p < 0.05), and melanoma samples (***p < 0.0001), 
when compared to normal skin. However, AGER expression in melanoma was also 
significantly higher in comparison to benign nevi (***p < 0.0001).  
In addition, tissue microarrays (TMA) containing benign nevi (n = 13) as well as primary 
melanoma (n = 27) and metastases samples (n = 37) were stained with an anti-RAGE 
antibody and visually scored according to a quantity/intensity-based IHC scoring system by 
two blinded individuals. The quantity, representing the percentage of positive cells, was 
scored with numbers ranging from zero to four, whereas the intensity of a staining was 
scored with numbers from zero to three. Upon scoring the TMA, a significant increase in 
RAGE expression was found in primary melanomas (IHC score 5.444 ± 0.4462) as well as in 
associated metastases (IHC score: 6.074 ± 0.4977) compared to melanocytic nevi (IHC 
score: 3.673 ± 0.7045) (*p < 0.05) (Figure 2B). Representative TMA images for benign nevi 
(left panel), primary melanoma (central panel) and metastases (right panel) are displayed in 
Figure 2C. However, no significant difference between primary and metastases samples was 
observed. 
VIII.2. RAGE enables melanocytic and melanoma cells to increase 
their viability, proliferation, and invasion capacity 
The described upregulation of RAGE during melanoma development and progression, as 
well as the lack of evidence of mutations within the protein, implicate gene dosage-effects for 
RAGE or transactivation of RAGE via hyperactive tumor-related transcription factors [280, 
361]. Therefore, overexpression of full-length RAGE provided a powerful tool to decipher the 
mechanism of action of this protein in melanocytic and melanoma cell lines. 
As illustrated in Figure 3A, the human melanocytic cell line MelSTV as well as two 
conventional, standard human melanoma cell lines, namely A375 and MeWo, were stably 
transfected with an empty pcDNA3.1. vector or with the respective overexpression construct 
containing fl-RAGE. All cell lines exhibited a basal endogenous RAGE level, which was 
relatively low in comparison to other melanoma cell lines (data not shown). Both constructs 
contained a geneticin-resistance gene allowing the selection of the transfected cells with 
geneticin (G418). The morphology of the RAGE-overexpressing cells (RAGE OE) in 
comparison to untransfected (Ø) and control cells (pcDNA3.1.) was assessed but no reliable 
differences were noted (Figure 3B). The cells were then validated for their AGER transcript 
levels using qPCR (Figure 3C). When normalized to the corresponding untransfected cell 
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lines, transfection with the RAGE OE construct but not with the empty vector resulted in a 
marked RAGE overexpression. The RAGE OE cells were characterized by a four - fold 
increase in AGER expression in MelSTV and MeWo, as well as a 28 - fold increase of AGER 
expression in A375 cells. 
 
Figure 3 RAGE overexpression (OE) alters human melanocytic (MelSTV) and melanoma (A375, 
MeWo) cell behavior. Experimental set up (A) and morphological appearance of stably transfected 
control (pcDNA3.1.) and RAGE OE cell lines (B). OE was verified via qPCR with 18S as endogenous 
control and untransfected cells as reference sample (C), and via immunoblotting using a rabbit-anti 
RAGE antibody and βACTIN as loading control (D). RAGE OE and control cells were analyzed 
72 hours after seeding for differences in cell metabolic changes using alamarBlue®. 2 hours after 
alamarBlue® administration fluorescence was measured and the mean value for control cells was 
used for normalization (E). Cells were stained with CSFE and their proliferation was determined by 
tracing the dilution of the dye via detection of the (geometric) mean fluorescent intensity (MFI) of the 
cells after 24°hours. Effects on proliferation were determined by normalizing the MFI of RAGE OE 
cells to the average MFI of control cells (F). Invasion through basal membrane extract-coated 
transwell inserts was compared by fluorescent staining of invaded cells and subsequent measurement 
of the relative fluorescence units (RFU) (G). Graphs display mean ± SD of three (alamarBlue®) and 
two (invasion) individual experiments with technical triplicates, and four (CSFE) biological replicates 
with technical duplicates. (*p < 0.05, **p < 0.005, ***p < 0.0001, Mann-Whitney U test (alamarBlue®, 
CSFE) unpaired student‘s t-test (invasion)) 
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Furthermore, successful RAGE overexpression in these cells was confirmed by Western 
Blot. Therefore, samples of untransfected, pcDNA3.1.- and RAGE OE construct-transfected 
cells were blotted and incubated with an anti-RAGE antibody, and with an antibody against 
βACTIN as loading control. RAGE protein was detectable in all three cell lines and was 
increased after the transfection with the overexpression construct (Figure 3D).  
After successful verification of RAGE overexpression, cells were functionally characterized 
for the implementation of melanoma hallmarks such as cell metabolism, sustained 
proliferation capacity, and invasion capacity. 
A potential gain-of-function effect on the survival of melanocytic and melanoma cell lines was 
found by Kang and colleagues showing that RAGE directly induces tumor survival by 
enhancing mitochondria function [249]. Based on these findings, experiments to elucidate the 
role of RAGE in this context were performed. Indeed, alamarBlue® assays demonstrated 
significantly increased cell metabolic activities upon RAGE overexpression for all three cell 
lines; melanocytic as well as melanoma cell lines (Figure 3E). In terms of numbers, cell 
metabolic rates were boosted by approximately 50 % (**p < 0.005, ***p < 0.0001). 
Noteworthy, analysis of the obtained raw data for untransfected and pcDNA3.1. transfected 
cells indicated highest cell metabolic activity in the MeWo cell line, followed by A375, and last 
MelSTV (data not shown). 
Next, the effect of the RAGE overexpression onto the proliferation capacity of the cells was 
examined. Labeling MelSTV, A375 and MeWo RAGE OE and control cells with the 
fluorescent dye 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) enabled tracing 
of multiple generations based on dye dilution by cell proliferation. Using flow cytometric 
analysis, a decrease in the mean fluorescent intensity (MFI) was observed for all three RAGE 
OE cell lines after 24 hours, with significant differences for MelSTV and A375 when 
compared to the corresponding controls (Figure 3F, *p < 0.05). A lower MFI is equivalent to a 
higher dilution of the fluorescent dye, and thereby to a higher proliferation rate. 
Consequently, RAGE OE was associated with an increased proliferation rate in all cell lines 
tested.  
In order to investigate characteristics not only associated with general tumor growth but also 
with the formation of melanoma metastases, RAGE OE and control cells were analyzed for 
their capacity to invade extracellular matrices in vitro. Therefore, cells were seeded in 
transwell chamber inserts coated with basement membrane extracts (BME). The amounts of 
cells that were able to proteolytically degrade the BME components, including laminin, 
collagen IV, entactin, and heparin sulfate proteoglycan, and consequently migrate to the 
lower chamber were measured (Figure 3G). Interestingly, RAGE overexpression had the 
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highest impact on invasion in MelSTV, which initially showed the lowest invasion capacity 
based on its melanocytic-like character. Here, the overexpression was accompanied with a 
three – fold higher number of cells invading through extracellular matrices in vitro as 
quantified by fluorescent staining (**p < 0.005). For the melanoma cell lines, this assay 
revealed an interesting pattern: The A375 cells, which displayed a significantly higher 
proliferation upon RAGE overexpression, failed to increase their invasion capacity. In 
contrast, MeWo RAGE OE cells showed only a slightly enhanced proliferation in comparison 
to control cells, but a significantly higher invasion (*p < 0.05). 
These experiments demonstrate that overexpression of RAGE significantly changes 
melanocytic as well as melanoma cell behavior. More specifically, it enhances cell 
metabolism and proliferation, and influences the invasion capacity in a cell line- or cell stage-
dependent manner. 
VIII.3. Pro-survival effects of RAGE OE are based on RAGE-
mediated inhibition of apoptosis 
The high plasticity of melanoma cells enabling them to switch between ‘proliferative’ and 
‘invasive’ phenotypes complexes the work on these two features [97]. Indeed, the results of 
the CSFE and the invasion assay might suggest that A375 and MeWo cells represent two 
different functional states. Here, further studies were focused on the role of RAGE-mediated 
pro-survival effects, which were consistent in all – melanocytic and melanoma – cell lines. 
In order to ensure that observed alterations were RAGE-specific and to exclude 
overexpression-associated artefacts, RAGE OE cells were additionally transfected with 
siRNA targeting AGER transcripts or correspondent control siRNA, as illustrated in Figure 
4A. Noteworthy, the AGER siRNA used in these experiments targets besides transcripts 
encoding for fl-length RAGE also soluble and other truncated RAGE forms comprising 
RAGE_v1, RAGE_v4, RAGE_v6, RAGE_v8, RAGE_v9, RAGE_v10, and RAGE_v16. The 
amino acid lengths of these alternative forms range from 342 to 390 aa (more information 
can be found in Table 16). The interference with the overexpression was successfully verified 
by determining AGER transcript levels via qPCR analysis (Figure 4B). In fact, AGER siRNA 
treatment abolished the overexpression in MelSTV and MeWo cells, and led to an 
approximately six - fold reduction of AGER expression in A375 RAGE OE cells. In contrast, 
treatment with control siRNA showed only slight effects in MelSTV and A375 RAGE OE cells 
while a greater side effect was observed in MeWo RAGE OE cells. Nevertheless, effects with 
the control siRNA were markedly lower than with AGER siRNA in all RAGE OE cell lines.  
Cells of the different conditions were then analyzed for alterations in cell metabolism using 
the alamarBlue® method. When normalized to control cells (pcDNA3.1.) the RNA 
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interference partially impaired the cell metabolism-dependent pro-survival effect of the RAGE 
overexpression in MelSTV, and significantly abolished the effects in A375 and MeWo RAGE 
OE cells (Figure 4C). A slightly impaired cell metabolism was also found in the RAGE OE 
cells transfected with control siRNA. Nevertheless, these side-effects were negligible since 
approaches using AGER-specific siRNA were still significantly impaired when compared to 
the control siRNA-treated cells. 
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The observed increase in cell metabolic activity strongly suggested an enhanced cell viability 
of the RAGE OE melanocytic and melanoma cell lines but provided no additional information 
about the affected aspect influencing cellular health. Therefore, a closer examination on the 
pro-survival effect of RAGE overexpression was conducted. Control and overexpression cells 
were stained with Hoechst and the dead cell-dye 7AAD, as well as with antibodies against 
Annexin V, and analyzed via flow cytometry (Figure 4D). The analysis showed that the 
overexpression of RAGE was accompanied with a decreased number of late apoptotic cells 
(Hoechst+, 7AAD+, Annexin V+), which was found to be significant for the melanocytic cell line 
MelSTV and for MeWo (*p < 0.05). The siRNA-mediated reversion of the overexpression 
could significantly abolish this effect in these two cell lines (*p < 0.05). The same tendency 
was also observed for the A375 cell line (Figure 4E). 
These results not only verified the pro-survival effect of the RAGE overexpression in 
melanocytic and melanoma cell lines but rather defined it as an anti-apoptotic effect. 
VIII.4. RAGE controls the transcription of DNA damage signaling 
molecules in human and mouse 
As described in section V.1.2, cancer cells, including melanoma, often display impaired 
apoptosis induction [76, 78]. Since apoptosis represents a possible outcome of DNA 
damage, one mechanism is circumventing DNA damage signaling [74]. Therefore, in a next 
step effects on the regulation of the DNA damage repair network in melanoma was 
investigated. 
The highest fold change in AGER transcript levels upon overexpression was observed in the 
A375 cell line. Hence, this cell line was used for studying a potential involvement of RAGE in 
the regulation of DNA damage repair molecules. Since the applied method necessitated a 
high sample quality, cDNA of A375 RAGE OE and control cells was tested for fulfilling the 
Figure 4 RAGE mediates pro-survival effects by inhibiting apoptosis in human melanocytic and 
melanoma cell lines. RAGE overexpressing cells were additionally transfected with control siRNA or 
siRNA targeting AGER transcripts to generate a reversion of the overexpression in MelSTV, A375 and 
MeWo cells (A). Knockdown was verified via qPCR with 18S as endogenous control and 
untransfected cells as reference sample (B). Control (pcDNA3.1.), untreated RAGE OE, RAGE OE + 
AGER siRNA, RAGE OE + Ctrl siRNA cells were seeded and analyzed after 72 h for differences in cell 
health as indicated by cell metabolic changes using alamarBlue®. 2 hours after alamarBlue® 
administration fluorescence was measured and the mean value for control cells was used for 
normalization (C). At the same time point (72 h after seeding), attached and floating cells of all 
conditions were harvested and stained with Hoechst, 7AAD, and an Annexin V antibody. Illustration of 
a flow cytometric analysis of the Annexin V+ 7AAD+ subpopulation (gated on Hoechst+ single cells 
(FSC-H/FSC-W)) of MelSTV pcDNA3.1., RAGE OE, RAGE OE + AGER siRNA, RAGE OE + Ctrl 
siRNA cells (D). Comparison of the revealed percentages for late apoptotic cells for all cell lines and 
conditions (E). Graphs display mean ± SD of three (alamarBlue®) individual experiments with 
technical triplicates, and three (apoptosis) biological replicates with technical duplicates. (*p < 0.05, 
***p < 0.0001, unpaired student‘s t-test) 
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quality recommendations, such as the appropriate 260 nm/ 280 nm and 260 nm/ 230nm 
ratio, and for a low intersample variance regarding the expression of the endogenous control, 
here 18S (Figure 5A).  
HMGB1, a ligand of RAGE (described in V.2.2.2.2), has shown to be involved in DNA 
damage responses upon drug administration [380], therefore consequences of RAGE 
overexpression on its transcript levels and associated side-effects were ruled out to 
guarantee optimal requirements for investigating RAGE-dependent regulation mechanisms. 
In fact, in none of the used cell lines the overexpression of RAGE was accompanied with an 
upregulation of HMGB1 transcripts (Figure 5B). 
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All these criteria allowed for the quantitative comparison of DNA damage signaling molecules 
and predicted a high stringency of the results. The applied ‘RT² Profiler™ Human DNA 
Damage Signaling Pathway PCR Array’ enabled the simultaneous monitoring of 79 DNA 
damage signaling-related genes with an average correlation coefficient higher than 0.99. 
This ensured a reliable detection of differences in expression between biological samples, 
here A375 RAGE OE and control cDNA. 
Normalizing the different expression values of the investigated DNA repair molecules to the 
two house-keeping genes βACTIN and 50S ribosomal protein L15 (RPLO), and consequent 
comparison of the obtained data sets for A375 RAGE OE and A375 control, revealed a 
deregulation of 28 % of all analyzed transcripts. Interestingly, only 2 % were upregulated in 
A375 RAGE OE cells, whereas 26 % were downregulated in comparison to control 
(pcDNA3.1.) cells (Figure 5C, left pie chart). 
The monitored genes were further subgrouped into distinct DNA repair pathways (allocations 
can be found in Table 13), namely ATM/ATR signaling, nucleotide excision repair (NER), 
base excision repair (BER), mismatch repair (MMR), double-strand break repair (DSB), other 
DNA repair genes, apoptosis, and cell cycle. 20 % of the deregulated genes were found 
within the double-strand break (DSB) repair pathway (Figure 5D, right pie chart). Indeed, 
40 % of the genes associated with DSB repair were differentially regulated between A375 
RAGE OE and A375 control cells. More specifically, BRCA1, H2AFX, LIG1, MLH1, PRKDC, 
RAD51, RPA, XRCC2, and XRCC6 were found to be downregulated, whereas there was no 
difference in ATM, BLM, CHEK1, HUS1, MDC1, MRE11A, NBN, RAD50, TP53BP1, 
RNF168, RNF8, SMC1A, TOPBP1, TP53 transcript levels. 
Figure 5 RAGE mediates the downregulation of DNA repair molecules in humans. A375 
pcDNA3.1. and RAGE OE cDNAs were validated for low intersample variance of the endogenous 
control 18S, as illustrated by a qPCR example analysis (A). If HMGB1 expression was affected by 
RAGE OE in MelSTV, A375, or MeWo was analyzed by comparing its transcript levels via qPCR 
analysis to the corresponding pcDNA3.1. cells with 18S as endogenous control (B). A375 pcDNA3.1. 
and RAGE OE cDNAs were analyzed for differentially regulated DNA damage signaling molecules 
applying RT2 Profiler PCR Arrays with normalization to βACTIN and RPLO transcript levels. 28 % of 
the monitored genes have found to be deregulated, with 2 % being up- and 26 % being downregulated 
upon overexpression (A375 RAGE OE vs pcDNA3.1.) (C) left graph. The ranking of affected 
pathways was performed by illustrating the percentage of deregulated genes within the distinct 
pathways. DSB repair (20 %), BER (17 %), NER (16 %) were identified as most affected pathways 
(C) right graph. Monitored transcript levels of molecules belonging to the DSB repair pathway were 
illustrated by their fold change to A375 pcDNA3.1. control cells. Transcript levels BCRA1, H2AFX, 
LIG1, MLH1, PRKDC, RAD51, RPA, XRCC2, XRCC6 were found downregulated in A375 RAGE OE 
cells in comparison to corresponding pcDNA3.1. control (D). Expression of genes involved in 
xeroderma pigmentosum such as XPC, XPA, ERCC1, ERCC2, and of the two genes ATR and 
PARP1, of which alterations have been associated with increased melanoma risk, was investigated 
(E). 
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However, also some genes commonly affected in the rare disease xeroderma pigmentosum 
(XP) [59], namely XPC and ERCC2 were found to be deregulated in the melanoma cell line 
upon RAGE overexpression (Figure 5E). In addition, these data were compared to the study 
by Zhang and colleagues, who evaluated 1,463 genetic variants across 60 DNA repair–
related pathway genes in relation to melanoma risk, thereby identifying SNPs in ATR and 
PARP1 to correlate significantly with a higher melanoma risk [63]. Interestingly, the 
expression of these two genes was found to be dysregulated upon RAGE overexpression in 
this study (Figure 5E). 
In order to verify the RAGE-mediated regulatory effect on the expression of molecules within 
DNA repair pathways, a comparable approach was performed using a completely different 
model; the murine B16F10 melanoma. 
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Since B16F10 cells show comparable features to human melanoma, such as the expression 
of mouse homologs of melanoma-derived antigens, rapid growth, capacity to form 
metastases, as well as a low MHC Class I expression, these cells were strongly 
recommended to represent a reasonable model for human melanoma [381]. 
In brief, B16F10 melanoma cells were plated and transduced with lentiviral particles as 
illustrated in Figure 6A. The lentiviral particles contained a puromycin resistance gene, as 
well as either a non-targeting shRNA or a shRNA targeting Ager transcripts. After antibiotic 
selection of the cells, generated B16F10 clones were validated by qPCR comparing Ager 
transcript levels with Hprt and Gapdh as endogenous control and untransfected B16F10 cells 
as reference sample (Figure 6B, upper graph). For conformation of the successful 
knockdown of Rage, protein levels were determined by immunoblotting using an anti-Rage 
antibody and βActin as loading control. Indeed, for B16F10 control clones more than one 
band for Rage were detected; however, all of these bands disappeared or impaired after 
Rage knockdown, suggesting that the applied shRNA targeted most murine Rage isoforms. 
Noteworthy, also higher-molecular weight bands were weakened upon knockdown.  
With cDNA from a B16F10 control clone and, respectively, cDNA from a Rage knockdown 
clone two RT² Profiler™ Mouse DNA Damage Signaling Pathway PCR Arrays were 
performed. Indeed, in this model Rage knockdown was associated with an upregulation of 
DNA damage signaling molecules. More specifically, when normalized to the two house-
keeping genes βActin and Hsp90ab1, not a single gene was downregulated, but 44 % of all 
monitored genes showed increased expression (Figure 6C, left pie chart). Beside these 
consistent findings, differences regarding the affected pathways were observed. For 
instance, most of the differentially regulated genes were not found within the DSB repair but 
instead in the mismatch repair (MMR) pathway (Figure 6C, right pie chart). 
Figure 6 Rage mediates the downregulation of DNA repair molecules in mice. Experimental set 
up of the stable Ager RNA interference (RNAi) in the murine B16F10 melanoma line using shRNA 
lentivectors (A). Knockdown was verified via qPCR with Hprt and Gapdh as endogenous controls and 
untransfected B16F10 cells as reference sample (B, upper graph), and via immunoblotting using a 
rabbit-anti Rage antibody and βActin as loading control (B, lower graph). B16F10 control (non-
targeting shRNA) and Rage knockdown (Ager shRNA) cell cDNAs were analyzed for differentially 
regulated DNA damage signaling molecules applying RT2 Profiler PCR Arrays with βActin and 
Hsp90ab1 as endogenous controls. 44 % of the monitored genes have found to be deregulated, with 
0 % being down- and 44 % being upregulated upon Rage knockdown (B16F10 Kd#2 vs Ctrl#2, (C, left 
graph). The ranking of affected pathways was performed by illustrating the percentage of deregulated 
genes within the distinct pathways. MMR repair (20 %), ATM/ATR signaling (17 %), cell cycle (16 %) 
were identified as most affected pathways. The DSB pathway contained 9 % of all differentially 
regulated genes (C, right graph). Monitored transcript levels of molecules belonging to the DSB repair 
pathway were illustrated by their fold change to B16F10 Ctrl#2 cells. About 35 % of the monitored 
genes showed enhanced expression. Chek1, H2afx, Hus1, Mlh1, Rad52, Rpa1, Xrcc2 transcripts were 
found upregulated upon Rage knockdown in B16F10 cells compared to corresponding controls (D). 
Expression of genes involved in xeroderma pigmentosum such as Xpc, Xpa, Ercc1, Ercc2, and 
transcript levels of Atr and Parp1 were investigated (E). 
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Nevertheless, since fragmentation, loss, or rearrangement of chromosomes are current 
events in melanoma, thereby highlighting the importance of DSBs and their repair for its 
pathogenesis [53], differentially regulated genes within the DSB repair pathway were 
analyzed next. Indeed, 35 % of the monitored genes were upregulated, namely Chek1, 
H2afx, Hus1, Mlh1, Rad52, Rpa1, Xrcc2. No differences in expression were observed for 
Atm, Blm, Brca1, Brca2, Lig1, Mdc1, Mre11a, Nbn, Prkdc, Rad50, Rad51, Tp53, and Xrcc6 
(Figure 6D). In line with the data for the human melanoma cell line, Rage interference also 
exhibited effects on the expression of XP-related genes [59], here Xpc, Xpa, Ercc1, and 
Ercc2, as well as on the genes, for which genetic alterations were associated with a higher 
risk for melanoma [63], namely Parp1 and Atr (Figure 6E). 
These findings suggest a function of the RAGE protein as negative regulator of DNA damage 
signaling molecules in melanoma. Besides proving that this is true for human and mouse, 
analyzing transcript levels of genes known to be affected in xeroderma pigmentosum, 
revealed a RAGE-dependent dysregulation of XPC and ERCC2 in the human system, and of 
Xpc, Xpa, Ercc1, Ercc2 in the murine B16F10 cell line. Furthermore, four gene homologs 
involved in DSB repair mechanisms were identified, which are regulated by RAGE in both 
species: H2AFX/H2afx, MLH1/Mlh1, RPA1/Rpa1, and XRCC2/Xrcc2. 
VIII.5. RAGE expression enhances cell-intrinsic stress levels and 
sensitivity of melanocytic and melanoma cells towards DNA 
damage caused by extrinsic stress 
In normal cells, cell metabolism and energetics are proportional to the intracellular ROS 
levels. However, in cancer cells the relation between ROS homeostasis and energy 
metabolism is more complex [382].  
As demonstrated in section VIII.2, RAGE overexpression was associated with a cell 
metabolic boost in both, melanocytic and melanoma cell lines (Figure 3). Therefore, 
alterations in ROS levels associated with RAGE overexpression were determined. In brief, 
MelSTV, A375, and MeWo control and RAGE OE cells were seeded and stained with the 
non-fluorescent dye DCFDA. Intracellular ROS levels were monitored by their capacity to 
oxidize DCFDA to the highly fluorescent compound DCF. Indeed, RAGE overexpression 
significantly induced DCF and accordingly ROS levels in all of the cell lines (Figure 7A 
*p < 0.05, ***p < 0.0001). In terms of numbers, RAGE OE cells showed a 1.2 - to five - fold 
higher ROS production compared to control cells. Although enhanced ROS levels stand for 
increased cell-intrinsic oxidative stress, RAGE promoted melanocytic and melanoma cell 
survival in vitro (Figure 4D & E). Therefore, the question raised whether RAGE cannot only 
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mediate a higher resistance to cell-intrinsic stress but also when facing extrinsic stress 
signals. 
 
 
In order to address this question MelSTV, A375, and MeWo control (pcDNA3.1.) and RAGE 
OE cells were seeded and effects of exogenous genotoxic stress were monitored. More 
specifically, applying alamarBlue® assays including doxorubicin (Doxo) (100 nM) insults or 
DMSO treatments as control, cells were analyzed for distinct cell metabolic responses. Doxo 
is a drug used in cancer chemotherapy, intercalating in DNA molecules and thereby 
interfering with replication and transcription [383]. Interestingly, increased RAGE levels were 
associated with a greater cell metabolic collapse induced by doxorubicin in all three cell lines. 
The increased sensitivity towards genotoxic stress was highly significant for MelSTV and 
A375 RAGE OE cells (***p < 0.0001), and a same tendency was also observed for MeWo 
Figure 7 RAGE enhances ROS production and sensitivity towards extrinsic genotoxic stress in 
human melanocytic and melanoma cell lines. MelSTV, A375, and MeWo control or RAGE OE cells 
were stained with DCFDA, allowing the measurement of endogenous levels of ROS by detecting its 
oxidized, and fluorescent state, namely DCF. RFUs of the RAGE OE cells were normalized to the 
corresponding control (pcDNA3.1.) (A). Comparison of changes in cell metabolism after 72 h 
Doxorubicin (100 nM) treatment between overexpressing and control MelSTV, A375 and MeWo cells. 
Values generated for the correspondent untreated cells were set as zero (B). MelSTV pcDNA3.1. 
RAGE OE, RAGE OE AGER siRNA, RAGE OE control siRNA were cultivated in the presence of 
100 nM Doxorubicin and analyzed for apoptotic cells after 72 h using flow cytometry. Illustrated is the 
amount of Annexin V+ 7AAD+ cells (gated on Hoechst+ single cells (FSC-H/FSC-W)) after subtraction 
of the monitored frequency for the corresponding untreated cell line (C). Graphs display mean ± SD of 
three (ROS, alamarBlue®) individual experiments with technical triplicates, and three (apoptosis) 
biological replicates with technical duplicates. (*p < 0.05, **p < 0.005, ***p < 0.0001, unpaired 
student‘s t-test) 
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RAGE OE cells (Figure 7B). Furthermore, Doxo treatment of control or RAGE OE MelSTV 
cells induced apoptosis in cells with elevated RAGE levels to a significantly higher extend 
compared to control (pcDNA3.1.) cells. More specifically, with 40 % Annexin V+ 7AAD+ cells 
after Doxo treatment the amount of late apoptotic cells doubled upon RAGE overexpression. 
This effect was partially abolished using AGER siRNA, but not with control siRNA (Figure 
7C). 
To further evaluate the role of RAGE in mediating drug sensitivity to exogenous DNA 
damage-inducing agents or factors for its general validity, the effect of UV radiation-induced 
DNA damage in the murine B16F10 model upon Rage knockdown was investigated.  
Two B16F10 Rage knockdown clones, as well as corresponding control clones, were UV-
radiated and the effect of the radiation onto the cells was monitored by investigating 
differences in their cell metabolism as described before. The alamarBlue® assays showed 
that upon UV radiation a significant drop in cell metabolism could only be observed for the 
control clones (*p < 0.05) but not for the Rage knockdown clones (Figure 8A). 
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In order to rule out that potential cell cycle deregulations induced by Rage knockdown were 
responsible for this effect, cell cycle analysis was performed. Briefly, cells were starved 
overnight using serum-free MEF medium to ensure cell cycle synchronization, and then 
stained with Vybrant® DyeCycle™ Violet stain. This dye is a DNA-selective stain, which 
exhibits emission signals proportional to DNA mass. Since DNA mass is different between 
the three major phases of cell cycle – G0/G1 phase, S phase, G2/M phase – one can 
investigate the amount of cells within the different phases using flow cytometry [384]. When 
comparing the amount of cells in S phase, the most vulnerable phase to DNA damage, no 
basal difference was observed (Figure 8B). This indicates a normal cell cycle regulation in 
the absence of extracellular stress induction. When B16F10 cells were radiated, numbers of 
control and knockdown cells in S phase increased (**p < 0.005). However, this radiation 
effect was significantly higher in RAGE knockdown cells (**p < 0.005), suggesting the 
presence of strengthened cell cycle checkpoints or checkpoint-associated mechanisms 
leading to accumulations of cells in the S phase. 
In order to investigate if these effects also influence the survival of B16F10 melanoma cells, 
control as well as knockdown clones were stained for apoptotic cells using Hoechst, 
live/dead stain 7AAD, and an antibody against Annexin V. Flow cytometric analysis revealed 
a significantly increased amount of early apoptotic cells (7AAD- AnnexinV+) after radiation of 
B16F10 control cells when compared to apoptosis inhibitor (Z VAD FMK)-treated cells 
(Figure 8C, *p < 0.05). The vice versa effect could be demonstrated for the living population, 
defined as 7AAD- AnnexinV-, of the B16F10 control cells (Figure 8D, *p < 0.05). However, 
these effects were not observed for the B16F10 Rage knockdown cells (Figure 8C, D). 
Summing up this part, human and murine melanoma cells respond to increased levels of 
RAGE protein with a higher sensitivity towards extrinsic stress signals. RAGE protein 
expression is thereby not only linked with positive effects for the cells, such as proliferation 
and pro-survival benefits (demonstrated in VIII.2 and VIII.3), but also with a higher 
vulnerability (VIII.5). This strongly suggests a complex regulation network controlling RAGE 
Figure 8 Rage enhances sensitivity towards extrinsic genotoxic stress in murine B16F10 
melanoma. B16F10 Rage knockdown (Rage Kd) and control (Ctrl) clones (clone 1 = plain, clone 2 = 
lined) were UV radiated (10J/m2) and effects on cell metabolism were monitored using alamarBlue® 
and normalized to untreated, untransfected B16F10 cells (A). Cell cycle analysis with Vybrant 
DyeCycle Violet stained B16F10 Ctrl and Rage Kd cells before and after UV radiation (50J/m2) was 
performed by flow cytometry. Revealed percentages of cells in S phase (gated on single, 7AAD- cells) 
were compared (B). Using flow cytometry, UV radiation-induced, Rage-dependent effects on 
apoptosis were investigated with Hoechst, 7AAD and Annexin V antibody-stained B16F10 control and 
Rage Kd cells. Percentages of early apoptotic (7AAD-, AnnexinV+ (C)) and living cells (7AAD-, 
AnnexinV- (D)) before and after UV radiation were compared. Radiated cells treated with an apoptosis 
inhibitor Z VAD FMK (20μM) served as control. Graphs display mean ± SD of three (alamarBlue®) 
with technical triplicates, and two (cell cycle) or three (apoptosis) biological replicates with technical 
duplicates. (*p < 0.05, **p < 0.005, unpaired student’s t-test) 
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function in melanoma. Experiments and results facing this question will be described in the 
next result sections.  
VIII.6. Aberrant localization of RAGE points towards a new control 
level of RAGE functionality in melanoma 
In section VIII.1 the observed overexpression of RAGE in melanoma in comparison to benign 
nevi was described. Taking a closer look at the TMA slides indicated an additional pattern of 
RAGE expression.  
 Nuclear RAGE found in benign nevi disappears upon malignant 
transformation 
Analyzing samples of benign nevi, primary melanoma, and melanoma metastases in regard 
to the subcellular localization of the RAGE protein revealed remarkable differences between 
the tissues. In total, 13 corresponding benign nevi, 27 primary melanoma as well as 37 
associated metastases samples were analyzed in this study by two blinded individuals. 
In contrast to benign nevi, which showed a high nuclear localization of RAGE (Figure 9A, 
lower panel, left picture), melanoma cells of the primary tumor as well as of metastases 
samples displayed a higher cytoplasmic staining for the protein (Figure 9A, central and right 
picture). In terms of numbers, 29 % of melanocytes within benign nevi were characterized by 
pure nuclear RAGE expression, while this value dropped to 8 % for primary melanoma cells, 
and 2 % for melanoma metastases. Interestingly, the difference was not only significant 
when both melanoma tissues were compared to benign nevi (***p < 0.0001), but also 
between primary melanoma and metastases samples (*p <0.005), suggesting that the loss of 
nuclear RAGE is an ongoing process during progression (Figure 9A). 
In addition, the percentages of cells with predominant nuclear RAGE expression were also 
significantly reduced in malignant tissues (***p <0.0001); however, in this case no significant 
difference between primary melanomas and metastases was noted. In contrast, percentages 
of cells with predominant cytosolic or pure cytosolic RAGE expression increased upon 
transformation. More specifically, only 19 % of melanocytic cells in benign nevi showed a 
pure cytosolic RAGE expression, while primary melanoma (45 %) and metastases (46 %) 
samples showed significantly higher proportions of these cells (***p <0.0001). The same 
tendency was observed for predominant cytosolic RAGE expression; however, these 
differences were not significant. 
Furthermore, the analysis of a diverse set of human melanoma cell lines suggested a similar 
expression pattern of primary melanomas and cultured melanoma cells. Briefly, melanoma 
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cells were either fixed and permeabilized (Figure 9B, upper panel of illustrative pictures) to 
allow cytoplasmic as well as nuclear staining, or fixed without subsequent permeabilization 
as control (Figure 9B, lower panel of illustrative pictures). In all non-permeabilized control 
cells membrane-bound RAGE was present, while its localization within the membrane was 
found to be heterogeneous (Figure 9B, illustrative pictures). However, permeabilized as well 
as non-permeabilized cells of each cell line were subgrouped according to predominant 
cytoplasmic (Figure 9B, left illustrative pictures) or nuclear staining (Figure 9B, right 
illustrative picture) and statistically analyzed. To exclude distortions by artefacts counts for 
nonpermeabilized cells were subtracted from cell numbers achieved for permeabilized 
samples. Indeed, four out of five cell lines showed a higher cytoplasmic expression of RAGE 
(Figure 9B), whereas the SKmel23 cell line was hallmarked by a predominant nuclear 
expression. 
 
 
RAGE has been mainly described as receptor present on the cell membrane or as cytosolic 
molecule; in fact, there is only one publication describing translocation of the cytosolic tail of 
Figure 9 Nuclear RAGE found in benign nevi disappears upon transformation. TMAs containing 
benign nevi (n = 13), primary melanoma (n = 27) and metastases (n =37) samples were stained with 
rabbit anti-RAGE antibodies and analyzed for subcellular localization of intracellular RAGE by two 
blinded individuals. The intracellular distribution of RAGE was illustrated on a percentage basis (black: 
nuclear, dark grey: nuclear >cytosolic, light grey: cytosolic > nuclear; white: cytosolic, upper panel) and 
compared between the different tissue types. Illustrative pictures (scale = 25 µm) are displayed in the 
lower panel (A). Cellular localization of RAGE in melanoma cell lines (upper panel: white: cytosolic, 
black: nuclear; lower panel: illustrative pictures, 1st row: permeabilized; 2nd row: non-permeabilized 
control, rabbit-anti-RAGE; scale = 25 µm) (B). (**p < 0.005, ***p < 0.0001, unpaired student‘s t-test) 
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RAGE into the nucleus [250]. This raised the question which of the multiple forms of RAGE 
accumulate in the nucleus of benign nevi and to a significantly lower extend in melanomas. 
Furthermore, the mechanism behind the translocation was never investigated, although it 
was demonstrated that the shed cytosolic tail can translocate into the nucleus [250].  
 Subcellular prediction tools revealed a potential role of RAGE as 
nuclear protein, and predicted NLS and NES as a potential transport 
mechanism 
To address this question, fl-RAGE (Uniprot ID: Q1509-1) as well as described isoforms were 
characterized in silico for features known to be important or obstructive for translocating 
proteins into the nucleus, such as the presence of a signal peptide, phosphorylation, 
glycation, and SUMOylation sites, and the existence of nuclear localization (NLS) and export 
signals (NES) (Table 16). 
In 1999, Günter Blobel described the signal peptide as intrinsic signal that governs protein 
transport and localization in the cell [385]. Its existence potentially enables the protein to 
translocate to the endoplasmatic reticulum from where it is later passaged to the secretory 
pathway. In silico prediction using the computational online tool Signal P3.0. verified fl-RAGE 
as well as 15 RAGE isoforms to harbor signal peptides (Table 16). However, not every 
protein with signal peptide is secreted and vice versa its absence does not exclude protein 
secretion, as one can see in terms of HMGB1 and the S100 proteins [275, 293].  
Taking advantage of the classification system CELLO, RAGE variants were assigned to 
subcellular localizations based on the physico-chemical properties of their amino acids [362]. 
Indeed, next to predictions of RAGE secretion to the extracellular space, cytosolic and 
mitochondrial localization, a large amount of isoforms (15/20) was allocated to the nucleus 
(Table 16). 
In addition, potential NLS and NES were detected by two different algorithmic NLS prediction 
tools (NLStradamus, cNLS Mapper) and by one for NES (NetNES). By applying these tools, 
five isoforms with potential NLS and 18 with potential NES were identified. Four of the 
predicted NLS-containing isoforms showed NES with an amino acid (aa) length larger than 
five aa, namely RAGE_v16 / Q15109-2, RAGE_v6 / Q15109-4, RAGE_v8 / Q15109-8, and 
Q15109-10 (Table 16). RAGE_v5 / Q15109-6 contained a potential NES of only one amino 
acid, and was therefore ranked lower. 
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Table 16 In silico prediction revealed potential NLS and NES in RAGE isoforms. Full-length 
RAGE (RAGE) and its isoforms (labeled using HUGO terminology and/or Uniprot ID) were screened 
for features, predicting their subcellular localization, such as the existence of signal peptides 
(SignalP3.0), and physico-chemical properties of their aa (CELLO). NLS and NES were predicted 
using the computational prediction tools NLStradamus; cNLS Mapper (*scores > 8, indicated strong 
NLS activities), and NetNES (Y: Yes, predicted site is present; N: No potential site detected; 
highlighted (orange): isoforms predicted to contain both signals). Posttranslational modifications with 
potential regulatory effect on subcellular localizations were predicted: Potential phosphorylation sites 
(NetPhos) and correspondend kinases (PhosK), O- (Net-O-Glyc 3.1) and N- (Net-N-Glyc 1.0) 
glycosylation sites, SUMOylation sites (SUMO sp). All prediction tools were run using the highest 
stringency settings. 
 
Furthermore, also potential posttranslational modifications, which might be involved in a 
regulation of the cytosol/nucleus-shuttling were characterized in silico. For instance, a 
quantitative (amount) and qualitative (highest score) prediction of phosphorylation sites and 
correspondent kinases was performed. Fl-RAGE showed 15 potential phosphorylation sites, 
with highest score at aa position 172, which is predicted to be a substrate for PKC. In fact, 13 
of the 20 (13/20) analyzed RAGE variants were predicted to be substrates for PKC. 
Nevertheless, also variants were identified, which were predicted to be phosphorylated by 
PKA or cyclin-dependent kinase 5 (CDK5). Furthermore, fl-RAGE as well as most other 
splicing forms were in silico predicted to contain O- (19/20) and N-glycosylation (15/20) sites. 
In contrast, posttranslational modification by SUMOylation was only predicted for half of the 
splice variants (10/20). 
 Melanoma cells exhibit a unique RAGE splicing factor expression 
Showing that structural properties potentially enable some RAGE variants to translocate into 
the nucleus, did not solve the question, why the nuclear expression was shown to be 
characteristic for benign nevi but not for melanoma (Figure 9). A possible explanation would 
be a differential expression of distinct RAGE variants upon malignant transformation. To 
address this possibility the splicing factors HNRNP A1, HNRNP H, and TRA2-β1, which have 
been demonstrated not only to favor specific RAGE isoforms but further to be deregulated in 
diseases such as Alzheimer ’s [240, 241], were analyzed. 
Comparative analysis of transcript levels of these splicing factors between normal skin, 
benign nevi, and melanoma samples was accomplished using microarray data incorporated 
in the Oncomine database provided by Talantov and colleagues [386]. HNRNP A1 transcript 
levels were found to be significantly downregulated in melanoma tissue in comparison to 
normal skin and benign nevi (Figure 10A, ***p < 0.0001). Additionally, melanoma cells 
displayed a downregulation of HNRNP H transcripts when compared to normal skin samples 
(***p < 0.0001). However, these alterations were also found for benign nevi, suggesting a 
deregulation of HNRNP H as early event in melanocyte transformation (Figure 10B, 
*p <0.05). In terms of TRA2-β1, transcript levels were found to be significantly downregulated 
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in melanoma when compared to benign nevi (**p <0.005), but not to normal skin samples 
(Figure 10C). 
 
 
Summing up these results, the comparative analysis of HNRNP A1, HNRNP H, and TRA2-β1 
revealed a melanoma-specific expression pattern of these factors, strongly recommending a 
unique RAGE splicing signature in melanoma. Differences in RAGE splicing might therefore 
represent one factor controlling RAGE protein localization. 
 RAGE isoforms depend (at least partially) on proteins of the 
import-/export machinery, such as CRM-1 
Since the in silico characterization of RAGE variants also revealed the existence of potential 
NLS and NES sites, a deregulated import-/export-machinery might be another factor leading 
Figure 10 Melanoma-specific pattern of RAGE splicing factor expression. Comparative 
expression analysis of the RAGE splicing factors HNRNP A1, HNRNP H, TRA2-β1 based on data of a 
human genome U133A array [386] provided by the Oncomine database. Illustrated are the transcript 
levels of HNRP A1 (A), HNRNP H (B), TRA2-β1 (C) in control skin (n = 7), benign nevi (n = 18), and 
melanoma samples (n = 45) in normalized expression units compared to the reporter. (*p < 0.05, 
**p < 0.005, ***p < 0.0001, unpaired student‘s t-test) 
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to aberrant localization of RAGE in malignant melanoma. Indeed, studies claimed an 
upregulation of proteins controlling the nuclear export in melanoma [387].  
Comparative analysis of export machinery proteins, such as CRM-1 and RANBP1, using a 
human genome array comprising normal skin, benign nevi and melanoma samples, 
demonstrated a significant upregulation of these molecules in melanoma compared to 
healthy tissues (Figure 11A, B, *p < 0.05, ***p < 0.0001).  
 
 
To verify the nuclear expression of RAGE in melanocytic cells and to prove if RAGE 
translocation is in fact depending on the import-/export-machinery a subcellular fractionation 
Figure 11 Nuclear/cytosol-shuttling of RAGE depends, at least partially, on NES-mediated 
export by CRM-1. Comparative expression analysis of the nuclear export proteins CRM-1 and 
RANBP1 based on data of a human genome U133A array [386] provided by the Oncomine database. 
Illustrated are the transcript levels of CRM-1 (A), and RANBP1 (B) in normal skin (n = 7), benign nevi 
(n = 18), and melanoma samples (n = 45) in normalized expression units compared to the reporter. 
Protein suspensions (30 µg) of cytosol (CE), soluble nuclear (SNE), and chromatin-bound nuclear 
extract (CNE) from the subcellular protein fractionation of MelSTV cells (method scheme (C)) were 
separated via SDS-gel electrophoresis, blotted onto PVDF membranes and incubated with rabbit-anti-
RAGE antibodies, while antibodies against histone 3 (H3) and βACTIN served as purification controls 
(D). MelSTV cells used for this experiment were either untreated (DMSO only) or treated with the 
CRM-1 inhibitor Leptomycin B (LMB, 4nM) prior lysis. Rage-/- and wildtype lung lysates served as 
internal antibody control. Signals were visualized using ECL™ Western Blotting Detection Reagents 
and the ImageQuant LAS biomolecular imager. (*p < 0.05, ***p < 0.0001, unpaired student‘s t-test) 
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of the MelSTV cell line was performed. This cell line was not only chosen because it displays 
best the situation in normal human melanocytes but because the finding that melanoma cells 
differentially express splicing factors regulating the expression of RAGE isoforms might favor 
variants lacking NLS and NES.  
MelSTV cells were separated in a step-wise manner into cytoplasmic (CE), membrane (ME), 
nuclear soluble (SNE), chromatin-bound (CNE) and cytoskeletal protein extracts (PE) using 
special extraction buffers, which address the physical properties of the distinct 
subcompartments (Figure 11C). In order to test if cytosolic/nuclear-shuttling of RAGE 
depends on exportins, such as CRM-1, some cells were treated with the CRM-1 inhibitor 
Leptomycin B (LMB) prior lysis. CE, SNE, and CNE lysates (30 µg) of untreated and LMB-
treated MelSTV were then separated via SDS-gel electrophoresis and transferred onto PVDF 
membranes. After blocking, membranes were either incubated with a primary antibody 
recognizing both, human and murine RAGE, or antibodies against histone 3 (H3) as nuclear 
and βACTIN as cytosolic loading control. Lysates of murine Rage-/- and wildtype lungs 
served as control for antibody specificity. 
The detection of RAGE isoforms within the SNE and CNE of MelSTV cells (Figure 11D) 
verified the nuclear appearance of RAGE in melanocytic cells found in the TMA (Figure 9). 
Interestingly, immunoblotting detected signals in the nuclear fraction, which did not appear in 
the cytosolic extract, at least with the protein concentration and illumination time used in 
these experiments. For instance, proteins with a molecular mass of approximately 60 kDa 
appeared in SNE and CNE, but not in the cytosolic extract. Noteworthy, with 404 aa fl-RAGE 
is the largest protein of the different variants (Table 16) resulting in a molecular mass of 
approximately 55 kDa [216]. In the SNE and CNE bands for proteins with approximately 20 
to 30 kDa were detected, as well as the aforementioned band with around 60 kDa. Within the 
SNE additional variants between 50 to 60 kDa, and bands illustrating higher-weight 
molecules with 80 to 120 kDa were detected (Figure 11D). Noteworthy, bands for 80 to 
120 kDa molecules were also detected by blotting immunoprecipitations of RAGE from 
nuclear lysates (data not shown), and disappeared upon shRNA-mediated knockdown in the 
B16F10 model (Figure 6B). All these experiments were performed under denaturating 
conditions. If these higher-order complexes are homo- or heteromultimers with strong 
disulfide bonds, or posttranslationally modified proteins can only be assumed at this time. 
Most interestingly, the signals for the 60 kDa band was markedly increased in the SNE, when 
cells were treated with LMB prior lysis. Furthermore, signals of bands illustrating proteins with 
a molecular mass of approximately 30 kDa, were also enhanced in SNE and also in CNE 
after LMB treatment (Figure 11D). 
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These results strongly recommend an isoform-dependent subcellular localization of RAGE in 
melanocytic cells. Nuclear expression of the proteins seems to at least partially depend on 
the import-/export machinery, and thereby on the existence of NLS and NES within RAGE 
variants. 
 Potential role of RAGE as DNA-binding transcription factor 
The nuclear presence of RAGE in melanocytic cells raises questions about the function of 
nuclear RAGE. Proteins within the nucleus can possess various functions. Besides acting as 
transcription factor by regulating gene expression, they can also function as so-called 
‘scaffold’ proteins tethering signaling components and localizing those to specific areas 
within the nucleus. Other functions include packaging of the DNA as well as processing and 
import or export of RNA molecules or of nuclear proteins. 
A first step in elucidating the role of a protein within the nucleus, is to estimate the time the 
proteins spends there. This indicates if the proteins might be involved in transporting 
molecules in and out of the nucleus, or if they have a more complex role within the nucleus. 
Therefore, all isoforms were then analyzed with an in silico prediction tool, namely NucPred, 
which provides information on the time a protein most probably spends in the nucleus (Figure 
12A). Interestingly, by comparing these values for isoforms lacking potential NLS and NES 
(0.1393 ± 0.02069) with isoforms predicted to harbor both (0.2980 ± 0.05678), the latter 
showed a significantly higher score and were accordingly claimed to spend more time in the 
nucleus (Figure 12B).  
To further approach the nuclear function of RAGE, variants were screened for the existence 
of potential DNA binding sites by applying algorithms of the BindN tool. These are based on 
sequence features, such as side chain acidity values, hydrophobicity index, and molecular 
mass of the respective amino acids [379]. 
The analysis showed that all isoforms contained potential DNA binding sequences, ranging 
from one to three alternative motifs within one molecule (Figure 12A). Whereas the observed 
average number of binding motifs (BM) for RAGE variants without NLS/NES was one to two 
(1.786 ± 0.2143), molecules with NLS/NES showed between two to three (2.800 ± 0.2000) 
different BMs (Figure 12C). These observations point towards the existence of structural 
differences of RAGE variants when compared to fl-RAGE, which is illustrated in Figure 12D. 
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Investigating the observed DNA binding motifs in more detail elucidated two general binding 
sites, from here on referred to as BM1 and BM2, which were found in fl-RAGE as well as in 
most of the other variants. BM1 composed of the aa sequence KETKSYNR and BM2 of 
KEQTRRH (Figure 12E). In addition, additional BMs were found for RAGE variants, which 
were not present in fl-RAGE: SRRSRKRP (BM3), KTRRKRRS (BM4). Whereas the binding 
motif labeled as BM4 was found in several variants with and without NLS/NES, BM3 was 
elusively found in two isoforms, both harboring predicted NLS/NES. 
To sum up, all this in silico predictions strongly recommend distinct nuclear functions of 
RAGE variants, which might also include direct binding of DNA. However, this needs to be 
verified in in vitro assays comprising methods such as site-directed mutagenesis. For some 
BMs site-directed mutagenesis was already successfully established, and verified using 
restriction-digest based methods and sequencing analysis (data not shown). Studies 
including exogenous expression of these mutants and functional analysis, as well as mass 
spectrometry for identifying nuclear interaction partners will be essential for further 
examination of the roles of nuclear RAGE.  
Although some in silico predictions highlighted RAGE variants with predicted NLS and NES, 
a contribution of RAGE isoforms lacking these sequences was not excluded, and thereby 
requires consideration in further examinations. 
Figure 12 Predicted DNA-binding sites within RAGE variants point towards a potential role as 
transcription factor. Fl-RAGE (RAGE) and its isoforms (labeled using HUGO terminology and/or 
Uniprot ID) with (highlighted in orange) or without predicted NLS/NES were screened for the time they 
probably spend in the nucleus (NucPred, scoring range: 0 (short residence) to 1 (long residence)), and 
for potential DNA binding sites based on their physico-chemical properties (A). Number of potential 
DNA binding sites were predicted using the computational prediction tool BindN. All prediction tools 
were run using the highest stringency settings. Comparative analysis of nuclear residence (Nuc pred 
time) (B) and numbers of DNA binding sites (C) between variants with or without NLS/NES was 
performed. The mean Nuc pred time of RAGE variants without NLS/NES was calculated as 0.1393 ± 
0.02069, and for variants with NLS/NES as 0.2980 ± 0.05678 (B). On average, variants lacking 
NLS/NES showed 1.786 ± 0.2143, and NLS/NES-containing RAGE forms 2.800 ± 0.2000 DNA binding 
sites (C). The structure of fl-RAGE is illustrated in (D). Amino acid sequence alignment of RAGE 
variants with NLS/NES and illustration of identified DNA binding motifs: KETKSYNR (BM1), 
KEQTRRH (BM2), SRRSRKRP (BM3), KTRRKRRS (BM4) (E). BM3 was elusive for two NLS/NES-
containing RAGE variants, but not found in RAGE forms without NLS/NES. (*p < 0.05, **p < 0.005, 
unpaired student‘s t-test) 
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IX. Discussion 
IX.1. RAGE acts on in trans control elements thereby driving 
genomic instability in melanoma 
Genomic instability is a hallmark of cancer cells but in particular it is a hallmark for malignant 
melanoma, where the mutation frequency is even higher compared to most other solid 
tumors [34]. Genomic aberrations have also been found in benign nevi suggesting an early 
role for the loss of genomic integrity in melanomagenesis. Furthermore, non-metastatic 
tumors have been demonstrated to be genomically more stable than metastatic ones, 
illustrating genomic instability as an ongoing process [51, 53, 54]. Interestingly, AGER 
transcript levels correlate to this pattern: After a first upregulation in benign nevi, they further 
increased upon transformation to melanoma (Figure 2A).  
All cells of our body are perpetually confronted with different types of DNA damage. It has 
been estimated that cells experience approximately 100,000 spontaneous DNA lesions, daily 
[388]. Different sources are contributing to DNA damage including exogenous factors, such 
as UV radiation. However, the majority of this damage is generated endogenously, for 
instance, by production of ROS [388]. Interestingly, upon RAGE overexpression melanocytic 
as well as melanoma cells displayed an increased generation of ROS, indicating an elevated 
cell-intrinsic stress level (Figure 7A). For protecting genome integrity cells developed highly 
regulated elements, preserving the genome and mediating cellular responses to occurring 
DNA damage. Among those so-called in trans elements involved in replication, cell cycle 
checkpoints, and DNA damage recognition are listed [389]. However, a complete protection 
against genomic instability cannot be guaranteed. Occurring mutations are often 
concentrated to specific instability hotspots, such as fragile sites and highly transcribed DNA 
sequences, defined as in cis elements. Recent studies including whole-exome sequencing 
data from melanoma tumor/normal pairs revealed great advances in characterizing in cis-
acting elements in malignant melanoma [10]. Noteworthy, the analysis of a panel of human 
melanoma cell lines harboring different in cis elements, such as BRAF and NRAS mutations, 
did not reveal a distinct pattern for RAGE expression in this study (data not shown). The 
impact of in trans-acting elements as well as mechanisms of their regulation or dysregulation 
in melanoma remain vague. A role for these elements is provided by the fact that patients 
with xeroderma pigmentosum (XP), a rare disease caused by mutations in DNA repair 
genes, exhibit a 1000 - fold higher frequency combined with early onset of malignant 
melanoma [59]. 
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In this study, the impact of RAGE overexpression or knockdown on in trans-acting elements 
in the human A375 and the murine B16F10 melanoma cell line was investigated (Figure 5 & 
6). More specifically, transcript levels of molecules involved in ATM/ATR signaling, nucleotide 
excision repair (NER), base excision repair (BER), mismatch repair (MMR), double-strand 
break repair (DSB), other DNA repair genes, apoptosis, and cell cycle (for complete 
transcript list, see Table 13) were analyzed. Since the RAGE ligand HMGB1 is a well-known 
factor for maintenance of genome integrity, an indirect mechanism of action for RAGE was 
ruled out by demonstrating that RAGE overexpression was not accompanied with 
upregulated HMGB1 levels in the tested MelSTV, A375 or MeWo cell lines (Figure 5B). 
Instead, experiments performed on human as well as on murine cells consistently identified 
RAGE as negative regulator of elements involved in DNA repair, cell cycle control, and 
apoptosis (Figure 5C, 6C). More specifically, gene expression analysis revealed that RAGE 
overexpression in the human A375 cell line was associated with a downregulation by 26 % 
(21/79) of the analyzed gene transcripts involved in DNA repair, cell cycle control, and 
apoptosis (Figure 5C). In the murine system, an even greater effect was recorded: shRNA-
mediated Rage knockdown in the B16F10 cell line was accompanied with vice versa 
upregulation by 44 % (35/79) of the gene transcripts (Figure 6C). However, not only 
differences in the extent of regulatory interference by RAGE were reported, but also affected 
pathways were found to be species-specific. Major pathways in the human system were DSB 
repair, BER, and NER, whereas in the murine system the majority of differentially regulated 
genes were found in ATM/ATR signaling, MMR, and cell cycle.  
In 2011, Zhang and colleagues evaluated 1,463 genetic variants across 60 DNA repair–
related pathway genes in relation to melanoma risk, thereby identifying SNPs in ATR and 
PARP1 to correlate most significantly with a higher risk to melanoma [63]. Interestingly, the 
expression of these two genes was found to be dependent on RAGE in both applied 
systems, human and mouse (Figure 5E, 6E). 
Furthermore, the comparative analysis of transcript levels of genes, known to be affected in 
XP, revealed a RAGE-dependent dysregulation of XPC and ERCC2 transcription in the 
human system, and with Xpc, Xpa, Ercc1, Ercc2 for the murine B16F10 cell line (Figure 5E, 
6E). Together, these results clearly demonstrate that RAGE is able to impair genomic 
integrity in human and murine melanoma cells. For tumors, including melanoma, an achieved 
genomic instability due to downregulation of DNA repair molecules favors additional 
acquirement of mutations, thereby allowing the generation of new tumor variants with growth 
advantages or immunoedited variants [390]. This is also indicated by the finding that the 
RAGE-dependent downregulation of DNA damage molecules was associated with a better 
survival in vitro, at least under non-toxic conditions (Figure 4D, E).  
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DSB repair signaling was found to be the major pathway affected upon RAGE 
overexpression in the human melanoma cell line (Figure 6D). DSBs occur when the 
phosphate-sugar backbones of both DNA strands are broken at the same position or in close 
proximity, leading to a physical dissociation. Cancer genome sequencing studies uncovered 
numerous chromosomal rearrangements harboring pathological DSB repair signatures, 
thereby demonstrating that not only DSBs themselves but also their misrepair contribute to 
genomic instability and tumorigenesis. In contrast to single-strand breaks, restoration of 
DSBs is more problematic, since the genetic information cannot be easily retained from the 
complementary strand. Therefore, DSBs might lead to fragmentation, loss, or rearrangement 
of chromosomes [391]. A RAGE/Rage-dependent dysregulation of DSB repair molecules 
was detected in the human melanoma cell line as well as in the murine B16F10 melanoma 
(Figure 5C, 6C). The fact that defects in DSB repair also favor melanoma growth in vivo, has 
been demonstrated by the loss of expression of DNA DSB-repair genes in human 
melanoma. For instance, MLH1 was demonstrated to be lost completely in 60 % of primary 
melanomas, and also losses of H2AX have been reported [392-394]. Noteworthy, in this 
study RAGE/Rage was identified as a negative regulator of gene expression for both of these 
proteins in melanoma (Figure 5D, 6D). 
The finding that metastatic tumors are genomically less stable combined with the results of 
the study from Leclerc and colleagues, demonstrating an upregulation of RAGE protein 
between stage III and stage IV melanomas, further indicated a correlation of genomic 
instability and RAGE expression in malignant melanoma [51, 53, 54, 280]. Indeed, in our 
study the TMA analysis also revealed a higher RAGE expression in metastases compared to 
primary melanomas (Figure 2B). However, the observed differences were not significant, 
which may be caused by the small number of samples analyzed. 
IX.2. RAGE establishes and drives melanoma hallmarks such as 
resistance to cell death, proliferative signaling, and enhanced 
invasion capacity 
Cancer cells display common characteristics, so-called cancer hallmarks; however, 
mechanisms causing these features are divergent between tumors of different localization 
and type. Elevated AGER transcript levels in benign nevi compared to normal skin (Figure 
2A) might suggest a role for RAGE in early events during transformation of normal human 
melanocytes to melanoma. 
The basis for all cellular functions of normal or transformed cells is created by an efficient cell 
metabolism. However, cancer cells seek ways to adapt cell metabolism to suit their altered 
functional properties, indicating that metabolic reprogramming represents an important 
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component of malignant transformation [395]. A role for RAGE in regulating cell metabolism 
was first demonstrated by Kang and colleagues in pancreatic cancer cells [249]. 
In order to investigate if RAGE might drive transformation of melanocytic and progression of 
melanoma cell lines by adapting cell metabolic activity, in vitro overexpression of RAGE in 
the melanocytic cell line MelSTV, as well as in two melanoma cell lines, A375 and MeWo, 
was performed (Figure 3E). Cell metabolism comprises metabolic reactions converting 
biochemical energy from nutrients into ATP, the so-called ‘molecular unit of currency’. The 
production of ATP is accompanied by the generation of coenzymes like nicotinamide adenine 
dinucleotide hydride (NADH) or flavin adenine dinucleotide hydroquinone (FADH2). The 
levels of these coenzymes were measured by the alamarBlue® method and used for 
illustrating cell metabolic changes in this study [396]. As expected, lowest basal cell 
metabolic activity was found for the melanocytic MelSTV cell line, whereas highest was 
exhibited by MeWo (data not shown). Upon RAGE overexpression the basal cell metabolic 
activity levels in both melanocytic and melanoma cell lines increased by approximately 50 % 
(Figure 3E). 
Kang and colleagues demonstrated that altered cell metabolic activity was caused by 
cytosolic but not membrane-bound RAGE in a HMGB1-dependent manner [249]. However, 
since the study was not addressing different RAGE isoforms, their roles in maintaining and 
regulating tumor cell bioenergetics remain unclear. Reverting RAGE overexpression in the 
melanoma cell lines using siRNA targeting AGER transcripts, did not only significantly return 
cell metabolic changes to their baseline condition, instead it even seemed to further impair 
cell metabolism in both melanoma cell lines, although this was not significant (Figure 4C). 
However, this indicates a potential role for other RAGE isoforms in maintaining and driving 
tumor cell bioenergetics. In their study, Kang et al. were able to demonstrate that HMGB1-
induced MEK-ERK-MAPK pathway activation resulted in the phosphorylation of cytosolic 
RAGE leading to its consequent translocation into the mitochondria, where it induced ATP 
production [249]. Since the hyperactivation of the MAPK pathway represents a hallmark of 
melanoma cells, a comparable regulatory function for RAGE might be conceivable. 
The fact that melanoma cells display enhanced and deregulated bioenergetics was also 
supported in vivo by the detection of high lactate dehydrogenase (LDH) levels in the blood of 
melanoma patients. Indeed, melanoma cells seem to deregulate their cell metabolism by 
favoring glycolysis and impairing citric acid cycle [89-91]. Although glycolysis is in general 
less efficient compared to the citric acid cycle regarding ATP production, glucose 
degradation provides cells with intermediates needed for biosynthetic pathways and is also 
accompanied with higher levels of NADH [395]. Therefore, the elevated coenzyme levels 
detected by alamarBlue® (Figure 3E, 4C), could not only represent a higher metabolic 
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activity upon RAGE overexpression, but also a shift of the equilibrium between bioenergetic 
pathways towards glycolysis. Further investigations including quantitative analysis of 
mitochondrial RAGE in melanocytes and melanoma, as well as RAGE isoform-specific 
approaches need to be performed in order to further elucidate the effect of RAGE on cancer 
cell metabolism. 
However, ATP and coenzymes like NADH or FADH2 are not the only molecules generated 
during cell metabolism. In fact, in normal cells the activity of the mitochondrial electron 
transport correlates to levels of reactive oxygen species (ROS) [382]. This could not only be 
verified for the melanocytic cell line MelSTV but also for both melanoma cell lines. More 
precisely, RAGE overexpression was accompanied with a 1.2- to five-fold higher ROS 
production compared to control cells (Figure 7A). When generated at low picomolar levels, 
ROS have been demonstrated to induce tumor cell proliferation, which led to the 
development of therapeutic strategies targeting tumor proliferation by alleviating intracellular 
ROS levels [397, 398]. 
Indeed, upon RAGE overexpression cell proliferation, measured by CSFE dilution, was found 
to be significantly higher, at least for MelSTV and A375 cells. For MeWo cells the same 
tendency was observed (Figure 3F). Furthermore, comparative analysis of RAGE 
overexpressing A375 (A375 RAGE OE) and control cells revealed a dysregulation of 8 % of 
the cell cycle-associated genes upon overexpression (Figure 5C). As mentioned above, 
melanoma cells display a high plasticity, and the existence of two distinct cell states. One 
can distinguish between melanomas and melanoma cell lines with a more ‘proliferative’, or a 
more ‘invasive’ phenotype. In 2012, Widmer and colleagues generated a systematic 
classification model in order to distinguish between the two states of melanoma cells by 
phenotype-specific gene expression mapping. In this study, MeWo cells were characterized 
as more ‘proliferative’, whereas A375 were defined as an ‘invasive’ melanoma cell line [98]. 
Indeed, the results for the basal cell metabolic activity (data not shown), with highest values 
for MeWo cells, verified this finding. A high basal proliferation level might therefore be the 
reason, why RAGE overexpression did not reveal such a tremendous effect on MeWo cells 
compared to MelSTV and A375 cells (Figure 3F). 
As mentioned before, early melanoma growth often comprises a radial growth phase, 
characterized by uncontrolled proliferation of melanoma cells, followed by a vertical growth 
phase, in which the proliferating cells acquire additional features enabling them to invade to 
new metastatic sites [5, 6]. Upon RAGE overexpression also a significant increase in 
invasion capacity was demonstrated, this time in MelSTV and MeWo cells, thereby again 
supporting the hypothesis that A375 and MeWo cell lines present distinct phenotypes (Figure 
3G). Indeed, comparing basal invasion levels lowest invasion capacity was found for 
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MelSTV, and highest for A375 cells. Evidence for a correlation of RAGE expression and 
invasiveness has been provided for gastric and prostate cancer by the studies of Kuniyasu 
and colleagues [343, 345]. A possible mechanism explaining the RAGE-dependent increase 
in invasion capacity, at least for the skin, might be an upregulation of matrix 
metalloproteinases, such as MMP9, and thereby of the proteolytic activity of skin cells as 
reported by Zhu and colleagues [399]. Furthermore, a role of RAGE in inducing angiogenesis 
in melanoma, thereby facilitating metastatic spread, has been suggested; however, studies 
regarding this topic created conflicting results [356, 357].  
In this study, there were neither morphological alterations of melanocytic, nor melanoma cell 
lines detected upon RAGE overexpression (Figure 3B). Meghnani and colleagues claimed a 
function of RAGE in EMT-like processes in melanoma, accompanied with the establishment 
of mesenchymal-like morphologies, higher migration abilities and reduced proliferation 
properties [358]. In the study presented, the finding that RAGE promotes proliferation as well 
as invasion in a melanoma cell line-specific manner, provides evidence that its function in 
melanomagenesis is not favoring one phenotype, instead, it seems to generally enhance 
melanoma aggressiveness. In addition, the lack of morphological alterations found in this 
study, also suggests that the findings of Meghnani et al. were most likely determined by the 
phenotype of the used melanoma cell line (WM115), and not melanoma-specific. Indeed, in 
the study of Widmer and colleagues WM115 showed neither a proliferative, nor an invasive 
phenotype and thereby does not represent a standard melanoma cell line, at least regarding 
these features [98]. Upregulated AGER transcript levels already found in benign nevi and not 
solely in melanoma tissue (Figure 2A), as well as the RAGE OE-induced establishment of 
melanoma cell hallmarks, such as higher cell metabolic activity, increased proliferation, and 
the capacity to invade, in the melanocytic cell line MelSTV (Figure 3), point towards a driving 
role of RAGE not only in melanoma progression and metastasis, but also in early events 
during melanomagenesis. 
IX.3. RAGE promotes melanoma growth and survival under non-
toxic conditions but sensitizes cells towards exogenous DNA 
insults 
The fact that AGER transcripts as well as RAGE protein have been found to be upregulated 
upon malignant transformation, already indicated a tumor-promoting function of RAGE in 
malignant melanoma (Figure 2A, B). This was proven by in vitro assays, demonstrating that 
RAGE enables melanocytic and melanoma cells to improve their bioenergetics, thereby 
achieving an enhanced proliferation and/or invasion capacity, as discussed in the last section 
(IX.2). Since all these features are indicators for improved cellular health, a contribution of 
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RAGE-dependent pro-survival effects to tumor promotion was hypothesized. However, the 
finding that RAGE overexpression was accompanied with an enhanced ROS production 
(Figure 7A) in the human melanocytic and melanoma cell lines questioned this idea. Normal 
cells avoid high ROS levels as they are associated with increased cellular stress and 
potential damage. Indeed, ROS are not only known to oxidize DNA bases, thereby causing 
DNA base changes, but also to produce mismatches and to enhance DNA deamination [400, 
401]. However ROS levels can also provide beneficial effects; for instance, ROS have been 
demonstrated to induce tumor cell proliferation [397, 398]. The latter results in the finding that 
tumor cells often acquire different mechanisms, such as impairing apoptosis induction, in 
order to tolerate higher levels of ROS [398, 402]. To address these questions, RAGE-
dependent effects on survival and apoptosis were investigated. 
Human melanocytic MelSTV and melanoma cell lines, A375 and MeWo, transfected with the 
control vector or with the RAGE OE construct, were stained with Hoechst, 7AAD and 
antibodies against Annexin V to distinguish between living, non-apoptotic cells (Hoechst+, 
7AAD-, Annexin V-) and apoptotic cells (Hoechst+, 7AAD+/-, AnnexinV+) (Figure 4D, E). Upon 
RAGE overexpression cells displayed lower numbers of apoptotic cells, when compared to 
control cells. Furthermore, this effect could be partially reverted by AGER-specific RNA 
interference. These results clearly demonstrate that RAGE provides pro-survival signals or 
more specifically anti-apoptotic signals to melanocytic and melanoma cell lines. 
Different causes could account for the observed alterations in apoptosis. For instance, RAGE 
overexpression could have led to a deregulated balance between pro- and anti-apoptotic 
molecules, but also to differences in molecules sensing apoptosis-inducing events. Examples 
for the latter would be a differential expression of death receptors, such as FAS (first 
apoptotic signal) or TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), or 
deregulated DNA lesion sensors and signal transducers. Comparative analysis of 
transcription levels of molecules covering the potential issues leading to impaired apoptosis 
of RAGE OE cells, such as ATM/ATR signaling, nucleotide excision repair (NER), base 
excision repair (BER), mismatch repair (MMR), double-strand break repair (DSB), other DNA 
repair genes, apoptosis, and cell cycle (for complete transcript list, see Table 13) were 
investigated in human and mouse. 
Indeed, studies on the human A375 and murine B16F10 melanoma cell lines, including 
RAGE overexpression and Rage knockdown, consistently demonstrated that transcript levels 
of DNA damage sensors and repair molecules were negatively controlled by RAGE/Rage, 
and that this was also true at a lower extend for genes encoding for proteins directly involved 
in the apoptotic cascade (Figure 5C, 6C). More specifically, in the human A375 melanoma 
cell line the majority of differentially regulated genes upon RAGE overexpression was found 
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within the DSB repair pathway, while the Rage knockdown in the murine B16F10 cell line 
was predominantly associated with altered gene expression in ATM/ATR signaling. As 
mentioned before, the apoptosis pathway was not among the top affected pathways in 
neither human nor mouse. However, pro- as well as antiapoptotic molecules are often 
controlled not via transcriptional regulation but via posttranslational modifications, such as 
phosphorylation, or direct inhibition [403]. One indication for such mechanism has been 
provided by the study of Chen and colleagues, demonstrating that in some tissues RAGE 
also directly interacts with P53, an important tumorsuppressor, known to regulate the 
expression of pro- and anti-apoptotic molecules [404]. A transcriptional deregulation of P53 
could not be observed in this study; however, direct protein-protein interaction of RAGE with 
apoptotic regulators was not investigated. Therefore, direct RAGE interactions or 
modulations of activation states cannot be ruled out and need to be further investigated in 
future studies. 
Tumor cells often possess features, which might be unfavorable for a single cell but 
beneficial for the tumor bulk. For instance, genomic instability can cause cell death on the 
one hand, and on the other it can lead to the development of new tumor variants, which 
might be important for immune evasion. Another example is the upregulation of ROS, which 
enhances cell-intrinsic stress levels but which also promotes tumor proliferation and invasion 
[397, 398]. This study could demonstrate a role of RAGE in both of these melanoma 
strategies (Figure 7A). However, the downregulation of molecules involved in DNA repair, 
and therefore in maintaining genomic integrity might also have disadvantages for melanoma 
cells under specific conditions.  
Indeed, upon RAGE overexpression MelSTV, A375, and MeWo cells were more sensitive 
towards treatment with doxorubicin, a drug used in cancer chemotherapy, which intercalates 
in between DNA bases, thereby producing large amounts of DNA double-strand breaks 
[383]. More specifically, all three overexpression cell lines responded with a greater cell 
metabolic collapse induced by doxorubicin compared to control cells. This was highly 
significant for MelSTV and A375 RAGE OE cells, but the same tendency was also observed 
for the MeWo cell line (Figure 7B). For MelSTV cells this could be further illustrated by 
following up apoptosis induction upon doxorubicin treatment. Indeed, the amount of late 
apoptotic cells after doxorubicin treatment doubled upon RAGE overexpression. This effect 
was partially abolished using AGER siRNA, but not by control siRNA (Figure 7C). For A375 
and MeWo comparable effects have been observed in one experiment; however, repetitions 
failed to generate consistent results. This might have different reasons; for instance, the high 
plasticity combined with the capacity of melanoma cells to circumvent apoptosis in various 
ways might dampen either doxorubicin sensitivity or doxorubicin-induced responses. 
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Furthermore, since excessive DNA damage also results in cellular necrosis, future 
experiments should include TUNEL assay and electron microscopy to distinguish between 
active and passive cell death. However, the finding that RAGE promotes sensitivity to DNA 
damage-inducing factors was verified using the murine B16F10 model. There, the Rage 
knockdown was associated with a lower sensitivity towards UV radiation. More specifically, 
UV radiation led to a significant cell metabolic collapse in control but not in Rage knockdown 
cells (Figure 8A). Additionally, control cells showed a significantly induced apoptosis (Figure 
8C), and a consequent reduction in the living cell population (Figure 8D); both features were 
not found for Rage knockdown cells upon radiation. Kang and colleagues demonstrated that 
RAGE is able to protect pancreatic tumor cells from ROS-induced cell damage, as well as 
from cell damage by chemotherapy-induced genotoxic stress. For melanoma cells, RAGE 
overexpression was associated with a higher ROS production (Figure 7A) but also with 
increased survival (Figure 4C, D), thereby proving that this finding is also true for the role of 
RAGE in malignant melanoma. However, the published finding, that RAGE protects 
pancreatic cancer cells from death induced by anticancer treatment could not be transferred 
to melanoma. A possible explanation might be different mechanisms of action of the 
anticancer drugs used. Indeed, while the latter study used alkylating agents (oxaliplatin, 
melphalan) and antimetabolites (gemcitabine), genotoxic insults in the here presented study 
were triggered using the anthracycline doxorubicin. Nevertheless, Kang and colleagues also 
verified their results using UV radiation, therefore suggesting that rather tissue-specific 
differences regarding RAGE modulators and isoform expression, as well as a distinct 
subcellular localization as described in section IX.4 might account for the observed 
differences. 
Interestingly, Rage knockdown in B16F10 melanoma was also accompanied with altered 
expression of genes classified as cell cycle pathway genes (Figure 6D). It has been 
demonstrated that cells within the S phase are most vulnerable towards genotoxic stress. 
Therefore, a dysregulation of the cell cycle leading to decreased basal numbers of cells 
within the S phase would also result in a lower sensitivity of Rage knockdown cells towards 
UV radiation. This was addressed by staining B16F10 control and Rage knockdown cells 
with Vybrant® DyeCycle™ Violet, a dye exhibiting emission signals proportional to DNA 
mass. Basal levels of S phase cells between control and Rage knockdown cells were 
compared and no difference was observed (Figure 8B). This illustrates that the RAGE/Rage-
dependent sensitivity of melanoma cells is not due to differences in cell cycle, but might be 
explained by altered expression of DNA damage signaling molecules (Figure 5C, 6C). For a 
close relative of Rage, the PRR Tlr4, a role in the repair of UV radiation-induced cutaneous 
DNA damage has already been proposed [405]. More specifically, Ahmad and colleagues 
investigated efficacy of DNA damage repair upon local UV exposure in Tlr4-/- and wildtype 
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mice. They found DNA damage repair being more efficiently repaired in the skin of Tlr4-/- 
mice as compared to the wildtype situation, and claimed that this was due to the higher 
expression of Xpa observed in the Tlr4-/- mice after UV exposure. A follow-up study provided 
evidence that the Tlr4-deficiency-dependent resistance to UV radiation was mediated by the 
protein Myd88 [406]. As mentioned before, Myd88 has also been described as adaptor 
protein for phosphorylated RAGE [300]. The same study showed that Myd88-deficiency led 
to a decreased caspase-mediated cleavage of Parp, a DNA repair molecule sensing DNA 
lesions, for which allelic variants have been described to confer higher risk for melanoma [63, 
406]. In fact, in the here-presented study Xpa as well as Parp1 transcript levels were 
demonstrated to be upregulated in murine Rage knockdown cells compared to control 
B16F10 melanoma cells (Figure 6E). This strongly recommends that the reduced response 
of the Rage knockdown cells to UV radiation is caused by impaired activation of downstream 
effectors, potentially shared with Tlr4 signaling, leading to an enhanced repair of DNA UV 
damage. Furthermore, upon UV radiation a significantly higher number of S phase cells was 
observed in Rage knockdown as compared to B16F10 control cells (Figure 8B). This points 
towards two things: First, cell cycle checkpoints in general seem to be still functional. 
Second, upon radiation Rage knockdown cells halt cell cycle in S phase, supporting the idea 
of an enhanced DNA damage sensing or DNA repair. 
Since doxorubicin and UV radiation predominantly induce double-strand breaks, genes 
involved in the DSB repair pathway and altered upon RAGE overexpression in the human 
A375 melanoma cell line or, respectively, upon Rage knockdown in murine B16F10 
melanoma cells, were investigated. Indeed, four gene homologs involved in DSB repair 
mechanisms were identified, which are regulated by RAGE/Rage in both species: 
H2AFX/H2afx, MLH1/Mlh1, RPA1/Rpa1, and XRCC2/Xrcc2 (Figure 5D, 6D). 
H2AFX encodes for the histone H2A variant X (H2AX) that constitutes 2 to 25 % of 
mammalian histone H2A depending on organism and cell type [407]. The structure of H2AX 
is highly similar to other H2A variants except for its C-terminal tail, which becomes rapidly 
phosphorylated to form γH2AX upon induction of DSBs. It was shown to play an important 
role in early responses to DNA damage by regulating the recruitment and accumulation of 
DNA repair proteins to sites of DSB [408]. Interestingly, mice lacking H2AX were shown to be 
more sensitive to radiation and more prone to cancer development in a p53 null background 
[409]. This is in line with the data presented here, showing that Rage knockdown in murine 
B16F10 melanoma is accompanied with upregulation of H2ax (Figure 6D) resulting in 
increased UV radiation resistance (Figure 8A,C,D). This indicates that H2AX functions as a 
genome damage sensitizer. Losses of H2AX protein have been demonstrated in melanoma 
[394], however, the remaining H2AX has been reported to be phosphorylated to a 
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significantly higher extend as compared to benign nevi [410], illustrating higher amounts of 
unrepaired DNA damage in melanoma. 
The replication protein A (RPA) is a highly conserved heterotrimeric protein involved in 
maintaining genomic integrity by binding single- and double-stranded DNA breaks and 
recruiting other DNA repair molecules, such as ATR. Furthermore, RPA has also been 
demonstrated to colocalize with RAD51 upon UV radiation of mouse fibroblasts [411, 412]. 
Interestingly, altered RAGE/Rage expression was not only accompanied by differential 
expression of RPA, but also of RAD51 (Figure 5D, 6D), and of ATR (Figure 5E, 6E) in both, 
human and mouse. A role for RPA in the S phase cell cycle checkpoint was demonstrated; 
more specifically, when bound to DNA RPA was shown to halt cell cycle progression until 
DNA repair is completed [413]. This fact and the observed upregulation of Rpa upon Rage 
knockdown might explain the increased number of cells in S phase after UV irradiation in 
B16F10 Rage knockdown compared to B16F10 control cells (Figure 8B). 
While the aforementioned downregulation of RAD51 upon RAGE overexpression in human 
melanoma could not be verified in the murine B16F10 model (Figure 5D, 6D), its importance 
was illustrated by another differentially regulated gene; XRRC2 (X-ray repair complementing 
defective repair in Chinese hamster cells 2). Its expression was found to negatively correlate 
with RAGE/Rage in human and mouse. Previous studies demonstrated that XRCC2 
enhances the activity of RAD51 and, consequently, that a loss of XRCC2 results in a delay of 
the early DNA damage response mediated by RAD51 [414]. This strongly indicates that the 
observed downregulation of both, RAD51 and XRCC2, in the human melanoma cell line 
A375 (Figure 5D) was accompanied with delayed and impaired DNA repair. Other studies 
reported that Xrcc2 knockout fibroblasts were hypersensitive to various anticancer drugs 
[415], thereby supporting the here presented finding that RAGE/Rage expression correlates 
with higher sensitivity to genotoxic insults in human and mouse (Figure 7B, C, Figure 
8A,C,D) by negatively influencing DNA damage repair genes like XRCC2/Xrcc2 (Figure 5D, 
6D). 
Another DSB repair gene deregulated upon altered RAGE/Rage expression, was encoding 
for the MUTL homolog1 (MLH1) protein (Figure 5D, 6E). MLH1 is a multifunctional protein 
with important roles in MMR but also reported to have tremendous importance in controlling 
DSB repair [416]. As aforementioned, MLH1 expression was found to be decreased in 
malignant melanoma [392, 393]. Within this study elevated RAGE levels were directly linked 
with impaired MLH1 gene expression (Figure 5D). The hypothesis of an inverse correlation of 
the genes is supported by studies in colorectal cancer, where a similar expression pattern of 
RAGE and MLH1 was observed but never connected [342, 417]. Instead, an association of 
BRAFV600E mutations with increased hypermethylation of the MLH1 gene was postulated 
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[417]. However, in the here presented study no effect of in cis elements, such as 
BRAFV600E, on RAGE expression could be observed (data not shown). Nevertheless, 
future studies with larger cohorts might give a better measure of a potential correlation of 
BRAFV600E mutation and RAGE, as well as of a possible involvement of RAGE in DNA 
methylation. 
 
 
As illustrated in Figure 13, these results demonstrate the benefits of high RAGE expression 
in leading to enhanced survival (Figure 4C, D) and higher aggressiveness of melanoma cells 
(Figure 3), and their association with negative effects such as a higher vulnerability to 
exogenous genotoxic stress (Figure 7B, C; Figure 8A,C,D). These findings as well as the 
characteristic of melanoma cells to rapidly establish resistance to chemotherapies indicate 
that melanoma cells possess strategies to regulate RAGE functionality, and these might not 
only comprise the control of gene expression but also alternative splicing and subcellular 
translocation as discussed in section IX.4. However, the ambivalent character of RAGE also 
raises questions regarding its potential as a novel target for therapeutic approaches. In vitro 
generation of isogenic, anticancer drug-resistant melanoma cell lines with concomitant 
analysis of RAGE/Rage expression would provide first insights. Furthermore, xenograft 
transplantations of control and RAGE overexpressing melanoma cell lines into 
Figure 13 Ambivalent role of RAGE in melanomagenesis. Dependent on the level of DNA damage 
RAGE either mediates tumor-promoting features by driving characteristic melanoma hallmarks (left 
side) or induces cell death (right side). 
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immunodeficient mouse strains, and/or B16F10 Rage knockdown or control injections into 
immunocompetent mice, with or without administration of anticancer drugs or UV radiation, 
would shed light onto the behavior of these cells under treatment.  
IX.4. Subcellular localization of RAGE: An important level of control 
in melanoma? 
Immunohistochemical analysis of TMA containing samples of benign nevi, primary melanoma 
and metastases did not only reveal a significantly higher expression of RAGE in non-
metastatic and metastatic melanoma samples compared to benign nevi, but also a 
predominant nuclear RAGE staining for the latter (Figure 2B, C, Figure 9A). This aroused 
great interest, since RAGE was mainly described as cell-surface receptor, and as secreted or 
cytosolic molecule. Interestingly, the percentage of cells with exclusive nuclear RAGE 
expression was not only significantly decreased in all melanoma cells in comparison to 
melanocytes, but a reduction was additionally observed comparing metastases to primary 
melanomas. This supports the notion that loss of nuclear RAGE is a relevant feature during 
process of progression (Figure 9A). However, potential effects mediated by the observed 
compartmental shift does not necessarily need to come along with loss of nuclear functions 
but also with a gain of toxic cytosolic functions of RAGE. In fact, while only 19 % of 
melanocytic cells in benign nevi showed a pure cytosolic RAGE expression, this value was 
found to be significantly higher in primary melanoma (45 %) and metastases (46 %) samples. 
The subcellular localization is a major characteristic of molecules since it has important 
impacts on the activation state, interaction network, and biological function [418]. Therefore, 
profiling the position of proteins within a cell is a mandatory task that can be achieved by 
screening proteins of interest for localization-specific features. Since fl-RAGE contains such 
a feature, namely a signal peptide indicating a potential secretion of the protein, RAGE 
variants were first screened for this motif [216]. In terms of numbers, 15 from the 20 analyzed 
RAGE variants contained such a secretion signal (Table 16). However, an existing secretion 
signal does not necessarily cause a secretion of the protein. The best example is fl-RAGE 
itself; due to its structure the protein cannot be secreted without further posttranslational 
modifications although exhibiting the signal for secretion. To date, only two studies indicated 
that RAGE might also possess functions in different cellular compartments, such as the 
mitochondria and the nucleus. One study demonstrated that a phosphorylation of RAGE by 
MAP kinases such as ERK1/2 initiated by HMGB1-dependent signaling enables RAGE to 
translocate into the mitochondria, where it is involved in the regulation of cellular 
bioenergetics [248, 249]. Since a hyperactivation of the MAPK pathways is a characteristic of 
melanoma cells, an aberrant intracellular distribution of RAGE might be due to a differential 
posttranslational modification state of the protein [94]. A study by Galichet and coworkers 
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provided evidence that upon MMP9-, ADAM10- or γ-secretase-induced proteolysis of 
membrane-bound RAGE its C-terminal fragment is not only found in the cytoplasm but has 
also been transported into the nucleus [250]. 
In order to investigate if the nuclear staining in benign nevi might result from enhanced 
RAGE shedding TMA samples and human melanoma cell lines were stained with multiple 
antibodies targeting different epitopes of the RAGE molecule (data not shown). The data 
indicated, that nuclear RAGE not only consists of the C-terminal fragment but instead 
comprises at least one additional RAGE variant. The cell fractionation of the human 
melanocytic MelSTV cell line, followed by the detection of RAGE within the cytosolic extract, 
as well as soluble nuclear and chromatin-bound nuclear fraction via Western Blot (Figure 
11C, D), verified the existence of more than one RAGE form. In the soluble nuclear (SNE) 
and the chromatin-bound (CNE) nuclear extract bands for proteins with approximately 20 to 
30 kDa were detected, as well as a band around 60 kDa. Within the SNE additional variants 
between 50 to 60 kDa, and bands illustrating higher-weight molecules with 80 to 120 kDa 
were stained (Figure 11D). Noteworthy, bands for 80 to 120 kDa molecules were also 
detected by blotting immunoprecipations of RAGE from nuclear lysates (data not shown) as 
well as in the murine B16F10 protein lysate, where they disappeared upon Rage knockdown 
(Figure 6B). Fl-RAGE consists of 404 amino acids (aa) resulting in a molecular mass of 
55 kDa. Shed or alternatively spliced RAGE variants range from 36 to 404 amino acids 
(Table 16). Without consideration of multimeric aggregates or posttranslational modifications, 
estimation of the isoform weights according to the mass of full-length RAGE, reveals a 
molecular weight between 5 to 55 kDa. The 60 kDa band could arise from posttranslation 
modifications, such as phosphorylation, glycosylation, and SUMOylation. Since fluorescence 
resonance energy transfer (FRET) showed that RAGE molecules can form homodimers, as 
well as homooligomers and heterodimers with HSPGs and TLRs [244], the observed higher-
molecular weight molecules could illustrate multimers formed by strong disulfide bonds, 
which were not denaturated under the described conditions. In combination these findings 
reveal that RAGE isoforms, and maybe also fl-RAGE, might be able to translocate into the 
nucleus under certain conditions; these conditions seem to be present in benign nevi but not, 
or at least to a lower extend, upon transformation to malignant melanoma. 
Recent studies illustrated the existence of a complex regulatory machinery enabling the 
selection of alternative AGER exons and further correlated differential expression of RAGE 
isoforms with pathological conditions found in Alzheimer’s disease and neurodegeneration 
[240-242]. The observed aberrant RAGE splicing events were connected to the intracellular 
concentration or activity of nuclear RNA binding proteins, such as HNRNP H, HNRNP A1, 
and TRA2-β1 [240, 241]. Comparative analysis of transcript levels of these splicing factors 
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between normal skin, benign nevi, and melanoma samples identified a significant 
downregulation of both HNRNP proteins, H and A1, in melanoma tissue in comparison to 
their expression in normal skin (Figure 10). In terms of HNRNP H, these alterations were also 
found in benign nevi, thereby providing two indications: First, a deregulation of HNRNP H 
might be an early event in melanocyte transformation (Figure 10B); second, a deregulation of 
HNRNP H alone is not sufficient to explain the observation since an aberrant RAGE 
localization was found by comparing melanoma and benign nevi tissues (Figure 9A). Instead, 
an additional downregulation of HNRNP A1 upon transformation to melanoma with 
consequent differential expression of distinct RAGE isoforms seems to be required (Figure 
10A). In terms of TRA2-β1, transcript levels were found to be significantly downregulated in 
melanoma when compared to benign nevi, but not to healthy skin samples (Figure 10C). In 
total, the comparative analysis of the proteins HNRNP H, HNRNP A1, and TRA2-β1 known 
to be involved in regulating RAGE splice variant expression, revealed the existence of a 
melanoma-specific splicing signature. Interestingly, bioinformatics and array data strongly 
suggest that the alternative splicing process is more prominent among genes playing 
regulatory functions, thereby underlining the importance of RAGE and the complexity of its 
regulation [419]. Accordingly, the observed differential expression of the RAGE splicing 
factors might not only lead to a differential expression of RAGE variants with distinct 
subcellular localization patterns but also to distinct biological functions. However, the function 
of many RAGE isoforms is still unknown; indeed, it is difficult to answer what fraction of the 
huge transcript variation found for RAGE is truly biologically relevant and not only stochastic 
noise of the splicing process. 
Studies dealing with the subcellular localization of RAGE [249, 250] focused on fl-RAGE and 
its posttranslational modifications but did not take a role of RAGE variants into consideration. 
Furthermore, no potential mechanism was reported for the observed nuclear localization of 
the cytoplasmic domain of RAGE. According to the molecular weights of RAGE variants 
found in SNE and CNE (Figure 11D), a translocation from the cytosol into the nucleus and 
vice versa, cannot be mechanistically explained by pure diffusion. In general, only molecules 
smaller than 40 kDa can passively diffuse through the nuclear pore complexes (NPCs) while 
most proteins with functions in the nucleus use active carrier-mediated transport [420]. With 
this in mind, all described RAGE variants were screened for nuclear localization sequences 
indicating such an active transport mechanism (Table 16). Alternative splicing processes but 
also posttranslational modifications can affect – delete or establish – protein target signals as 
shown for the signal peptide. The computational methods used in this study attempt to 
predict nuclear localization by applying two different prediction approaches: First, similarity-
based models grounded on establishing the similarity of RAGE with already known nuclear 
proteins; second, NLS-based models detecting target signals and other properties pertinent 
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to the nuclear import machinery. The best-characterized nuclear target signal is the classical 
NLS, which is recognized by the protein importin (IMP)-α, leading to the formation of a 
heterotrimeric cargo complex that is able to enter the nucleus [420]. Indeed, using NLS-
based models (NLStradamus, cNLS Mapper, NetNES; Table 16) five of 20 analyzed RAGE 
variants, namely RAGE_v16 / Q15109-2, RAGE_v6 / Q15109-4, RAGE_v8 / Q15109-8, and 
Q15109-10, RAGE_v5 / Q15109-6, were identified to contain NLS and NES, whereas full-
length RAGE was not found to harbor any of these signals. However, despite the classical 
pathway several alternative pathways have been characterized lacking these classical 
localization/export sequences. Noteworthy, cNLS mapper incorporates an additive scoring 
approach intended to identify classical NLS only [363], whereas NLStradamus represents a 
probabilistic model allowing screens for classical and non-canonical NLS [369]. Based on 
these distinct approaches, the different results obtained by the two tools (Table 16) might be 
explained. Interestingly, the Nuc pred score of NLS/NES-containing RAGE isoforms, 
essentially corresponding to the statistical probability of nuclear localization, was significantly 
higher compared to the other RAGE isoforms (Figure 12A, B). Besides structural properties 
enabling proteins to translocate into the nucleus via active transport, molecules were 
identified, which ‘piggyback’ into the nucleus by binding to other NLS/NES-containing 
molecules. Multiple ligands of RAGE, such as HMGB1 and S100 family members [284, 285], 
are known to translocate into the nucleus, thereby representing a potential alternative 
mechanism for RAGE molecules without NLS/NES to bypass motif-dependent cargo 
transport. Therefore, the existence of a NLS and NES strongly recommends a role of those 
RAGE variants in the nucleus but the absence does not exclude a nuclear function. 
Taking advantage of the classification system CELLO, a software tool predicting the 
subcellular localization of proteins, the position of RAGE variants were modeled based on 
the physico-chemical properties of their amino acid sequence [362] (Table 16). Indeed, next 
to predictions of RAGE secretion to the extracellular space, cytosolic and mitochondrial 
localization, a large amount of isoforms (15/20) were allocated to the nucleus. Since 
NLS/NES were only present in five of the isoforms, other variants might use different 
transport mechanisms, or CELLO identified some false-positive nuclear RAGE forms. 
Interestingly, the RAGE variant Q15109-10 was identified to contain NLS and NES, but was 
also defined as secretion protein via CELLO. This example illustrates that in silico predictions 
may provide important information but need to be interpreted with caution. 
When treating the melanocytic MelSTV cells with Leptomycin B, a specific inhibitor of the 
NES-dependent nuclear export protein CRM-1 (chromosomal maintenance 1) prior to cell 
lysis, signals for RAGE proteins with approximately 30 and 60 kDa enhanced in the 
separated nuclear extracts (Figure 11D). On the one hand this verified the results obtained 
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via in silico prediction that some RAGE variants do contain NES, on the other hand it proved 
that at least some of these RAGE forms utilize active nuclear transport systems. These 
findings suggest that alterations in the active cargo transport might also be a potential 
mechanism controlling subcellular localization of RAGE and might contribute to the aberrant 
cytosolic localization demonstrated for melanoma (Figure 10A). Indeed, previous studies 
claimed an upregulation of proteins controlling nuclear export in melanoma [387]. Performing 
comparative analysis applying a human genome array, which comprises normal skin, benign 
nevi and melanoma samples, a significant upregulation of the exportins CRM-1 and also 
RANBP1 could be observed in melanoma when compared to healthy tissues (Figure 11A, B). 
This indicates that besides a differential RAGE isoform expression, an enhanced nuclear 
export could also lead to the observed switch from nuclear to cytosolic localization of RAGE 
proteins in melanoma. Noteworthy, immunofluorescence stainings of human melanoma cell 
lines for RAGE mainly revealed comparable patterns for its subcellular distribution as 
obtained by TMA analysis, with the exception of SKmel23 (Figure 9A, B). However, the 
observation that despite the loss of cell-cell and cell-matrix contacts human melanoma cell 
lines still display the in vivo situation in regards to RAGE localization, as well as the 
identification of a melanoma cell line showing a different pattern, provides a good starting 
point for future studies, including expression analyses for distinct RAGE variants. 
As mentioned before, posttranslational modifications also represent an important regulatory 
mechanism of reversible protein translation. A prime example is the phosphorylation-
dependent unmasking of the NLS present in the NF-κB transcription factor family. NF-κB 
activity is regulated by its cytosolic inhibitor IκB. More specifically, IκB binds to NF-κB, 
thereby masking its NLS and retaining it in the cytoplasm. Signals from extracellular stimuli, 
such as TNFα but also DNA-damaging agents, induce the phosphorylation and consequent 
ubiquitination and proteolysis of IκB. Subsequently, the NLS of NF-κB gets unmasked and 
allows the transcription factor to translocate into the nucleus [421, 422]. Kang and colleagues 
provided evidence that phosphorylation of RAGE in fact regulates its subcellular localization, 
i.e. in their settings the translocation into the mitochondria [249]. On average, 11 
phosphorylation sites were predicted in RAGE proteins, ranging from two to 15 (Table 16). 
Most of the analyzed RAGE variants were predicted to be substrates for PKC. Nevertheless, 
also variants were identified, which were predicted to be phosphorylated by PKA or cyclin-
dependent kinase 5 (CDK5). The functional impact of these phosphorylation sites, in other 
words if these sites are involved in signaling, stability or proteolysis of RAGE variants, or in 
their subcellular distribution, needs to be further investigated. Furthermore, fl-RAGE as well 
as most other splicing forms were in silico predicted to contain O- (19/20) and N-
glycosylation (15/20) sites. Glycosylation-dependent nuclear transport was first supported in 
1989 by studies assuming that sugar residues could act as nuclear targeting signals [423]. In 
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fact, Duverger and colleagues verified this assumption by demonstrating that fluorescein-
coupled BSA substituted to sugars could translocate to the nucleus, while unsubstituted 
could not [424]. Nowadays, a role of glycosylation in regulating subcellular localization of 
proteins is widely accepted, although it is still under discussion if it functions as nuclear 
targeting signal or rather as signal for nuclear residence [425]. Posttranslational modification 
by SUMOylation was only predicted for the half of the splice variants (10/20; Table 16). 
Nevertheless, SUMOylation was already reported to be involved in the nucleocytoplasmic 
transport of molecules belonging to the RAGE network. In fact, the mutation of SUMOylation 
sites within the RAGE ligand S100A4 abolished its ability to translocate into the nucleus 
[426]. 
Taken together, these data identified RAGE as a nuclear protein in melanocytes and 
indicated a loss of nuclear RAGE as characteristic of human malignant melanoma. 
Furthermore, the translocation of RAGE in the nucleus and vice versa has been 
demonstrated to at least partially depend on classical nuclear targeting sites, and 
consequently on the active cargo transport proteins, including the exportin CRM-1. The 
results further indicated possible mechanisms behind the aberrant subcellular localization of 
RAGE upon malignant transformation, such as a pathological upregulation of nuclear export 
proteins, and differential expression of splicing factors with subsequently altered frequency 
pattern of distinct RAGE isoforms. Ongoing experiments, including affinity 
enrichment/purification strategies coupled with mass spectrometry-based protein analysis, 
will provide more information on the identity of nuclear RAGE, as well as on potential 
posttranslational modifications enabling nuclear transport. Furthermore, taking advantage of 
stable isotope labeling by amino acid in cell culture (SILAC), a quantitative analysis of RAGE 
and its isoforms between melanocytic and melanoma cells will be achieved. 
IX.5. Potential role of nuclear RAGE 
In 2013, Sirois and colleagues demonstrated that RAGE functions as atypical nucleic-acid 
sensing immune receptor on the cell surface. Usually, these receptors are solely expressed 
in endolysosomal compartments or in the cytosol, thereby limiting receptor engagement by 
self-nucleic acids present in the extracellular space under homeostatic conditions. More 
specifically, RAGE was reported to bind to double-stranded DNA via interactions with the V1-
C1 unit [427]. Many studies proved that RAGE is able to induce the transcription of several 
genes, including the AGER gene itself; however, this was believed to happen elusively in an 
indirect manner. Since this study was able to demonstrate that RAGE also occurs as nuclear 
protein (Figure 9), the question rose whether it can also bind to nuclear DNA, and maybe 
influence gene expression in a direct manner by functioning as transcription factor or in 
transcription factor complexes. Transcription factors bind to conserved sequence patterns in 
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promoters of their target genes, nevertheless, also binding to different primary sequence 
patterns but similar DNA structures has been described. Interaction of RAGE with 
extracellular DNA has been supposed to occur in a sequence-independent manner via 
binding to the charged sugar-phosphate backbones [427].  
When screening RAGE proteins for potential DNA binding sites, fl-RAGE as well as eight 
other RAGE variants displayed two sites within the C1 domain, hereinafter referred to as 
binding motif 1 (BM1) and 2 (BM2) (Figure 12A, E). Interestingly, alternative splicing resulted 
in the generation of additional predicted DNA binding sites, labeled as either BM3 or BM4, in 
seven of the investigated RAGE isoforms (Figure 12A, E). When comparing the number of 
the predicted DNA binding sites between the different RAGE variants, the ones harboring 
potential NLS/NES displayed a significantly increased amount (Figure 12C). Surprisingly, the 
binding motif BM4 was found in both groups in contrast to BM3, which was elusively 
predicted in isoforms containing NLS and NES. Also differences regarding their localization 
were observed: BM3 was localized in the C1 domain while BM4 was found in the cytosolic 
portion of the RAGE protein (Figure 12E). So far, posttranslational modifications of RAGE 
isoforms have not been investigated. Nevertheless, Galichet and colleagues demonstrated a 
translocation of the intracellular domain of RAGE upon proteolytic cleavage into the nucleus 
[250]. Consequently, it can assumed that modified RAGE variants might also be shed by 
matrix metalloproteinases, thereby gaining the ability to translocate into the nucleus by pure 
diffusion. One indication for RAGE as component of transcription factor complexes was given 
by the results of Chen and colleagues, showing a direct interaction of RAGE and the tumor 
suppressor p53 in adipocytes [404]. 
However, all these findings are purely speculative at this stage. Ongoing experiments, 
combining affinity enrichment and mass spectrometry-based protein analysis of the RAGE 
protein, will provide more information on a potential nuclear interaction network. Furthermore, 
electrophoretic mobility shift assay (EMSA) studies with immunoprecipitated nuclear RAGE 
and genomic DNA will answer the question if RAGE is able to bind not only to extracellular 
but also to nuclear DNA. These results will shed more light onto the functional consequences 
of the nucleus-to-cytosol switch observed upon transformation from benign nevi to 
melanoma. In fact, the compartmental shift does not necessarily need to come along with 
loss of nuclear functions but also with a gain of toxic cytosolic functions of RAGE.  
Taken together this work proposes a beneficial role of RAGE for melanoma development, 
growth, and progression. RAGE was demonstrated to be involved in the establishment and 
regulation of characteristic melanoma hallmarks, such as genomic instability and mutation, 
resisting cell death, deregulating cellular energetics, sustained proliferative signaling, 
activating invasion and metabolism. Besides highlighting the importance of investigating 
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RAGE isoforms separately, this study showed for the first time that the subcellular 
localization of RAGE proteins is deregulated during the process of progression from benign 
nevi to malignant melanoma and metastasis, at least partly mediated via an active cargo 
transport to the nucleus. However, from a translational point of view the finding that RAGE 
causes a higher sensitivity of melanoma cells towards UV radiation but also towards 
anticancer treatment might be of great relevance. 
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XI. Abbreviations 
 
°C 
 
Degree Celsius 
 
% Percentage  
µ Micro  
7-AAD 7-amino-actinomycin 
A A Alanine 
aa Amino acid  
AD Alzheimer’s disease  
ADAM10 A disintegrin and metalloproteinase domain-containing protein 10  
AEC 3-amino-9-ethylcarbazole  
AGE Advanced glycation end-product  
AGER Advanced Glycosylation End Product-Specific Receptor (Gene 
name) 
 
AJCC American Joint Committee on Cancer  
AKT/PKB Protein kinase B  
AP1/2 Activator protein 1 / 2  
APS Ammonium persulfate  
ARAF A rapidly accelerated fibrosarcoma  
AMM Amelanotic malignant melanoma  
ATM Ataxia telangiectasia mutated  
ATP Adenosine triphosphate  
ATR Ataxia telangiectasia and Rad3-related protein  
Aβ Amyloid β 
B BAD Bcl-2-associated death promoter 
BCA Bicinchoninic acid assay  
BCL2 B-cell lymphoma 2  
BCL2A1 Bcl-2-related protein A1  
BER Base excision repair  
bFGF Basic fibroblast growth factor  
BIM Bcl-2 interacting mediator of cell death  
BIRC7  Baculoviral IAP repeat-containing protein 7  
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(ML-IAP) 
BLM Bloom's syndrome protein  
BM Binding motif  
BME Basement membrane extract  
BRCA1/2 Breast cancer susceptibility gene 1/2  
BSA Bovine serum albumin 
C C Cysteine 
C domain Constant domain  
CaCl2 Calcium chloride  
CAM-II Ca2+ /calmodulin-dependent protein kinase II  
CDC Cell division control protein  
CDK Cyclin-dependent kinase  
CDKN2A Cyclin-dependent kinase inhibitor 2A  
cDNA Complementary DNA  
CE Cytosolic extract  
CHEK Checkpoint kinase  
CKI Cyclin-dependent kinase inhibitor  
CKII Casein kinase II  
CLP Cecal ligation and puncture  
CNE Chromatin-bound nuclear extract  
CRAF C rapidly accelerated fibrosarcoma  
CREB cAMP-responsive element binding protein  
CRM-1 Chromosomal maintenance 1 (exportin 1)  
CSFE Carboxyfluorescein succinimidyl ester  
CTGP Connective tissue glycoprotein  
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
D DAMP Damage-associated molecular patterns 
DAPI 4’,6-diamidino-2-phenylindole  
DC Dendritic cells  
DCF Dichlorodihydrofluorescein  
DCFDA 2’,7’ –dichlorofluorescin diacetate  
DIA-1 Diaphanous-1  
Abbreviations 
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DKK1 Dickkopf-related protein 1  
DM Diabetes mellitus  
DMBA 7,12-dimethylbenz-[a]-anthracene  
DMEM Dulbecco’s Modified Eagle Medium  
DMSO Dimethyl sulfoxide  
DNA Deoxyribonucleic acid  
Doxo Doxorubicin  
DSB Double-strand break  
DTH Delayed type hypersensitivity 
E ECL Enhanced chemoluminescence 
ECM Extracellular matrix  
EDTA Ethylene diamine tetraacetic acid  
EGF-R Epidermal growth factor  
EGR1 Early growth response protein 1  
EMA European medicines agency  
EMT Epithelial-to-mesenchymal transition  
ER Endoplasmatic reticulum  
ERCC1/2 Excision repair cross- complementation group  
ERK Extracellular signal-regulated kinase  
ETS1 V-ets avian erythroblastosis virus E26 oncogene homolog 1 
F FACS Fluorescence activated cell sorting 
FADH2 Flavin adenine dinucleotide hydroquinone  
FAS First apoptotic signal  
FCS Fetal bovine serum  
FDA Food and drug administration  
fl-RAGE Full-length RAGE  
FRET Fluorescence resonance energy transfer 
G G Glycine 
GalNAc N-Acetylgalactosamine  
GAPDH Glyceraldehyde 3-phosophate dehydrogenase  
GLUT1 Glucose transporter 1  
GP100 Glycoprotein 100  
Abbreviations 
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GSK-3 Glycogen synthase kinase 3 
H h Hours 
H2AFX/H2AX H2A histone family member X  
H3 Histone 3  
HDM2 Human double minute 2  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
Hgf Hepatocyte growth factor  
HIF1α Hypoxia-inducible factor 1 α  
HMGB1 High-mobility group box 1  
HMGS Human melanocyte growth supplement  
HNRNP Heterogeneous nuclear ribonucleoprotein  
Hs Homo sapiens  
HS Heparan sulfate  
HSP Heat shock protein  
HSPG Heparan sulfate proteoglycan  
HUGO Human genome organization  
HUS1 Human cell cycle checkpoint gene 1 
I Ig domain Immunoglobulin domain 
IL Interleukin  
IMP-α Importin-α  
INSR Insulin receptor 
J 
K 
JARID1A Jumonji AT-rich interactive domain 1A 
K Lysine 
KCL Potassium chloride  
KD Knockdown  
kDa Kilodalton  
KO Knockout 
L LB Lysogeny broth 
LDH Lactate dehydrogenase  
LIG1 Ligase 1  
LMB Leptomycin B  
LMM Lentigo maligna melanoma  
Abbreviations 
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M m Meter 
m Milli  
MAPK Mitogen-activated protein kinase  
MART1 Melanoma antigen recognized by T-cells  
MDC1 Mediator of DNA damage checkpoint protein 1  
MDSC Myeloid-derived suppressor cells  
ME Membrane extract  
MEF Murine embryonic fibroblasts  
MEK Mitogen activated protein kinase 1 (MAP2K1)  
MHC Major histocompatibility complex  
MIA Melanoma inhibitory activity  
min Minutes  
MITF Microphthalima-associated transcription factor  
MLH1 MUTL homolog 1  
ML-IAP Melanoma inhibitor of apoptosis  
Mm Mus musculus  
mM Millimolar  
MMP-3 Matrix metallo-protease-3  
MMR Mismatch repair  
MMTV Mouse mammary tumor virus  
MOI Multiplicity of infection  
MRE11A Meiotic recombination 11 homolog A  
mRNA Messenger RNA  
MTC Mitomycin C  
MyD88 Myeloid differentiation primary response gene 88 
N n Nano 
NaCl Sodium chloride  
NADH Nicotinamide adenine dinucleotide  
NBN Nibrin  
NCT National center of tumor diseases  
NEAA Non-essential amino acids  
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NER Nucleotide excision repair  
NES Nuclear export signal  
NF-κB Nuclear factor kappa B  
NHM Normal human melanocytes  
NLS Nuclear localization signal  
NMM Nodular malignant melanoma  
NO Nitric oxide  
NONO Non-POU domain containing octamer-binding protein  
NRAS Neuroblastoma rat sarcoma oncogene  
N-region Negative-charge regulatory domain 
O OE Overexpression 
ORF Open reading frame  
OSCC Oral squamous cell carcinoma 
P p Pico 
P14ARF P14 ADP ribosylation factor  
P16INK4A P16 inhibitor of cell cycle kinase 4A  
PBS Phosphate-buffered saline  
PCR Polymerase chain reaction  
PD1 Programmed death receptor 1  
PD-L1 Programmed death receptor ligand 1  
PE Pellet extract  
PFA Paraformaldehyde  
PI3K Phosphoinositide 3-kinase  
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate  
PKA/C/G Protein kinase A/C/G  
PRKDC Protein kinase, DNA-activated, catalytic polypeptide  
PTEN Phosphatase and tensin homolog  
PVDF Polyvinylidene difluoride 
Q qPCR Quantitative real-time polymerase chain reaction 
Q Glutamic acid 
R 
R Arginine 
RAC-1 Ras-related C3 botulinum toxin substrate 1  
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RAD50/51/52 RecA homolog 50/51/52  
RAGE Receptor for advanced glycation end-products  
RANBP1 RAN-specific binding protein 1  
RB Retinoblastoma protein  
RGP Radial growth phase  
RHO Ras homologue  
RNA Ribonucleic acid  
RNF8/168 Ring finger protein family member 8/168  
ROS Reactive oxygen species  
RPA Replication protein  
RPLO 50S ribosomal subunit protein L15  
RSK Ribosomal s6 kinase  
RTK Receptor tyrosine kinase 
S S Serine 
S100B S100 calcium-binding protein B  
SAPK/JNK Stress-activated protein kinase/c-Jun-NH2-terminal kinase  
SDS Sodium dodecyl sulfate  
shRNA Short-hairpin RNA  
SILAC Stable isotope labeling by/with amino acids in cell cultur  
siRNA Small-interfering RNA  
SMC1A Structural maintenance of chromosomes 1A  
SNE Soluble nuclear extract  
SNP Single nucleotide polymorphism  
SP-1 Specificity protein-1  
SRC Proto-oncogene tyrosine-protein kinase Src  
SSM Superficial spreading melanoma  
STAT Signal transducer and activator of transcription  
SUMO Small ubiquitin-related modifier 
T T Threonine 
TAM Tumor-associated macrophages  
TBHP Tert-Butylhydroperoxid  
TBS Tris-buffered saline  
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TEMED Tetramethylenediamine  
TGF-β Transforming growth factor β  
TIM-3 T-cell immunoglobulin and mucin domain-containing protein 3  
TIRAP Toll-interleukin 1 receptor (TIR) domain containing adaptor protein  
TLR Toll-like receptor  
TMA Tissue microarray  
TNF-α Tumor necrosis factor α  
TOPBP1 DNA topoisomerase 2-beta-binding protein 1  
TP53 Tumor protein 53  
TP53BP1 TP53 binding protein 1  
TPA 12-O-tetradecanoylphorbol-13-acetate  
TRA-2β1 Transformer 2 β homolog-1  
TRAIL Tumor necrosis factor-related apoptosis-inducing ligand  
Tregs Regulatory T cells  
TTF-1 Thyroid transcription factor 1  
TUNEL TdT-mediated dUTP-biotin nick end labeling  
TXNIP Thioredoxin-interacting protein  
TYR Tyrosinase 
U 
V 
UV Ultraviolet 
V 
region/domain 
Variable region/domain 
VEGF Vascular-endothelial growth factor  
VGP Vertical growth phase 
W WNT Wingless/Integrated 
WPRE Woodchuck hepatitis virus posttranscriptional regulatory element  
Wt Wildtype 
X XP Xeroderma pigmentosum 
XPA/C Xeroderma pigmentosum group A/C protein   
XRCC2/6 X-ray repair complementing defective repair in Chinese hamster cells 
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